




The Dissertation Committee for Suzanne Novak
Certifies that this is the approved version of the following dissertation:
AN ANALYSIS OF THE LONG-TERM
COST-EFFECTIVENESS OF INTENSIVE 
LIFESTYLE INTERVENTION FOR 
TYPE 2 DIABETES MELLITUS 
PREVENTION
Committee:






AN ANALYSIS OF THE LONG-TERM
COST-EFFECTIVENESS OF INTENSIVE 
LIFESTYLE INTERVENTION FOR 
TYPE 2 DIABETES MELLITUS 
PREVENTION
by
Suzanne Novak, B.A., M.D.
Dissertation
Presented to the Faculty of the Graduate School of 
the University of Texas at Austin
in Partial Fulfillment
of the Requirements
for the Degree of
Doctor of Philosophy
The University of Texas at Austin
May 2005
Dedication
This work is dedicated to the following people:
My beloved parents, George and Marcellyn Novak, 
who always told me I could do anything I wanted to, 
and provided me with every means to do so.  
My beloved husband, William Nemeth, M.D.  
Without his support, I would have been unable to complete this task.
My beloved daughter, Katherine Nemeth.  
Thank you for being an example to me.
Acknowledgements
I would like to first acknowledge the members of my dissertation committee.  Their
support through this project, as well as throughout my entire tenure at the University of
Texas is forever appreciated.  In particular, I would like to thank Kenneth Lawson, my
advisor.  His guidance has made me both a better researcher and a better writer on every
project we have embarked on together.  I look forward to all of our future collaboration.
I wish to thank James Wilson and Robert Salzman for allowing me to be a Teaching
Assistant, and ultimately an Assistant Instructor for the Pharmacotherapy Laboratories.
The experience I had there enhanced my clinical training, and allowed me to be able to
feel comfortable enough to have the knowledge to write about metabolic disease.
I wish to thank all of my family: my parents, George and Marcellyn Novak; my hus-
band, William Nemeth; my daughter, Katherine Nemeth; and my brother and sisters, Kelly
Novak, Laurie Morian, and Jennifer Novak.  They have provided incredible love and emo-
tional support.  In addition I would like to thank several of my friends that have walked
every step of graduate school with me.  They include Nina Beucler, Judy Haralson, Ann
Hurt, Melissa Hahn, and Cindy Stone.  I would not have been able to complete this adven-
ture without them.
Thank you all from the bottom of my heart!
v
AN ANALYSIS OF THE LONG-TERM
COST-EFFECTIVENESS OF INTENSIVE 
LIFESTYLE INTERVENTION FOR 




The University of Texas at Austin, 2005
Supervisor: Kenneth A. Lawson
The purpose of this dissertation was to assess the long-term cost-effectiveness of
type 2 diabetes mellitus prevention from a state of impaired glucose tolerance with the use
of intensive lifestyle intervention.  The analysis was primarily based on findings by the
Diabetes Prevention Program (DPP). Additional goals of the analysis were: (1) to exam-
ine the effect of obesity on the results; and (2) to examine the effect of the study design of
the DPP, in particular the healthcare exclusion criteria, on the analysis. 
Two basic Markov models were designed for the dissertation.  The first was
designed to closely approximate the Diabetes Prevention Program study design and
results, and the second was designed to attempt to approximate a more generalized U.S.
population.  These two basic models were then divided into two subcategories: a subcat-
vi
egory that with adjustments intended to reflect the effects of obesity in the analysis; and
a subcategory with no adjustments for obesity.  This subdivision was then further divided
by duration of effect of the three-year intervention: a three-year duration of effect and a
lifetime duration.
The results showed, in all models examined, the lifestyle intervention arm of the
analysis dominated the placebo arm.  The incremental cost-effectiveness ratios derived for
the models exhibited a wide range (-$551/LY to -$19,496/LY).  The variables that
appeared to most influence this wide range of ratios included the following: (1) overall
direct medical costs; (2) effects of obesity on mortality rates; (3) effect of obesity on con-
trol cost of illness; and (4) duration of intervention.  In addition, the maximum acceptable
cost of intervention for any one of the models also depended on these variables.
Overall, diabetes prevention from the state of impaired glucose tolerance appears to
dominate non-intervention.  However, a large range of values were derived for both incre-
mental cost-effectiveness ratios and maximum acceptable cost of intervention. These val-
ues appear to depend on cost inputs as well as obesity-adjustments to the models used for
analysis.  Researchers and policy makers should consider studying these possible influ-
ences in interpreting the study findings, conducting future research, or making decisions
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CHAPTER 1 - INTRODUCTION
1.1 Overview of theTopic
Type 2 diabetes mellitus (T2DM) is an epidemic in the United States (U.S.).  In
the year 2004, the Centers for Disease Control (CDC) estimates that at least 18 million
American adults have diabetes (type 1 diabetes mellitus, T2DM, gestational diabetes, and
all other categories), and lists this disease as the sixth leading cause of death.1 The mul-
tiple complications of diabetes include microvascular complications such as retinopathy,
renal disease, and peripheral neuropathy, as well as macrovascular complications of coro-
nary heart disease, peripheral vascular disease, and stroke.2 The 2002 cost of diabetes in
the U.S. was estimated to be $132 billion, with direct medical cost accounting for $92 bil-
lion.3 Diabetes is unfortunately a world-wide problem, with approximately 150 million
people currently estimated to have this condition.4 The current cost of treatment of dia-
betes and its complications is similar in most "westernized" countries, and is estimated at
7% to 14% of total healthcare costs.5
Obesity is considered to be one of the most preventable risk factors in the devel-
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
1 Centers for Disease Control and Prevention. Diabetes: Disabling, Deadly, and on the Rise: At a
Glance. National Center for Chronic Disease Prevention and Health Promotion. Available at:
http://www.cdc.gov/nccdphp/aag/aag_ddt.htm. Accessed March 2004.
2 American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases.
Prevention or delay of type 2 diabetes. Diabetes Care. 2004;27:S47-S54.
3 Centers for Disease Control and Prevention. Diabetes: Disabling, Deadly, and on the Rise: At a
Glance. National Center for Chronic Disease Prevention and Health Promotion. Available at:
http://www.cdc.gov/nccdphp/aag/aag_ddt.htm. Accessed March 2004.




opment of T2DM.6, 7 As with T2DM, the condition of obesity is also associated with mor-
bidity and mortality, with overweight and obese persons possibly experiencing dyslipi-
demia, high blood pressure, and cardiovascular disease in addition to insulin resistance,
hyperinsulinemia, and ultimately glucose intolerance.8 Other disease conditions related to
obesity include arthritis; cancers such as those of the breast, colon, and endometrium;
gallbladder disease; and sleep disorders.9 The condition of obesity is also characterized
as an epidemic by the CDC.  There was a 74% increase in the prevalence of obesity in
U.S. from 1991 to 2000.10 The American Obesity Association currently estimates that 127
million adults (64.5%) in the U.S. are overweight as defined by a body-mass index (BMI)
≥ 25 kg/m2, 60 million (30.5%) are obese (BMI ≥ 30 kg/m2), and 9 million (4.7%) are
severely obese (BMI ≥ 40 kg/m2).11
Recent randomized controlled trials suggest that implementing lifestyle mainte-
nance programs that emphasize weight loss and increased physical activity in  patients
with impaired glucose tolerance (IGT), a health state that is considered to be a 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
6 Burke JP, Williams K, Narayan KMV, et al. A population perspective on diabetes prevention: whom
should we target for preventing weight gain? Diabetes Care. 2003;26:1999-2004.
7  Leibson CL, Williamson DF, Melton III LJ, et al. Temporal trends in BMI among adults with dia-
betes. Diabetes Care. 2001;24:1584-1589.
8  Kannel WB, Wilson PWF, Nam B, et al. Risk Stratification of obesity as a coronary risk factor.
American Journal of Cardiology. 2002;90:697-701.
9  American Obesity Association. AOA Fact Sheets. Available at:
http://www.obesity.org/subs/fastfacts/obesity_US.shtml. Accessed March 2004.
10  Centers for Disease Control and Disease Prevention. Obesity Trends: 1991-2001 Prevalence of
Obesity Among U.S. Adults, by Characteristics. National Center for Chronic Disease Prevention and
Health Promotion. Available at: http://www.cdc.gov/nccdphp/dnpa/obesity/trend/prev_char.htm. Accessed
March 2004.
11  American Obesity Association. AOA Fact Sheets. Available at:
http://www.obesity.org/subs/fastfacts/obesity_US.shtml. Accessed March 2004.
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pre-diabetic condition, may result in postponement or actual prevention of progression to
T2DM. 12, 13 The Diabetes Prevention Program (DPP) is one such study which included
3,234 subjects with a diagnosis of IGT as defined by a two-hour post-load glucose ≥ 140
mg/dL and < 200 mg/dL, and a fasting plasma glucose of 95 mg/dL to 125 mg/dL. 14 The
inclusion criteria also specified that the subjects had no other major disease state abnor-
malities, including cardiovascular disease. 15
The starting cohort was randomized into one of three intervention groups. 16 The
intervention groups included a cohort that received intensive lifestyle intervention, and
two masked medication cohorts that received either metformin or a placebo.  The latter
two groups also received standard diet and exercise recommendations.
After an average follow-up of 2.8 years, there was a 58% relative reduction in pro-
gression from IGT to T2DM in the lifestyle intervention group, and a 31% relative reduc-
tion in the metformin group when compared to the placebo group.  Weight loss in addition
to increased physical activity were assumed to be the contributing factors for the success
of the lifestyle intervention group.  The goal of ≥ 7% weight reduction was achieved in
50% of this group.
Therefore, the DPP results are very encouraging for the possibility that lifestyle  
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x
12  Tuomilehto J, Lindstrom J, Erikisson JG, et al. Prevention of type 2 diabetes mellitus by changes in
lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine.
2001;344:1343-1350.
13  Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
14  Diabetes Prevention Program Research Group. The Diabetes Prevention Program: design and 
methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22:623-634.
15  Ibid.
16  American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases.
Prevention or delay of type 2 diabetes. Diabetes Care. 2004;27:S47-S54.
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interventions requiring only a modest amount of weight loss may be used to prevent pro-
gression from IGT to T2DM.  It has been noted, however, that the weight loss achieved
by these subjects required a very intensive delivery of treatment that might be difficult to
reproduce in a setting other than a clinical trial. 17 Perhaps of even greater importance is
that by using the criteria implemented in the DPP, approximately 17.1% of adults in the
U.S. would currently qualify for diabetes prevention lifestyle interventions.. 18, 19 This
translates to approximately 9.1 million adults, aged 45 years to 74 years.. 20 The potential
costs of implementing lifestyle intervention programs for a group this large are stagger-
ing. An additional problem is that lifestyle counseling is not routinely reimbursed by the
U.S. health care system. 21  
Current economic analyses of the results of the DPP have been limited to an analy-
sis of costs associated with the program itself 22 and an analysis of within-trial cost-effec-
tiveness comparing the metformin and lifestyle intervention arms of the study.23 This
latter study was limited to the three-year time horizon of the DPP, and did not
17  Teutsch S. The cost of preventing diabetes: what do we know and what do we need to know?
Diabetes Care. 2003;26:238-239.
18  Diabetes Prevention Program Research Group. The Diabetes Prevention Program: design and 
methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22:623-634.
19  Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burden of death attributable to diabetes in
the United States. American Journal of Epidemiology. 2002;156:714-719.
20  Benjamin SM, Valdez R, Geiss LS, et al. Estimated number of adults with pre-diabetes in the US in
2000: opportunities for prevention. Diabetes Care. 2003;26:645-649.
21  American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases.
Prevention or delay of type 2 diabetes. Diabetes Care. 2004;27:S47-S54.
22  Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2
diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36-47.
23 Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention
or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
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incorporate the impact of long-term costs of diabetes morbidity and mortality.  In addition,
none of the effects of elevated BMI on healthcare costs, mortality, or utilities is included.
These effects primarily would be related to disease abnormalities associated with obesity
in addition to diabetes, such as coronary heart disease, hypertension, gallbladder disease,
certain cancers, and osteoarthritis.
The American Diabetes Association (ADA) and the National Institute of Diabetes
and Digestive and Kidney Diseases have both suggested that the cost-effectiveness of a
DPP-like lifestyle intervention requires further research to determine if intervening in
individuals at high risk of developing T2DM, such as those individuals with IGT, will
"cost-effectively reduce the morbidity and mortality associated with diabetes."24 They
also suggest that the "additional health benefits" 25 of lifestyle intervention programs may
directly influence the overall cost-effectiveness of the strategies. These additional health
benefits may include all of those that occur secondary to weight loss, including improve-
ments in the multitude of other disease conditions that are related to obesity.
1.2 Overview of the Dissertation
The dissertation attempts to address three major questions: (1) What is the long-
term cost-effectiveness of the use of intensive lifestyle intervention to prevent T2DM from
the state of IGT? (2) What is the effect of obesity on this evaluation? and (3) How does
the evaluation change if an attempt is made to make the analysis more generalizable using
a hypothetical population that may be more representative of that which is currently
foundin the U.S. rather than the cohort studied by the DPP?
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
24 American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases.
Prevention or delay of type 2 diabetes. Diabetes Care. 2004;27:S47-S54.
25 Ibid.
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While current research suggests that lifestyle intervention to prevent progression
from IGT to T2DM is effective, it is not currently known whether this method of inter-
vention is cost-effective over the lifetime of a subject.  One option for the long-term analy-
ses required for this project is to follow the DPP cohort over the duration of the subjects’
lifetimes.  While possible, this does not provide the information required to develop pol-
icy guidelines that are urgently needed today.  Another more useful option is to use mod-
eling techniques to incorporate the data derived by the DPP to project beyond the time
horizon of the trial.
To use modeling to project beyond the DPP results, additional data will be required
besides that found in the study.  The literature review was therefore designed not only to
address the above questions, but also to build a "database" to populate the parameters
required for the Markov models that are discussed in the dissertation.
The information required for the dissertation is presented in the following manner.
Chapter 2 begins with a discussion of the pathophysiology of abnormal glucose home-
ostasis, and introduces the reader to the basics of T2DM.  Current published transition
probabilities through the stages of normal glucose tolerance (NGT) to IGT to T2DM in
studies other than the DPP are described. The role of obesity in the development of T2DM
is then examined.  The chapter ends with a discussion of studies leading to the DPP, and
finally a discussion of the DPP itself.
Chapter 3 elaborates on the use of a cost-effectiveness analysis (CEA) for this disser-
tation.  The underlying theory behind the methodology is discussed as a precursor to cur-
rently published studies on the long-term cost-effectiveness of lifestyle intervention for
diabetes prevention.  The DPP cost-analysis and three-year cost-effectiveness studies are
then discussed.
Further data needed for the dissertation model is then explored.  These data include
6
the cost of illness of the obese T2DM, IGT, and NGT subject.  Current literature regard-
ing the effect on mortality rates of abnormal glucose homeostasis, obesity, and their com-
bined states is described.  Additional literature on possible health-state utilities for these
same populations is also given.  
The generalizability of results found in the DPP study group is examined through-
out the discussion of the above variables.  One major factor that may influence lack of
generalizability is the healthcare exclusion criteria found in the design of the DPP (sub-
jects were excluded if they had cardiovascular disease, hypertension, renal disease, pul-
monary disease, cancer or anemia).26 The specific effects on direct healthcare costs and
mortality resulting from these exclusions is emphasized.  The conclusion of Chapter 3 lists
the proposed hypotheses for the dissertation and their rationales.
Chapter 4 describes the methodology used for the dissertation.  Markov modeling
is introduced, as well as a discussion of the use of sensitivity analyses, and in particular,
probabilistic sensitivity analyses.  The discussion defines in detail the input parameters
used in the models, and ranges required for one-way, two-way, and probabilistic sensitiv-
ity analyses.
Chapter 5 presents the results derived from the analysis.  Base-case analyses for
each model are given first, and the presentation of theses results is concluded with the
application of the findings to the hypotheses tests presented in Chapter 3.  Comparisons
of the base-case results are then described in detail.  An emphasis is placed on both the
effect of cost inputs on the analyses as well as the effects of obesity adjustments.  The
chapter also includes an examination of the maximum acceptable cost of lifestyle inter-
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx Diabe
26 Diabetes Prevention Program Research Group. The Diabetes Prevention Program: design and 
methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22:623-634.
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vention for each model presented, and the factors that influence this value.  Time free of
diabetes and cost per glucose homeostasis state (NGT, IGT, and T2DM) are then 
presented.  The chapter ends by describing results of sensitivity analyses conducted for the
dissertation, including the following; (1) increasing the discount rate from 0% to 5%; (2)
decreasing the treatment effect; (3) increasing the progression from IGT to NGT; and (4)
inserting a possible reversion from T2DM to IGT.
Chapter 6 completes the dissertation with a discussion of the results and how they
relate to the goals of the study.  In addition, the possible impact of the results on policy
making surrounding diabetes prevention using lifestyle intervention is presented.  Future
research required to adequately evaluate cost-effectiveness of diabetes prevention and
limitations of the study conclude this chapter.
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CHAPTER 2 – LITERATURE REVIEW: 
TYPE 2 DIABETES MELLITUS (T2DM)
There are two main purposes of this literature review.  The first is to examine data
that support the hypotheses that have been proposed for this model.  As noted in the intro-
duction, the general questions that will be examined include the possibility of long-term
cost-effectiveness of T2DM prevention, the effect of obesity on this analysis, and finally,
an attempt to extend the results of this analysis to a more generalizable cohort than that
studied by the DPP.  As these questions are addressed, a second goal, to accumulate data
with which to populate the models of the dissertation, will also be accomplished. 
As a first step, the underlying pathophysiology of the continuum from NGT to
T2DM will be described.  Important variables for the model such as the progression prob-
abilities of NGT to IGT, IGT to T2DM, and the reversion probabilities of IGT to NGT will
be examined.  The risk factors that influence these transitions, including obesity will then
be discussed.  Finally, prevention studies that preceded the DPP will be examined as an
introduction to a discussion of the study.
2.1 Natural History of T2DM
To understand diabetes prevention, one must first have a working knowledge of
the underlying pathophysiology of T2DM.  The following sections will outline the disease
states that are currently thought to occur in the development from NGT to T2DM.
2.1.1 PATHOPHYSIOLOGY OF T2DM
Diabetes mellitus is a metabolic disorder of multiple etiologies.  T2DM, a specif-
ic diagnostic classification of the general category of diabetes mellitus, is a chronic, pro-
9
gressive disease, which represents 80% to 90% of diabetes cases, with the other most
common classification being type 1, or as previously known, insulin-dependent diabetes
mellitus.27
T2DM is considered a heterogeneous multifactorial, polygenic disease.28 The most
common group of patients with this diagnosis, or approximately 70% to 85% of patients,
have a poorly defined etiology for their condition.  Of the remaining 15% to 30% of
patients, 5% to 10% of patients are commonly classified as having maturity onset diabetes
of youth, 5% to 10% are classified as having adult onset, autoimmune diabetes, and 5%
to 10% are thought to have a rare genetic disorder as the etiology of their T2DM. 29
Type 2 diabetes is a disease that appears to require a genetic basis as well as envi-
ronmental or acquired factors to manifest itself.  The environmental factors may be mod-
ifiable such as obesity or sedentary activity, or non-modifiable, such as aging. 30 In most
individuals, the disease involves defects of both insulin resistance (also referred to as
insulin sensitivity) and ß-cell insulin secretion. 31
Genetic factors, which are still incompletely identified, are thought to predispose
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
27 Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired
insulin sensitivity. Endocrine Review. 1998;19:491-503.
28  Hayden MR. Islet amyloid, metabolic syndrome, and the natural progressive history of type 2 dia-
betes mellitus. Journal of Pancreas. 2002;3:126-138.
29  Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired
insulin sensitivity. Endocrine Review. 1998;19:491-503.
30  Aitman T, Todd J. Molecular genetics of diabetes mellitus. Baillieres Best Practice and Research:
Clinical Endocrinology and Metabolism. 1995;9:631-656.
31  Report of the WHO Consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and
its Complications: Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health
Organization; 1999.
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an individual to T2DM.32, 33 Early life events in genetically susceptible individuals, such
as intrauterine nutrition, low birth weight, and formula feeding may be some of the first
environmental factors that additionally influence the propensity to develop T2DM.34
The vast majority of patients with T2DM initially exhibit some degree of insulin
resistance, although the disease can occur rarely in its absence.  More importantly, insulin
resistance may occur without the development of T2DM.35 It is postulated that in patients
who develop T2DM, insulin resistance has two components: an inherited component and
a component that is environmentally acquired secondary to factors such as obesity and
lack of physical activity. 36
Multiple studies, conducted in a wide variety of ethnic populations, have reported
that insulin resistance occurs in a pre-diabetic state which may last for many years before
T2DM is diagnosed.37 Insulin resistance ultimately leads to increased basal hepatic glu-
cose production.  Patients with insulin resistance are generally able to maintain normal
plasma glucose concentrations because insulin secretion from the pancreatic ß-cells
becomes augmented.38 Many years of insulin resistance may ultimately ensue in the 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
32  Aitman T, Todd J. Molecular genetics of diabetes mellitus. Baillieres Best Practice and Research:
Clinical Endocrinology and Metabolism. 1995;9:631-656.
33  Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals 
destined to develop type 2 diabetes? Diabetes. 2002;51:S117-S121.
34  Ozanne SE, Hales CN. Pre- and early postnatal nongenetic determinants of type 2 diabetes.
Cambridge University Press. Available at: http://www.expertreviews.org/02005240h.htm. Accessed March
2004.
35  Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of
type 2 diabetes mellitus. Mayo Clinic Proceedings. 2003;78:447-456.
36  Olefsky JM, Kruszynska YT. Insulin resistance. In: Porte D, Sherwin RS, Baron A, eds. Ellenberg &
Rifkin's Diabetes Mellitus. 6 ed. New York: McGraw-Hill; 2003:367-400.
37  Ibid.
38 Inzucchi SE. Classification and Diagnosis of Diabetes Mellitus. In: Porte D, Sherwin RS, Baron A,
eds. Ellenberg & Rifkin's Diabetes Mellitus. New York: McGraw-Hill; 2003:265-275.
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patient who is destined to develop T2DM.39 Ultimately, the final stage of pathogenesis
occurs, ß-cell function deteriorates, and the patient is clinically diagnosed with T2DM.
2.1.2 THE CLINICAL STAGES OF T2DM
The following sections outline the currently hypothesized clinical development of
T2DM.
2.1.2.1 Preclinical Phase
Type 2 diabetes mellitus appears to have a preclinical stage, characterized by
insulin resistance, that is compensated for by increased secretion of insulin by ß-cells.
This preclinical phase, which is thought to be silent in the patient, is not readily diagnosed,
and is thought to occur for as long as nine to twelve years prior to an easily detectable pre-
clinical phase such as IGT or impaired fasting glucose (IFG).40, 41
2.1.2.2   Impaired Glucose Tolerance (IGT) and Impaired Fasting Glucose (IFG)
The selection criteria for the DPP were defined as a two-hour post-load glucose ≥
140 mg/dL and < 200 mg/dL, and a fasting plasma glucose (FPG) of 95 mg/dL to
125mg/dL.42 The definitions and significance of these states will now be discussed.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
39 Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals des-
tined to develop type 2 diabetes? Diabetes. 2002;51:S117-S121.
40 Harris MI, Klein R, Welborn TA, et al. Onset of NIDDM occurs at least 4-7 yr before clinical diagno-
sis. Diabetes Care. 1992;15:815-819.
41 Harris R, Donahue K, Rathore SS, et al. Screening adults for type 2 diabetes: a review of the evi-
dence for the U.S. preventive services task force. Annals of Internal Medicine. 2003;138:215-234.
42  Diabetes Prevention Program Research Group. The Diabetes Prevention Program: design and 
methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22:623-634.
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2.1.2.2.1   Definition and Prevalence
IGT is currently defined in the U.S. by the 1997 ADA criteria as a plasma glucose
level of  ≥ 140mg /dL to < 200 mg/dL at two hours after an oral glucose challenge.43 IGT
is considered to be a metabolic state that is intermediate between normal glucose home-
ostasis and diabetes, and it is considered to be a risk category for future T2DM.44, 45
Patients with a diagnosis of IGT have an increased prevalence of cardiovascular disease
risk factors.46 These include dyslipidemia, hypertension, and microalbuminuria.
IGT should not be confused with a state referred to as impaired fasting glucose
(IFG), which is currently diagnosed as a fasting plasma glucose of ≥ 100 mg/dL and < 126
mg/dL.47 At the time of the DPP, IFG was diagnosed as a fasting plasma glucose of ≥ 110
mg/dL to < 126 mg/dL.  Of note, all of the studies used in this dissertation, unless speci-
fied, were completed using the earlier diagnostic criteria with the higher cut point of 110
mg/dL. At the time of the DPP, IFG was diagnosed as a fasting plasma glucose of ≥
110mg/dL to < 126 mg/dL.48 Of note, all of the studies used in this dissertation, unless
specified, were completed using the earlier diagnostic criteria with the higher cut point of
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
43  National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories
of glucose intolerance. Diabetes. 1979;28:1039-1057.
44  Report of the WHO Consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and
its Complications: Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health
Organization; 1999.
45  Meigs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose tol-
erance to type 2 diabetes in the Baltimore Longitudinal Study of the Aging. Diabetes. 2003;52:1475-1484.
46  Benjamin SM, Valdez R, Geiss LS, et al. Estimated number of adults with pre-diabetes in the US in
2000: opportunities for prevention. Diabetes Care. 2003;26:645-649.
47  American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care.
2004;27:S5-S10.
48  The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert
Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2000;23:S3-S4.
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110 mg/dL.
The DPP may have anticipated this lowered threshold, which was officially
announced in January 2004 by the ADA,49 when they designed their study criteria with a
lower FPG cut point of 95 mg/dL.  The rationale for the ADA change is primarily based
on the fact that the IFG and IGT categories are defined in order to characterize patients
who may develop T2DM.  The two tests now define similar proportions of individuals,
whereas previously, IGT was a more sensitive test.50
A concern that remains is that researchers feel there may be two distinct pheno-
typic pathways to development of T2DM.  This is based, in part, on the finding that
regardless of the diagnostic threshold for IFG, patients may develop either isolated IGT
or IFG.51 Insulin resistance is found in both, but patients with the less frequently occur-
ring "IFG" pathway appear to have more pronounced ß-cell abnormalities, and increased
endogenous glucose production.52
In an analysis using NHANES III data of overweight people (BMI > 25 kg/m2)
with the previous IFG diagnostic threshold of 110 mg/dL, 11.9 million people (22.6%)had
either IFG or IGT. 53
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
49  American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care.
2004;27:S5-S10.
50  Davidson MB, Landsman PB, Alexander CM. Lowering the criterion for impaired fasting glucose
will not provide clinical benefit. Diabetes Care. 2003;26:3329-3330.
51  Meigs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose tol-
erance to type 2 diabetes in the Baltimore Longitudinal Study of the Aging. Diabetes. 2003;52:1475-1484.
52  Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting 
glucose and/or impaired glucose tolerance. Diabetes. 1999;48:2197.
53 Benjamin SM, Valdez R, Geiss LS, et al. Estimated number of adults with pre-diabetes in the US in
2000: opportunities for prevention. Diabetes Care. 2003;26:645-649.
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2.1.2.3   T2DM
2.1.2.3.1 Definition, Screening, and Prevalence
T2DM is defined as a fasting plasma glucose ≥ 126 mg/dl and/or a two-hour post
glucose load of ≥ 200 mg/dl.54 As noted in the introduction, the current estimated adult
prevalence of T2DM in the U.S. is 18 million adults.55 By the time that T2DM is clini-
cally diagnosed, 20% to 30% of patients are found to have microvascular complications
such as retinopathy, nephropathy, and neuropathy, and macrovascular complications such
as cardiovascular, peripheral vascular and cerebrovascular disease.56
Approximately one-third of patients with T2DM are undiagnosed and untreated.57
To put this number in perspective, it was estimated that the prevalence of undiagnosed dia-
betes in the U.S. population aged 20 years to 74 years was 3.2% from 1988 to 1994.58
Undiagnosed diabetes is a major problem in that approximately one-third of these patients
have microvascular complications that would respond to improved glycemic control.59
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
54  Report of the WHO Consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and
its Complications: Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health
Organization; 1999.
55  Centers for Disease Control and Prevention. Diabetes: Disabling, Deadly, and on the Rise: At a
Glance. National Center for Chronic Disease Prevention and Health Promotion. Available at:
http://www.cdc.gov/nccdphp/aag/aag_ddt.htm. Accessed March 2004.
56  Segal L, Dalton A, Richardson J. Cost-effectiveness of the primary prevention of non-insulin depend-
ent diabetes mellitus. Health Promotion International. 1998;13:197-209.
57 Harris MI, Eastman RC. Early detection of undiagnosed diabetes mellitus: a US perspective.
Diabetes/Metabolism Research and Reviews. 2000;16:230-236.
58  Harris M, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and
impaired glucose tolerance in U.S. adults. Diabetes Care. 1998;21(4):518-524.
59 Roman SH, Harris MI. Management of diabetes mellitus from a public health perspective.
Endocrinology and Metabolism Clinics of North America. 1997;26:443-474.
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In spite of the high rate of undiagnosed T2DM patients in the U.S., screening for
T2DM remains controversial.  In 2003, the U.S. Preventative Task Force concluded that
"the evidence is insufficient to recommend for or against routinely screening asympto-
matic adults for type 2 diabetes, impaired glucose tolerance, or impaired fasting glu-
cose."60 The ADA currently recommends routine screening of all adults beginning at age
45 years, with repeat tests every three years.  If a patient has one or more of the risk fac-
tors listed in Table 2.1, screening is recommended at a "younger age" or "more frequent-
ly," though these values are not defined.61
Table 2.1   Risk Factors for Type 2 Diabetes Mellitusa
a Source: American Diabetes Association. Screening for Type 2 Diabetes. Diabetes Care. 2003;26:S21-
S24.
HDL, high-density lipoprotein; kg/m2, kilograms per meter squared; mg/dL, milligrams per deciliter;
mmHg, millimeters of Mercury
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
60  U.S. Preventative Services Task Force. Screening for type 2 diabetes mellitus in adults: recommenda-
tions and rationale. Annals of Internal Medicine. 2003;138:212-214.
61  American Diabetes Association. Screening for Type 2 Diabetes. Diabetes Care. 2003;26:S21-S24.
Age ≥ 45 years
Overweight (BMI ≥ 25 kg/m2)
Family history of diabetes (first or second degree relative)
Habitual physical inactivity
High risk ethnicity (African American, Hispanic, Native American, Asian
American, Pacific Islander)
Previously identified impaired fasting glucose or impaired glucose tolerance
History of gestational diabetes or delivery of a baby weighing > 9 lbs.
Hypertension (≥ 140/90 mmHg in adults)
Dyslipidemia (HDL cholesterol≤ 35 mg/dL and/or triglyceride level≥ 250 mg/dL)
Polycystic ovarian disease
History of vascular disease
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2.1.2.3.2  Possible Changes from the IGT State
Receiving the diagnosis of IGT does not automatically mean that the patient will
progress to T2DM.  In fact, while at an increased risk for T2DM when given this diagno-
sis, a patient with IGT may revert to NGT.62, 63 In a review of five studies done by Yudkin
et al., a repeat glucose tolerance test after a positive test at any time from less than 7 days
to a mean of 8.5 months had a reversion to normal of 35% to 76%, and progression to
T2DM of 4% to 9%.64
A possible explanation given for reversion to NGT by these authors is the phe-
nomenon of "regression to the mean."  An even more intriguing explanation for the vari-
ability found in patients tested with an OGTT for IGT is the possibility that the two-hour
glucose tolerance test may reflect a "stress effect" when first performed, which may not
occur on the repeat administration.65 Interestingly, the DPP notes that "IGT may revert to
NGT" in their article on the baseline characteristics of the randomized cohort.66 This
statement is not repeated in the published articles focused on the intervention.
The rate of progression from IGT to T2DM is also discussed by the DPP.  The
Diabetes Prevention Program Research Group suggests that rates of progression range
from 2.3% per year to approximately 11%, with the higher values recorded in non-white
ethnic groups.67 These values were analyzed by Edelstein et al. in preparation for the 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
62  Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteris-
tics of the randomized cohort. Diabetes Care. 2000;23:1619-1629.
63  Yudkin JS, Alberti KGMM, McLarty DG, et al. Impaired glucose tolerance: is it a risk factor for dia-
betes or diagnostic ragbag? British Medical Journal. 1990;301:397-402.
64  Ibid.
65  Ibid.
66  Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteris-
tics of the randomized cohort. Diabetes Care. 2000;23:1619-1629.
67  Ibid.
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DPP, and are summarized in Table 2.2.68 This work was done in part to establish the range
of rates of progression to T2DM from IGT in order to predict the sample size and power
needed for the study.  
Six prospective studies were analyzed, and the conversion rate ranged from 35.8
(S.D. 2.6) per 1,000 person-years in the Baltimore Longitudinal Study of Aging (95%
Caucasian, average age 59.4 years), to 87.3 per 1,000 person-years in the Pima
IndianStudy (100% Pima Indians, average age 43.2 years).69 For groups that included a
mixture of Caucasians and Hispanics, age was an important factor in conversion rate.  The
San Antonio Heart Study, with an average age of 48.3, had a conversion rate of 43.5 per
1,000 person-years.  On the other hand, the San Luis Valley Diabetes Study, with an aver-
age age of almost 60, had a conversion rate of 72.9 per 1,000 person-years.  The average
value of the six studies was 5.8% per year (58 cases per 1,000 person-years).  
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
68 Edelstein SI, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance
to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701-710.
69  Ibid.
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Table 2.2 A Comparison of Studies of Progression of Impaired Glucose Tolerance 
to Type 2 Diabetes Mellitusa
a Source: Edelstein SI, Knowler WC, Bain RP, et al.  Predictors of progression from impaired glucose
tolerance to NIDDM: an analysis of six prospective studies.  Diabetes. 1997;46:701-710.
b  Conversion rate ± standard deviation
CI, confidence interval
The DPP ultimately chose a conversion factor of 65 per 1,000 person-years.  This
translates to a one-year probability of 0.0672 assuming a constant yearly transition prob-
ability.  This was based on the entry criteria required by the DPP study of an abnormal
IGT plus a FPG of 95 mg/dL to 125 mg/dL, and a diagnosis of diabetes being made using
ADA diabetic criteria for a fasting or two-hour plasma glucose level.70 As noted above,
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
70 Diabetes Prevention Program Research Group. The Diabetes Prevention Program: design and methods
for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22:623-634.
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59.4                
(23.2-92.5)
95% Caucasian,  4% 
African-American, 
1% Other
73.8% Men         
26.2% Women




68.0         
(52.0-82.0)
100% Caucasian 35.5% Men      
64.5% Women




48.3                
(25.0-65.0)
26.6% Non-
Hispanic White,   
73.4% Mexican-
American
36.3% Men         
63.7% Women
43.4 ± 4.2                      
(35.2-51.6)
Nauru Study 37.3                
(12.0-75.0)
100% Micronesian 45.6% Men         
54.4% Women
62.8 ± 5.3                      
(52.5-73.1)
San Luis Valley 
Diabetes Study
59.7                
(31.2-75.0)
47.5% Non-
Hispanic White,  
52.2% Hispanic
39.6% Men        
60.4% Women




43.2                
(20.0-89.3)
100% Pima Indian 37.1% Men         
62.9% Women
87.3 ± 4.2                      
(79.0-95.6)
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this lower fasting plasma glucose threshold value may approximate the prevalence of
abnormal two-hour plasma glucose populations in the U.S. population.71
For the sake of clarification, one-year probabilities will be reported throughout the
literature review.  This is because probabilities will be required for the model, and the
cycle length that will be used is a one-year period.  In examining the literature evaluated
for this project, two specific adjustments are often required to obtain these one-year val-
ues.  The first is that findings are presented as probabilities, but in time frames other than
that of one year.  These probabilities must be converted to rates before they are adjusted
to probabilities for one-year periods.  In addition, many results are reported as rates, so
they must be converted to probabilities.  
The formula used to convert a probability to a rate is the following: 72
µ = -ln[1-P(t)]/t
where µ equals the one-year rate, which is also called the annual hazard rate, t is the time
period, and P(t) is the probability that an event occurs over this t time period.  The fol-
lowing formula is then used to reconvert back to the needed probability value:
P(t) = 1 – exp (-µ).
2.1.2.3.3  Progression from Normal Glucose Tolerance(NGT) to IGT
In anticipation that the dissertation model will require a value for progression from
NGT to IGT, a value not given by the DPP, the following two studies have been selected
to calculate a preliminary value.  Both studies are important for consistency because they 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
71 Meigs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose tol-
erance to type 2 diabetes in the Baltimore Longitudinal Study of the Aging. Diabetes. 2003;52:1475-1484.
72 Kuntz K, Weinstein M. Ch. 7 - Modeling in Economic Evaluation. In: Drummond M, McGuire A, eds.
Economic Evaluation in Health Care: Merging Theory with Practice. New York: Oxford University Press;
2001:141-171.
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include data for the progression from NGT to IGT that is derived from studies used by the
DPP to calculate progression from IGT to T2DM, as seen in Table 2.2.
2.1.2.3.3.1  Values Calculated from the Baltimore Longitudinal Study of Aging
The Baltimore Longitudinal Study of Aging (BLSA)73 is a prospective study that
was begun in 1958 by the National Institute of Health (NIH), and is ongoing.  The data
studied for this analysis were derived from a population of subjects of mainly Caucasian
race, and of middle and upper-middle socioeconomic class.  The average age of the par-
ticipants was 57 years.  The mean BMI for this particular study was not given.  The design
is an open-cohort model, with dropouts replaced before every two-year exam period to
maintain a study population of approximately 1,000.  The study allows for calculation of
transition probabilities from a state of NGT (as defined as a two-hour post challenge glu-
cose level of < 140 mg/dL and a FPG < 110 mg/dL) to a state of IGT, as defined by abnor-
mal two-hour post glucose levels.  Therefore, the subject is not required to have an
abnormal fasting plasma glucose to fall into this category.  This is important, as this study
design approximates the study criteria of the DPP.
The one-year transition probability that is calculated for this group of study sub-
jects based on a ten-year follow up (assuming a constant annualized transition) is 0.0624.
This is based on a ten-year cumulative incidence of 47.5%.74 Using a five-year follow up
(and again assuming a constant annualized transition), the one-year probability is calcu-
lated as 0.0718.  This is based on a five-year cumulative incidence of 31.1%. 75
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
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2.1.2.3.3.2  The Pima Indian Study
The highest rate of progression from IGT to T2DM noted in Table 2.2 was in the
Pima Indian Study76 (87.3 per 1000-person years, or a 1-year probability of 0.0836).  This
study also calculated estimates of the rate of progression from NGT to IGT.  They found
that 79 of 254 subjects developed IGT from NGT over an approximate 3.9-year follow up
(31.1%).  The calculated 1-year probability is 0.0767.
2.1.2.3.4  Do You Have to Pass Through IGT to get to T2DM?
Is it possible to progress from NGT to T2DM without first being characterized as
having either an abnormal FPG, IGT, or both?  Meigs et al. addressed this question and
felt this was an extremely rare occurrence. 77
The authors found that of the 488 subjects who started the BLSA in a state of NGT
using a FPG of < 110 mg/dL and a 2-h post glucose value of < 140 mg/dL, only 12 patients
(2.46%) progressed to T2DM without first passing through some category of abnormal
glucose homeostasis over the initial eleven-year study period.78 The estimated one-year
probability of this occurrence is 0.0023.
2.1.2.3.5  Reverting from T2DM to IGT or NGT
For completeness of the dissertation model, the possibility that a subject might
revert from T2DM to IGT must be investigated.  It is thought that the progressive ß-cell
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
76 Weyer C, Tataranni P, Bogardus C, et al. Insulin resistance and insulin secretory dysfunction are inde-
pendent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development.
Diabetes Care. 2001;24(1):89-94.
77 Meigs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose tol-
erance to type 2 diabetes in the Baltimore Longitudinal Study of the Aging. Diabetes. 2003;52:1475-1484.
78  Ibid.
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destruction found in T2DM subjects makes it unlikely that a patient will revert back to
IGT without some sort  of treatment intervention.79 The goal becomes even more diffi-
cult in obese subjects.80
Weight loss has also been investigated as a treatment option for newly diagnosed
patients with T2DM.  Weight loss is thought to decrease fasting insulin levels in these
patients, but has little effect on insulin secretion.81 While a small but steady weight loss
is suggested as the most "rewarding action" as an initial intervention for obese, type 2 dia-
betics, the mechanism of action may be more influenced by the state of negative caloric
balance than the achievement of a lower, steady-state weight.82, 83 It is generally thought
that glycemic control improves very quickly with the energy restriction associated with
low calorie diets, and this effect is independent of weight loss.84 As energy restriction is
relaxed, this improvement has been found to decrease, even in the presence of continued
weight-loss maintenance.85
The UKPDS has evaluated the use of a low-fat, high-carbohydrate, high-fiber diet 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
79 UKPDS Group. UK Prospective Diabetes Study 16: overview of six years' therapy of type 2 diabetes-
a progressive disease. Diabetes. 1995;44:1249-1258.
80  Turner RC, Cull CA, Firghi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in
patients with type 2 diabetes mellitus. JAMA. 1999;281:2005-2012.
81 Robbins D, Shair E. Current strategies for managing obesity in type 2 diabetes. Medscape from
WebMD. Available at: http://www.medscape.com/viewprogram/341_pnt. Accessed Sept. 2004.
82  Ibid.
83  Kelley DE, Wing R, Buonocore C, et al. Relative effects of caloric restriction and weight loss in non-
insulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism. 1993;77:1287-
1293.




as a monotherapy to treat newly diagnosed type-2 diabetics.86 Using an outcome of a
hemoglobin A1c (HbA1c) < 7%, the currently ADA-recommended "normal" value, 23%
of overweight subjects (defined as > 120% ideal body weight) maintained this "normal"
level after three years on diet-therapy alone.  The weight loss achieved was approximate-
ly 5 kg over the first three months.  By six years, the percentage of subjects with a HbA1c
< 7% had decreased to 12%, and by nine years the level had again decreased slightly to
11%.  These results are difficult to translate to FPG and two-hour post challenge glucose
values due to imperfect correlation of the tests.87
Few additional studies have evaluated the long-term effects of weight-loss main-
tenance in this population.  Pascale et al. have studied the effect of calorie and calorie plus
fat restriction in obese, T2DM subjects.88 The authors found significant decreases in glu-
cose levels after the sixteen-week intervention in both treatment intervention arms, but
these values had returned to baseline after a one-year follow-up.  The deterioration of
glycemic improvement at the one-year follow-up was also found by Wing et al. in a study
of 144 obese, type-2 diabetic subjects treated in a behavioral weight control program.89
Therefore, an apparent improvement in glycemic control with weight loss occurs
in obese, type-2 diabetic subjects.  This highest effect appears in the early stages of
weight loss, and is apparently secondary to energy restriction as well as actual weight 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
86 Turner RC, Cull CA, Firghi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in
patients with type 2 diabetes mellitus. JAMA. 1999;281:2005-2012.
87  The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert
Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2002;25:S5-S20.
88  Pascale RW, Wing RR, Butler BA, et al. Effects of a behavioral weight loss program stressing calorie
restriction versus calorie plus fat restriction in obese individuals with NIDDM or a family history of dia-
betes. Diabetes Care. 1995;18:1241-1248.
89 Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss on type II diabetic
patients. Archives of Internal Medicine. 1987;147:1749-1753.
24
loss.  In addition, the effect seems to dissipate over long-term follow-up.  Results are also
difficult to interpret as most studies have used HbA1c values or FPG values that do not
correlate with the IGT definitions used by the DPP.  
In addition, current literature does not support reversion from T2DM to IGT as
found in the case of reversion from IGT to NGT as described in section 2.1.2.3.2.  It may
be that there will be "fuzzy areas" in which a patient is found to cross back and forth from
IGT to T2DM with the decrease in cut-off point for diagnosis for T2DM from 140 mg/dL
to 126 mg/dL, but this research has not currently been undertaken.
2.1.2.3.6  The Risk Factors for IGT and T2DM
Multiple factors are associated with an increased risk of IGT.  These include obe-
sity, increased age, a family history of diabetes, ethnicity, and lipid abnormalities.90 These
factors are also associated with increased risk of T2DM, and have been examined in mul-
tiple studies with varying results as to their influence on progression from IGT to T2DM.91
In the analyses performed in preparation for the DPP, Edelstein et al. noted that
there was remarkable consistency in the risk factors for progression from IGT to T2DM
in the six studies that were examined.92 The most significant risk factors for progression
in all six studies were higher baseline fasting and two-hour postchallenge glucose con-
centrations, and obesity.  Family history was inconsistently associated with increased rate
of progression from IGT to T2DM.  This is likely because subjects with IGT were 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
90 Edelstein SI, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance




already an "enriched high risk group."  Sex was not a predictor of progression of IGT to
T2DM in any of the studies.  Non-Caucasians were found to have a substantially higher
risk of progression.  Baseline age varied substantially in the six studies as a risk factor,
and this factor is dependent on ethnicity as to rate of progression.  Those populations with
higher risk, such as Pima Indians or Hispanics, are more likely to progress from IGT to
T2DM at an earlier age (before age 40 years to 50 years) than groups that were mainly
Caucasian.93
As noted above, BMI was an independent predictor of progression from IGT to
T2DM across the six combined studies.  When the six studies were analyzed separately,
BMI was an independent predictor of progression in the Baltimore Longitudinal Study,
the Rancho Bernardo Study, and the San Antonio Heart Study.  The three cohorts with
T2DM across the six combined studies.  When the six studies were analyzed separately,
BMI was an independent predictor of progression in the Baltimore Longitudinal Study,
the Rancho Bernardo Study, and the San Antonio Heart Study.  The three cohorts with the
highest T2DM incidence rates did not show BMI as a strong independent predictor of
T2DM (the Naura Study, the San Luis Valley Diabetes Study, and the Pima Indian Study).
This was thought to be in part because these populations, which were considered "very
overweight," had reached a saturation point for obesity as a risk factor, at which point no
additional risk for conversion to T2DM would be seen with additional weight.
2.2  The Role of Obesity In T2DM
Obesity is considered one of the most important, preventable risk factors in the devel-
opment of T2DM.94 One author noted that between 1970 and 1999, there were at least
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
93 Ibid.
94 Costacou T, Mayer-Davis E. Nutrition and prevention of type 2 diabetes. Annual Review of Nutrition.
2003;23:147-170.
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least 28 prospective studies that confirmed the role of obesity as a strong predictor of
T2DM.95 It is estimated that 60% to 90% of the variance in T2DM status is related to
obesity. 96,97
2.2.1   MEASUREMENT AND CLASSIFICATION OF OBESITY
A common measure of obesity that will be used throughout this dissertation is BMI.
This measure, which takes into account body weight and height, is calculated by dividing
weight in kilograms by height in meters-squared.98 There are five major categories of BMI
using the World Health Organization (WHO) 2000 guidelines.99 These are listed in Table 2.3.
Table 2.3  Body-Mass Index Weight Classificationa
a Source: World Health Organization. Obesity: Preventing and Managing the Global Epidemic.  Report of
a WHO Consultation on Obesity. 2000. Geneva, World Health Organization.
kg/m2, kilograms per meter squared
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
95 Brancati FL, Wang, N Y, Mead LA, et al. Body weight patterns from 20 to 49 years of age and subse-
quent risk for diabetes mellitus: the Johns Hopkins  Precursors Study. Archives of Internal Medicine.
1999;159:957-963.
96 Colditz GA, Willett WC, Stampfer MJ, et al. Weight as a risk factor for clinical diabetes in women.
American Journal of Epidemiology. 1990;132:501-513.
97 Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review
with meta-analysis of clinical studies. Journal of the American College of Nutrition. 2003;22:331-339.
98 Kortt MA, Langley PC, Cox ER. A review of cost-of-illness studies on obesity. Clinical Therapeutics.
1998;20:772-779.
99 World Health Organization. Obesity: Preventing and Managing the Global Epidemic.  Report of the
WHO Consultation on Obesity. Geneva: World Health Organization; 2000.
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Classification Body-Mass Index (BMI) 
in kg/m2
Underweight Less than 18.5
Normal Range 18.5 - 24.9
Overweight (Preobese) 25.0 - 29.9
Obese Class I 30.0 - 34.9
Obese Class II 35.0 - 39.9
Obese Class III (Severely Obese) Greater than or equal 40
The WHO has suggested that BMI may be used as a simple measure of obesity.  The
advantages of using BMI include that is easily assessed on physical exam, and can also be
determined by self report.100 The disadvantage of the measure is that it is not always an
accurate indicator of obesity.101 A high degree of adiposity is not always indicated by the
calculated value because the etiology of increased weight is not distinguished, and may be
a result of increased muscle mass or bone in addition to excess fat.  There is much con-
troversy over the most accurate measurement of adiposity in both clinical and research
settings.  The discussion of this controversial topic is beyond the scope of this dissertation
report.  BMI has been chosen as an obesity measurement as this is the value used by the
DPP.
2.2.2   THE CORRELATION OF BODY-MASS INDEX (BMI) AND T2DM
There are few articles that have examined the correlation of BMI subcategories and
the development of T2DM; however, there is general agreement that increased BMI is
accompanied by an increased rate of diabetes.  An examination of this topic is helpful to
the dissertation model in two ways.  First, an overview of this topic is required to help to
explain why extensive lifestyle intervention emphasizing weight loss is successful.  The
second reason for examination is that as will be noted later, the DPP results suggest that
lifestyle intervention to prevent T2DM may be less successful in subjects with a BMI ≥
35 kg/m2.  A review of the correlates of BMI to development of T2DM may clarify the
reasons for this difference in efficacy of treatment.  
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
100 Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and
diabetes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
101 James WP. What are the health risks?  The medical consequences of obesity and its health risks.
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The studies for this portion of the review were chosen in a MEDLINE search using
the medical subject headings (MeSH) headings of BMI, Obesity and T2DM.  Studies were
selected to show the strikingly different results that have been presented on the correlation
of BMI subcategories and T2DM.  A brief explanation of the effect of study design and
study population on the results will also be included.
2.2.2.1  Articles Suggesting That Increased BMI Increases Risk of Diabetes
Colditz et al. examined data collected in the Nurses’ Health Study, a prospectively
designed survey study of 121,700 female nurses aged 30 years to 55 years established in
1976.102 At the beginning of the study, no participant was diagnosed with diabetes.  At the
end of the 14-year study period, the risk for developing T2DM in relation to attained
weight over the period was evaluated.  The age-adjusted relative risk (RR) reference was
considered a BMI < 22 kg/m2.  The age-adjusted RRs determined for a BMI of 31 kg/m2
to < 33 kg/m2, 33 kg/m2 to < 35 kg/m2, and ≥ 35 kg/m2 were 40.3, 54.0, and 93.2, respec-
tively.  After adjusting for age, BMI was the predominant risk factor for T2DM.
Table 2.4 has been constructed from the data presented in the study to estimate annu-
al age-standardized incidence rates, and one-year probabilities of developing T2DM.  The
table has been constructed assuming that the transition rate to T2DM was constant over
each year.  This relationship held for both whites and African-Americans. 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
102 Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mel-
litus in women. Annals of Internal Medicine. 1995;122:481-486.
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Table 2.4 Incidence Rate per Fourteen-Year Period and One-Year Probability
of Transition to T2DM in the Nurses’ Health Study a
a  Source:  Colditz GA, Willett, WC, Rotnitzky A, et al.  Weight gain as a risk factor for clinical diabetes
mellitus in women.  Annals of Internal Medicine. 1995;122: 481-486.
BMI, body-mass index; kg/m2, kilograms per meter squared; T2DM, type 2 diabetes mellitus
The Nurses’ Health Study findings were extended to 1996, and the authors again found
that during the total 16 years of follow-up, "the most important risk factor for type 2 dia-
betes was body-mass index."103 When defining overweight as a BMI of 25 kg/m2 or high-
er, 61% of cases of T2DM are attributed to this factor.
Chan et al. examined 51,529 male health professionals aged 40 years to 75 years over
the period of 1987 to 1992 using a survey technique and observed similar relationships
between BMI and T2DM.104 When controlling for age, men with a BMI of ≥ 35 kg/m2
had a multivariate RR of 42.1 compared to those men with a BMI < 23 kg/m2.
2.3  Can Type 2 Diabetes Be Prevented?
Because of the epidemic increase in prevalence of T2DM, preventive activities merit
serious investigation.  One very compelling reason for prevention is suggested by data
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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104 Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk-factors
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25 to 26.9 0.00104 0.00104
27 to 28.9 0.00204 0.00204
29.0 to 30.9 0.00354 0.00355
31.0 to 32.9 0.00521 0.00523
33.0 to 34.9 0.00704 0.00706
 Greater than or equal 35 0.01191 0.01198
generated by the United Kingdom Prospective Diabetes Study (UKPDS).105 Intensive
pharmacologic treatment of T2DM successfully lowered microvascular complications.  It
was also noted though that while blood glucose was lowered during the ten-year study
period, fasting plasma glucose and HbA1C progressively increased.  It has been suggest-
ed that "intervention prior to the onset of diabetes may be the only way of stopping peo-
ple from getting onto this slippery slope." 106
2.3.1  REQUIREMENTS FOR DISEASE PREVENTION
Four requirements are generally listed to justify a disease-prevention program.107
These are listed in Table 2.5.
Table 2.5  The Four Requirements for Disease Prevention a
a Source: U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd Edition.
Washington, DC. U.S. Department of Health and Human Services, Office of Disease Prevention and
Promotion, 1996.
There is no question that the first two of these requirements are easily met when dis-
cussing T2DM.  The third is not so easily established.  As previously noted, while diag-
nostic criteria for both pre-diabetes and T2DM are well established, screening for 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
105 United Kingdom Prospective Diabetes Study  (UKPDS) Group. Intensive blood-glucose control
with suplhonylureas or insulin compared with conventional treatment and risk of complications in patients
with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
106 Zimmet P, Shaw J, Alberti KGMM. Preventing type 2 diabetes and the dysmetabolic syndrome in
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107 U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd Edition.
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The disease is an important health problem.
The natural history of the disease is understood sufficiently to measure progression.
Screening for high risk individuals should not be burdensome and should be cost-effective.
A safe, effective, and reliable method of prevention exists.
diabetes has not been effective, although it is currently recommended by the ADA. Most
diabetes prevention studies have avoided the question of screening and have generally
enrolled only subjects at high risk of progressing to T2DM, such as those in the category
of IGT.  The fourth requirement, the establishment of a safe and reliable method of T2DM
prevention, has been described by the DPP. 
A fifth requirement, while not listed, is discussed by the U.S. Preventive Services Task
Force Guide.108 This requirement is that the intervention should be cost-effective.  The
task force does not systematically incorporate cost-effectiveness analysis into their rec-
ommendations, but they do suggest that "cost-effectiveness analysis raises important
questions about the opportunity costs of alternative choices that decision-makers should
consider."  The problem is that currently, the long-term cost-effectiveness of intensive
lifestyle intervention to prevent T2DM remains unknown, and this is a central issue
addressed in this dissertation.  
2.3.2 DESCRIPTIONS OF DIABETES PREVENTION STUDIES OTHER 
THAN THE  DIABETES PREVENTION PROGRAM 
2.3.2.1 The Malmo Feasibility Study
The Malmo study was a non-randomized study that consisted of dietary treatment and
increased physical activity to attempt to prevent progression from IGT to T2DM.109 The
average BMI was > 25 kg/m2 for the 181 male study participants, and the age range was
47 years to 49 years.  A body weight reduction of 2.3% to 3.7% in the intervention sub-
jects over a six-year period resulted in normalized glucose tolerance in 50% of subjects
with IGT.  
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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2.3.2.2  The Da Qing Impaired Glucose Tolerance and Diabetes Study
The Da Qing study was published in 1997.110 The study was methodologically limit-
ed because randomization was performed based on clinics rather than by individual
patient.  The study, which lasted over a six-year period, examined 577 subjects with IGT
who were randomized to a diet group, exercise group, or a combined diet and exercise
group.  The mean age of the subjects was 45 years, and the mean BMI was 26 kg/m2.
There was a 13.3% incidence of progression to T2DM in the control group, 8.3% in the
diet group, 5.1% in the exercise group, and 6.8% in the diet and exercise group.  Using a
proportional hazards analysis that adjusted for baseline BMI and fasting glucose, the diet,
exercise, and combined groups were associated with a 33% (p < 0.03), 47% (p < 0.0005),
and 38% (p < 0.005) respective reduction in incidence of conversion to T2DM when com-
pared to the control group.  The cumulative incidence of conversion to T2DM in the con-
trol group at six years was 67.7% (95% C.I,: 59.8% to 75.2%).
2.3.2.3  The Finnish Diabetes Prevention Study (DPS)
The results of the Finnish Diabetes Prevention Study (DPS) were published in 2001.111
The study, which was conducted over a mean duration of 3.2 years, randomly assigned
522 subjects (172 men and 350 women) to a control group (brief diet and exercise coun-
seling) or a lifestyle intervention group.  The intervention group received individual coun-
seling with a nutritionist for seven sessions during the first year of the study, and one
session every three months thereafter.  
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The mean BMI of the subjects enrolled was 31.2 kg/m2, the mean age was 55 years,
and the mean fasting plasma glucose was 110 mg/dL. The weight loss goal was 5%
weight reduction, which was achieved by 43% of the intervention group and 13% of the
control group.  The exercise goal was > 150 minutes of exercise per week; this was
achieved by 86% of the intervention group and 71% of the control group.
During the first year, the mean body weight decreased by 4.2 ± 5.1 kg in the inter-
vention group versus 0.8 ± 3.7 kg in the control group.  At two years, the intervention
group maintained a significantly different mean weight loss than the control group at 3.5
kg ± 5.5 kg versus 0.8 ± 4.4 kg.  At the end of a five-year period, the intervention group
had maintained a mean weight loss of 2.1kg.
IGT progressed to T2DM at a rate of 3% per year in the intervention group, and 6%
per year in the control group.112 At four years, the cumulative incidence of T2DM was
11% (95% C.I.: 6% to 15%) in the intervention group, and 23% (95% C.I.: 17% to 29%)
in the control group.   The authors state that "according to the Cox regression analysis of
all person-years accumulated, the cumulative incidence of diabetes was 58% lower in
the intervention group than in the control group (hazard ratio, 0.4; 95% C.I.: 0.3 to 0.7;
p < 0.001)."113 The number needed to treat to prevent one case of T2DM was 22 for
one year and 5 for five years.
2.3.3  THE DIABETES PREVENTION STUDY (DPP)
The DPP randomly assigned 3,234 subjects from 1996 to 1999 to one of three
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interventions: placebo, metformin, or intensive lifestyle intervention.114 The emphasis of
the discussion of this study will be on the placebo and lifestyle intervention arms of the
study, as these are the results that this model will evaluate.
Selection criteria included an age of at least 25 years and a BMI of > 24 kg/m2 (> 22
kg/m2 in Asians).  As previously noted, the subjects’ main entry criterion was a diagnosis
of IGT based on the results of a single 75-g OGTT (two-hour post-load glucose ≥ 140
mg/dL and < 200 mg/dL), and a FPG of 95mg/dL to 125 mg/dL.115
Multiple exclusion criteria were incorporated into the DPP design.116 These included
any history of cardiovascular disease or uncontrolled hypertension (systolic blood pres-
sure > 180 mmHg or diastolic blood pressure > 105 mmHg).  Other exclusion criteria
included the following: history of cancer within five years of the study; history of renal
disease (creatinine ≥ 1.4 mg/dL for men or ≥ 1.3 mg/dL for women); anemia (hematocrit
< 36% for men and < 33% for women); hepatitis; pulmonary disease; chronic infection
such as human immunodeficiency virus (HIV) or active tuberculosis; or history of
endocrine disease.  The authors stated that "most exclusion criteria were chosen to reduce
the risk of adverse effects related to the interventions."117
The average age of the subjects was 50.6 years, the average BMI was 34.0 kg/m2
(obese class I), and there were 32.3% males and 67.7% females enrolled.  Ethnic mixture
included 54.7% whites, 19.9% African Americans, 15.7% Hispanics, 5.3% American
Indians, and 4.4% Asians.  A positive family history for T2DM was reported in 69.4% of 
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subjects.  Fasting plasma glucose averaged 106.5 ± 8.3 mg/dL, and the two-hour post glu-
cose level average was 164.6 ± 17.0 mg/dL.  Average follow-up time was 2.8 years, with
a range of 1.8 to 4.6 years.  The blinded treatment phase was terminated in May 2001.
The lifestyle intervention consisted of individual counseling on nutrition and exercise
for sixteen sessions over the first twenty-four weeks of the program.  The subjects were
then followed at a minimum of a monthly follow-up for the duration of the program.  
The goal of the lifestyle intervention program was a 7% weight loss, which was
achieved by 50% of the subjects in this arm of the study at the end of the twenty-four week
curriculum.  At the time of the most recent visit of the lifestyle subjects, 38% had a 7%
weight loss.  The lifestyle group lost approximately 5.45 kg (an average of 5% of body
weight) at the end of two years, and 4.1 kg (an average of 3.5% body weight) at the end
of three years.118
The primary outcome measurement of the study was a diagnosis of T2DM.  Subjects
were tested annually with an OGTT, and semiannually with a FPG test.  Cut-off values for
normal were ≥ 200 mg/dL for the OGTT, and ≥ 126 mg/dL for the FPG values.  The sub-
ject was unmasked when these values were reached, but the subject was asked to remain
on their assigned treatment regimen until their FPG exceeded 140 mg/dL.
The crude incidence of developing T2DM was 11.0 cases per 100 person-years in the
placebo group, versus 4.8 cases per 100 person-years in the lifestyle intervention group.
The incidence of T2DM was higher in the placebo group than expected and was thought
to be secondary to the selection of patients at higher risk (abnormal IGT and higher IFG),
or perhaps to the increased frequency of glucose testing.  The estimated cumulative inci-
dence of T2DM at three years was 28.9% in the placebo group and 14.4% in the lifestyle 
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group.  Cumulative incidence is very important because this value is used to calculate the
one-year probability of transition from IGT to T2DM for the Markov Model.  The one-
year probability of developing T2DM is 0.1075 for the placebo group and 0.0505 for the
lifestyle group.
Approximately 3% to 5% of the lifestyle cohort, and 6% to 11% of the control group
developed diabetes on a yearly basis.  Intensive lifestyle intervention reduced the risk of
progression of IGT to T2DM by 58% (95% C.I.: 48% to 66%) when compared to the con-
trol group.  The number needed to treat over a three-year period to prevent one case of
T2DM is 6.9 (95% C.I., 5.4 to 9.5) for the lifestyle intervention group.  
It is also important to note the percentage of subjects who had reverted to NGT in each
group at the end of the three-year period.  Using a definition of NGT as both a two-hour
post-challenge glucose of < 140 mg/dL and a FPG of < 110 mg/dL, approximately 30%
of patients in the lifestyle group and 19% of the placebo group reverted to normal.  These
values are given as estimations from graphical DPP presentations.  The one-year proba-
bility of reversion to NGT then becomes approximately 0.1121 for the lifestyle group and
0.0678 for the placebo group.
The most common adverse effect in the lifestyle intervention group was a complaint
of musculoskeletal symptoms, which had an occurrence of 24.1 events per 100 person-
years, versus 21.1 events per 100 person-years in the placebo group.  There were no sta-
tistically significant differences in the incidence of adverse events, hospitalizations or
deaths between the two groups. 119
There were three deaths in the lifestyle intervention group and five deaths in the 
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placebo group over the first three years of the study (1.023 and 1.689 deaths per 1,000 per-
son-years, respectively).120 The one-year probability of death is 0.001 for the lifestyle
group and 0.0017 for the placebo group using these figures.  As a comparison, the proba-
bility of death for a subject of average age of 52 years is approximately 0.005 using data
from life tables published in the National Vital Statistics Reports.121
It has been suggested by the authors of the DPP that the lifestyle group had a more
successful effect in those subjects who had a BMI < 35 kg/m2.  Table 2.6 gives the inci-
dence of T2DM according to baseline BMI.  In addition, the estimated probability per one-
year period is also calculated. 
Table 2.6 Incidence of T2DM by Initial Body-Mass Index in the Diabetes       
Prevention Programa
a Source: The Diabetes Prevention Program Research Group.  Reduction in the incidence of type 2 dia-
betes with lifestyle intervention or metformin.  New England Journal of Medicine 2003;346:393-403.
b Body-Mass Index reported in kg/m2
CI, confidence interval; kg/m2, kilograms per meter-squared; T2DM, type 2 diabetes mellitus
Compared to the placebo group, the lifestyle intervention group experienced a 65%
(95% C.I.: 46% to 77%) reduction in incidence of T2DM in the BMI subcategory of 
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Placebo Lifestyle Placebo Lifestyle
22 to less      
than 30
9.0 3.3 0.094 0.034
30 to less      
than 35
8.9 3.7 0.093 0.038
Greater than 
or equal 35
14.3 7.3 0.154 0.076
Incidence                 
(In Cases per 100 Person-
Years)
In Probability per 1-
Year Period
22 kg/m2 to < 30 kg/m2, a 61% (95% C.I.: 40% to 75%) reduction in the BMI subcate-
gory of 30 kg/m2 to < 35 kg/m2, and a 51% reduction (95% C.I.: 34% to 63%) in reduc-
tion in the BMI subcategory ≥ 35 kg/m2.
2.3.4  CHAPTER SUMMARY
The basic pathophysiology of the development of T2DM has now been described as
well as the role of obesity in this development. Given this background for the disease state
of T2DM, the literature review will now turn to current studies on prevention of T2DM,
and the possible cost-effectiveness of intensive life style intervention.
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CHAPTER 3 – LITERATURE REVIEW: 
COMPONENTS OF A COST-EFFECTIVENESS ANALYSIS 
OF PREVENTION OF T2DM
3.1  Chapter Overview – An Introduction to Cost-Effectiveness
Analysis 
How does a health care provider decide to allocate resources for health care, and in
particular, preventive health care?  Preventive care emphasizes a reduction in morbidity
and mortality and involves a great deal of uncertainty.  Diagnostic and treatment-oriented
care interventions may be comparatively easier for the health care provider to analyze, and
ultimately favor, because an "identifiable life" is part of the equation.122 The dilemma
where there are limited resources for health care is how to apply these resources: to allo-
cate towards those in healthcare need, to allocate to prevent this need in the first place, or
both. 123
A cost-effectiveness analysis (CEA) is one method to aid in distribution of health care
resources.  Torrence et al. made the following statement about the value of a CEA when
assessing the impact of introducing a new intervention: "Cost-effectiveness analysis
describes and contrasts the costs and outcomes of a "treatment" course of events that
would be expected to occur with the intervention and the costs and outcomes of a "com-
parator" course of events without the intervention."124 A CEA "summarizes the expected
benefits, harms, and costs of adopting and translating a clinical recommendation into 
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122 Beauchamp TL, Childress JF. Ch. 6 - Justice. In: Beauchamp TL, Childress JF, eds. Principles of
Biomedical Ethics. New York: Oxford University Press; 1994.
123  Ibid.
124 Torrance GW, Siegel JE, Luce BR. Ch. 3 - Framing and Designing the Cost-Effectiveness
Analysis. In: Gold MR, Russell LB, Siegel JE, et al., eds. Cost-Effectiveness in Health and Medicine.
New York: Oxford University Press; 1996.
40
practice."125 The analyst attempts to find the alternative that offers the maximal benefits
for a given health expenditure.  An alternative explanation might be that the analyst wish-
es to minimize the cost of achieving the health care benefit.126
The results of a cost-effectiveness analysis are commonly presented as a ratio with the
net increase in health care cost in the numerator and the net increase in health care bene-
fit in the denominator.  Hunink et al. use the following formula to represent this ratio:127
∆C/∆E = (∆CProg + ∆CInd + ∆CMorb + ∆CSE + ∆CProg∆LE)/∆E
in which the numerator is represented by ∆CProg = the cost of the program; ∆CInd = the
cost or savings created by implementing the intervention; ∆CMorb = the cost or savings
secondary to averting mortality; ∆CSE = the cost of treatment of side effects; and
∆CProg∆LE = the cost of health care related to the disease addressed by the intervention
in added years of life.  The denominator, ∆E, represents the change in health benefit,
which may be represented by values such as number of cases averted, number of life-years
saved, or the combined measure of quality-of-life year, which allows for an interaction of
quality of life with length of life.
For this dissertation analysis, it appears that the use of intensive lifestyle intervention
is effective in preventing T2DM on a short-term basis at an acceptable cost (as will be
described later in this chapter).  Unfortunately, the decision to implement lifestyle inter-
vention programs on a long-term basis for prevention of T2DM cannot wait until the cur-
rent cohort under investigation lives out another 20 to 30 years (the anticipated range of 
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life expectancy for the cohort with an average age of 50.6 years) in order to use the actu-
al data generated to produce a CEA.
Researchers who wish to evaluate cost-effectiveness in this sort of situation turn to
what is described by Torrence et al. as a "what if" study, or a threshold analysis.128 This
type of analysis allows the researcher to explore the uncertainty of the problem using tech-
niques such as sensitivity analyses to address issues including range of costs for the pro-
gram, or acceptable efficacy rate of the intervention.  This type of analysis may also be
implemented for any of the other variables in the cost-effectiveness formula to help to
generate information useful to policy makers when formulating recommendations to max-
imize health benefits within a defined health care budget.  The Third U.S. Preventive
Services Task Force also recommends using these types of sensitivity analyses to help
delineate population subgroups that might benefit most from a healthcare service. 129
The next section of this chapter will describe some of the theoretical bases behind
CEAs.  Current studies that have attempted to model and evaluate long-term cost-effec-
tiveness of T2DM will be presented.  The data that will be incorporated into the numera-
tor and denominator of the cost-effectiveness model will then be discussed.
3.2  The Theory Underlying Cost-Effectiveness Analysis
There are two similar theoretical models upon which cost-effectiveness analysis is
based.  The first, welfare economics, is the basic underlying theoretical foundation for
economic evaluation of health care.  Garber et al. states that "welfare economics is 
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concerned with the means by which we can assess the desirability – from the societal point
of view – of alternative allocations of resources."130 The main assumption of welfare eco-
nomics is that individuals maximize a preference function.131 This preference function, or
"utility" is assumed to follow a logical consistency, and the overall welfare of society is a
function of these individual preferences.132 In a perfectly competitive market, the above,
"rational" individuals will chose to maximize their utility, and therefore maximize social
welfare. 133
One basic concept of welfare economics is that each individual is the best judge of his
or her welfare.134 No new intervention is adopted if movement to an alternative creates a
"worse" state for at least one individual.  This leads to the concept of Pareto optimality.  A
situation is found to Pareto optimal if by re-allocation of resources, you cannot make
someone better off without making someone worse off. 135
An important concept in employing welfare economics as a theoretical framework for
economic evaluation of healthcare is the use of a "social utility function," which is defined
as the aggregate of individual utilities.136 Problems arise not only in attempting to define
this aggregate, but also in actually defining the person’s utility itself.  In addition, welfare 
130 Garber AM, Weinstein MC, Torrance GW, et al. Ch. 2 -Theoretical Foundations of Cost-
Effectiveness Analysis. In: Gold MR, Russell LB, Siegel JE, et al., eds. Cost-Effectiveness in Health and
Medicine. New York: Oxford University Press; 1996.
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132  Ibid.
133  Raftery J. Economic evaluation: an introduction. British Medical Journal. 1998;316:1013-1014.
134 Tsuchiya A, Williams A. Ch. 2 - Welfare economics and economic evaluation. In: Drummond M,
McGuire A, eds. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford
University Press; 2001.
135  McGuire A. Ch. 1 - Theoretical concepts in the economic evaluation of health care. In:
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economics does not allow for inclusion of any other aspect of utility other than that gen-
erated by the consumption of goods and services.137
As an alternative to welfare economics, the concept of "extra-welfarism" has been
introduced.  Utility, as measured by the extra-welfarists, is not only a value generated by
consumption of goods and services, but also includes "extra" value from an individual’s
characteristics, such as that derived from an emotional or physical state.138 An excellent
explanation of these differences is given by Dhanani who states that welfare economics
defines health care as "something that contributes to overall well being" while extra-wel-
farist economics defines health care as contributing to health itself.139 The emphasis is
on health in addition to utility.  Extra-welfarists have been noted to stress the concept of
need instead of the more traditional economic concept of demand.  Culyer, in describing
extra-welfarism, makes the statement that "need depends on the ability to benefit from
healthcare; demand depends on preferences backed by the ability to pay.140 Welfare eco-
nomics, therefore, stresses concepts such as "willingness to pay" whereas extra-welfarists
emphasize the concept of need when making assessments of the efficiency of health care
systems.
One major problem which occurs when using either of these models is that they both
assume the market is in perfect competition.  The implications are that there is perfect
information, free entry and exit from the market, the products are homogeneous, and the  
137 Dhanani K. The neo-classical and extra-welfarist approaches to health. Available at:
http://www.econ.qmw.ac.uk/NHS_reforms.com/student_file/welfare4.1pdg. Accessed March 2004.
138  Ibid.
139  Ibid.
140  Culyer AJ, Newhouse JP. Handbook of Health Economics. New York: Elsevier; 2000.
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buyers and sellers are unable to affect price.141 This is obviously not the case when
describing the health care market.  
The differences between these two basic theoretical concepts allow for the different
methodologies used for what has been broadly described here as "cost-effectiveness
analysis."  The methodologies include a cost-benefit analysis (CBA), a cost-effectiveness
analysis (CEA), and a cost-utility analysis (CUA).  All effects of an intervention are val-
ued in monetary units in a CBA.142 A CEA uses some non-monetary terms to measure
some effects.  This is particularly noted in valuation of life, which is measured in a non-
monetary unit of health outcome.  One difficulty described in using a CEA methodology
is that one is unable to compare interventions using different outcomes, such as life-year
saved, or cases of a disease prevented.   A CUA is considered by many to be a form of
CEA, in which effectiveness is measured as a preference-adjusted outcome, referred to as
a utility. The most common utility measurement used is the quality-adjusted life-year
(QALY), which allows for combining quantity and quality of life outcomes.143 Using util-
ity as an outcome, and therefore deriving a cost per quality-of-life ratio, helps to address
the problem of comparisons across different outcomes that arises with the use of CEAs.
3.3   Current Evaluations of Long-Range Cost-Effectiveness of T2DM Prevention
The following studies attempt to assess the long-range cost-effectiveness of the use 
141 Dhanani K. The neo-classical and extra-welfarist approaches to health. Available at:
http://www.econ.qmw.ac.uk/NHS_reforms.com/student_file/welfare4.1pdg. Accessed March 2004. 
142 Chrischilles EA. Ch. 5- Cost-Effectiveness Analysis. In: Bootman JL, Townsend RJ, McGhan
WF, eds. Principles of Pharmacoeconomics. Cincinnati: Harvey Whitney Books Company; 1996.
143  Coons SJ, Kaplan RM. Ch. 6- Cost-Utility Analysis. In: Bootman JL, Townsend RJ, McGhan
WF, eds. Principles of Pharmacoeconomics. Cincinnati: Harvey Whitney Books Company; 1996.
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of lifestyle intervention for prevention of T2DM.  Before examining these studies, it is
important to note the currently suggested limits for cost-effectiveness of a treatment used
in the U.S.  The U.S. Public Health Service has made no recommendation for a threshold
value for cost effectiveness,144 but a commonly cited value is $50,000 per QALY. 145, 146
Other guidelines suggest that a treatment is considered to be highly cost-effective at less
than $20,000 per life-year saved or $20,000 per QALY, moderately cost-effective in the
$20,000 to $40,000 range, and borderline cost-effectiveness in the $40,000 to $60,000
range.  These same guidelines suggest that treatment is considered expensive at values of
> $60,000 per life year saved or QALY.147
3.3.1   LONG-TERM PROJECTION IN THE U.S. USING DPP DATA
In an abstract presented at the 18th International Diabetes Federation Congress in
2003, Palmer et al. used a simulation model (a Markov model with Markov states of IGT,
T2DM, and death, an unknown perspective, and unknown Markov cycle) to calculate
costs per life-year gained over a patient’s lifetime comparing the three treatment arms of
the DPP: intensive lifestyle changes, metformin, or placebo.148 Table 3.1 gives the results
of the placebo and lifestyle comparisons.  The lifestyle intervention was considered "high-
ly cost-effective when judged by current international health economic standards."  The 
144 Barnett PG. Introduction to cost-effectiveness analysis. VA Health Service Research and
Development Center. Available at: http://www.herc.research.med.va.gov/CEM.htm. Accessed October
2004.
145  Ibid.
146  Owens DK. Interpretation of cost-effectiveness analyses. Journal of General Internal Medicine.
1998;13:716-717.
147  Gruninger U. Economic evaluation in health: a primer and/or a cheat sheet. Available at:
http://ourworld.compuserve.com/Homepages/Ulrich_Grueninger/AVAL_1.html. Accessed July 2004.
148 Palmer AJ, Roze S, Cabrieres L, et al. Long-term projection of the costs of the Diabetes
Prevention Program in the USA using the CORE diabetes prevention model: intensive lifestyle changes
and metformin are both cost-effective. Paper presented at: 18th International Diabetes Federation
Congress, 2003; Paris.
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authors state in the abstract that the outcomes were most sensitive to the following vari-
ables: the efficacy of the lifestyle intervention to prevent development of T2DM; the prob-
ability of developing T2DM in the placebo arm; the duration of the effect of the
interventions; the relative risk of mortality for the state of T2DM compared to IGT; and
the costs of the intervention program.
Table 3.1  Results of the Long-Term Projection of the Costs of the Diabetes 
Prevention Program by Palmer et al.a
a Palmer AJ, Roze S, Cabrieres L, et al.  Long-term projection of the costs of the diabetes prevention 
program in the USA using the CORE diabetes prevention model: intensive lifestyle changes and met-
formin are both cost-effective.  Paper presented at: 18th International Diabetes Federation Congress, 2003;
Paris.
3.3.2  LONG-TERM PROJECTIONS USING INTERNATIONAL DATA
Palmer et al. have also addressed the cost-effectiveness of implementing DPP-like
interventions in Australia, France, Germany, Switzerland, and the United Kingdom.149 A
three-state Markov model was again utilized (IGT, T2DM, and death), and direct-medical
costs were included.  Results showed an overall mean incremental improvement in life-
expectancy of 0.90 years for the lifestyle intervention.  The mean improvement in non-
discounted life expectancy was 0.22.  Cost savings were noted in all countries but the
United Kingdom. Outcomes of this model were most sensitive to the same variables
described in the Palmer et al. study presented in section 3.3.1: the efficacy of the lifestyle
149 Palmer AJ, Roze S, Valentine WJ, et al. Intensive lifestyle changes or metformin in patients with
impaired glucose tolerance: modeling the long-term health economic implications of the Diabetes
Prevention Program in Australia, France, Germany, Switzerland, and the United Kingdom. Clinical
Therapeutics. 2004;26:304-321.
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Treatment Arm Life-Expectancy in Years





Placebo 23.8 (16.5) 80,045 Comparator
Lifestyle 
Intervention 24.6 (16.9) 84,652 11,518
intervention to prevent development of T2DM; the probability of developing T2DM in the
placebo arm; the duration of the effect of the interventions; the relative risk of mortality
for the state of T2DM compared to IGT; and the costs of the intervention program.
3.3.3  EARLY COST-EFFECTIVENESS STUDIES OF DIABETES PREVENTION
Segal et al. evaluated the cost-effectiveness of multiple programs to prevent T2DM in
a paper published in 1998.150 Programs selected included intervention studies that were
of both randomized control and observational study design.  Table 3.2 describes the six
major program types that were analyzed.
Table 3.2  Programs Analyzed by Segal et al.a
a Segal L, Dalton A, Richardson J.  Cost-effectiveness of the primary prevention of non-insulin depend-
ent diabetes mellitus.  Health Promotion International.  1998; 13:197-209.
IGT, impaired glucose tolerance
Outcomes used for the study were reduction in diabetes years and life-years saved.
The authors stated they made no attempt to use QALYs as an outcome because the type-
of evidence required was not available.  This evidence would include utility scores for dia-
betes (preferably by disease stage), for obesity, and for successful and failed weight loss.  
150  Segal L, Dalton A, Richardson J. Cost-effectiveness of the primary prevention of non-insulin
dependent diabetes mellitus. Health Promotion International. 1998;13:197-209.
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Program Type Targeted Group
Intensive diet and behavioral modification Seriously obese                                                
With and without IGT
Intensive diet and behavioral modification Women with previous gestational diabetes      
IGT only
Surgery for severe obesity Seriously obese                                           
With and without IGT
Group behavioral modification for men Overweight and obese                                 
With and without IGT
General practitioner advice Obese                                                           
With and without IGT
Media campaign with community support General population
A five-year Markov-cycle model was developed for each program using the Markov states
of T2DM, IGT and NGT.  Transitions matrices were developed based on the results of the
studies evaluated.  Mortality vectors were derived for each program type, with one set of
vectors developed for those subjects who maintained weight loss, and a second set for
those who were either in the control group or were unsuccessful (both groups were
assumed to have the same morbidity and mortality outcomes).  
Potential downstream cost savings that were assumed to be generated secondary to
prevention of T2DM were incorporated into the model. The cost of diabetes in Australia
was estimated at A$1,800 per annum (A$ ~ US$1,340).  A discount rate of 5% per annum
was used for future benefits and costs.  
Due to the variability in types of programs analyzed, there were great fluctuations in
the life-years gained and reduction in diabetes years.  Both of the first two programs
described in Table 3.2 incorporated diet and behavioral modification, which are similar to
the DPP lifestyle intervention.  Costs of both of these programs are listed as A$2,500 (A$
~ US$1,860) and are apparently a one-time charge in the first five-year Markov cycle.
The intensive diet and behavioral modification program for the seriously obese (for the
IGT group) resulted in a gross cost per life-year saved of US$4,300, and a net cost per life-
year saved of US$1,900.  This study had a reduction of incidence of T2DM from 70% to
30%.  
Similar results were found for the intensive diet and behavioral program aimed at
women with previous gestational diabetes.  This program resulted in a gross cost per life-
year saved of US$3,300 in the IGT only group, and net cost per life-year saved of
US$1,700.  There was 50% reduced incidence of T2DM in this group.  At the time of this
study, the authors stated that all of the programs "fell well within community expectations
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of what constitutes reasonable cost to gain a year of life." 151
There were numerous limitations to this study.  The models were not particularly
dynamic, as a single transition matrix was used to progress the cohorts in each model
through the Markov states.  The authors also felt the downstream cost-savings value was
underestimated, in part due to the fact that "costs of managing other diseases, such as car-
diovascular, for which weight and physical activity are also risk factors," were excluded.152
3.3.4  SUMMARY
The primary question addressed in this dissertation, "Is primary prevention of T2DM
cost-effective on a long-term basis?" seems to be answered in the affirmative by the above
studies.  However, the studies also confirm the need for further research on the topic.
The Segal et al. study uses a very limited methodology.153 The Palmer et al. studies do
not incorporate NGT into the model.  Neither set of authors incorporate the effect of obe-
sity on costs, or mortality.  In addition, neither study attempted to incorporate utilities into
the evaluation. All of these limitations are addressed in this dissertation.
3.4  Current Economic Analyses of the DPP
The Diabetes Prevention Program Research Group (DPPRG) has published two eco-
nomic analyses based on the results of the DPP.  These studies include a cost-analysis of





vention and metformin treatment arms to each other and to the placebo group.154,155 A
detailed description follows.
3.4.1  A COST-ANALYSIS OF THE DPP
In January 2003, a cost analysis of the DPP was published by the DPPRG.156 The
details of the intervention and results are discussed in Section 2.3.3.  The costs include
those for the intervention, direct medical costs, direct non-medical costs, and indirect
costs, and are adjusted to year 2000 U.S. dollars using the Consumer Price Index and the
Medical Consumer Price Index.157 The research component of the study was omitted,
which included the costs of recruitment, data collection, and surveillance.  Direct medical
costs included screening, the actual intervention, and care outside of the DPP.  These costs
were those "usually paid by health systems."158 A description of these costs, which will
be incorporated into the model used in this dissertation follows.
3.4.1.1  Screening
Screening was performed using an OGTT.  The authors "estimated the direct medical
cost of identifying one subject with IGT as the number of OGTTs performed to success-
154 Diabetes Prevention Program Research Group. Costs associated with the primary prevention of
type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36-47.
155  Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle interven-
tion or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
156  Diabetes Prevention Program Research Group. Costs associated with the primary prevention of
type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36-47.
157  Labor Statistics Data. Consumer Price Index: Medical Care Services. U.S. Bureau of Labor
Statistics. Accessed April 2004.
158  Diabetes Prevention Program Research Group. Costs associated with the primary prevention of
type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36-47.
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fully identify one randomized participant times the unit cost of the OGTT."159 The direct
medical cost of an OGTT was estimated at $17, and 8.1 OGTTs were required to identify
a subject for successful randomization.  The value used for the direct medical cost of
OGTT per subject randomized was $139.
3.4.1.2  Cost of the Intervention
The lifestyle intervention, a sixteen-lesson curriculum including diet, exercise and
behavioral modification, was given to each subject one-on-one over the first twenty-four
weeks of the study.  The subjects then continued to meet with counselors, either individ-
ually or in groups on a monthly basis.  The intervention was most intensive in year one
and was calculated to be $1,399 for this period. The cost of staffing for this year was $750
(54%).  Year two cost was calculated to be $679, with staffing cost calculated to be $339
(50%).  Year three cost was calculated to be $702, with staffing calculated at $337 (48%).
The total cost of the intervention for three years was $2,780, which includes the cost of
screening.  The placebo group received what was described as standard lifestyle recom-
mendations.    The cost in year one for this arm was $43, and in year two and three was
$18, for a total of $79.  The cost rises to $218 for the three-year period when screening is
included.
3.4.1.3  Cost of Care Outside of the DPP
The final component of direct medical costs was those costs that were "incurred or
averted by the interventions that were captured by costs of medical care outside the




there was a significantly different rate of adverse musculoskeletal symptoms between the
lifestyle group and the placebo group (see Section 2.3.3), the cost analysis of the report
states that "there were no statistically significant differences in the incidence of serious
adverse events or adverse events among the three intervention groups." 161
The DPPRG used cost estimates for the following variables to calculate the direct
costs of medical care outside of the DPP: hospital days; emergency room visits; urgent
care visits; outpatient visits; calls to providers; and prescription medications (for medica-
tions outside of the DPP).  The report does not indicate if these costs are secondary to
adverse events related to the intervention, costs related directly to IGT or T2DM, or costs
secondary to a health condition unrelated to either of the above.  Interestingly, the authors
state that costs of treatment for evaluations such as the exercise stress tests that were
required in 19% of the lifestyle intervention subjects were "captured as adverse events."
This was based on a pre-design requirement that participants who experienced new
episodes of cardiovascular symptoms/events were eligible to continue DPP intervention
except for those in the lifestyle arm.  Cardiac risk in these subjects was designed to be
evaluated by exercise testing in order to modify the exercise program if necessary.  
The per capita direct medical costs over the three-year period were $5,011
($1,670/year) for the placebo group and $4,579 ($1,526/year) for the lifestyle group (a
9.4% difference).  Resource utilization was lower in five of the six categories evaluated
for the lifestyle group (costs for emergency room visits were higher for the lifestyle group
than for the placebo group).  
3.4.1.4  Summary – How Useful is the DPP Data?
The authors state that "the per capita costs of the lifestyle intervention relative to
161  Ibid.
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the placebo intervention were $2,269 over three years from the perspective of a large
health system."162 Conclusions drawn from the analyses suggested that most of this addi-
tional cost was secondary to "staff time used for counseling and adherence monitoring."163
This information provides a very useful starting point for a value to include for the cost of
an intensive lifestyle intervention in the dissertation model.  
The calculated per capita direct medical costs of care outside of the DPP, while in an
excellent format for a standard decision-tree model, are problematic for use in a Markov
model format.  The main difficulties in using these data are that a control group (non-IGT)
value of health care is not given, and there is no differentiation between the costs of
patients in each group who develop T2DM versus those who do not.  These difficulties
will be discussed in following sections that cover cost of illness of these states.
3.4.2  THE WITHIN-TRIAL COST-EFFECTIVENESS DPP ANALYSIS
3.4.2.1  Model Design
The cost-analyses provided by the above study allowed the DPPRG to perform a with-
in-trial cost-effectiveness of the lifestyle intervention versus placebo for prevention of
T2DM.164 A decision-analysis model was utilized using the three-year study period.  The
analyses were run using two perspectives: the perspective of the health system and a soci-
etal perspective.  Costs were adjusted to year 2000 U.S. dollars.  The analyses were per-
formed both undiscounted and using a discount rate of 3% for costs and benefits.  
Outcomes used were cases of diabetes prevented and QALYs.  Analyses using the
health system perspective included only direct medical costs.  Analyses from a societal 
162  Ibid.
163 Ibid.
164 Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle inter-
vention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
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perspective for cost per case of diabetes prevented included direct medical costs, direct
nonmedical costs, and indirect costs.  The societal perspective analyses of cost per QALY
gained included direct medical and nonmedical costs. 
3.4.2.2  Health Utilities
Health utilities were measured using the Self-Administered Quality of Well-Being
Index.  This quality of life instrument was administered annually.  Table 3.3 gives the
annual utility scores obtained for the lifestyle group and the placebo group.  
Table 3.3  Utility Scores of the Diabetes Prevention Programa
a The Diabetes Prevention Program Research Group.  Within-trial cost-effectiveness of lifestyle interven-
tion or Metformin for the Primary Prevention of Type 2 Diabetes.  Diabetes Care. 2003;26:2518-2523.  
There were three deaths in the lifestyle group (1.023 deaths per 1,000 person-years)
and five deaths in the placebo group (1.689 deaths per 1,000 person-years).  Over the
three-year period, the total QALYs gained in the lifestyle group versus the placebo group
was 0.072.  
3.4.2.3  Results 
Results from the health system perspective will be emphasized, as that is the proposed
perspective of the Markov model to be used in this dissertation.
Based on a number needed to treat of 6.9 participants to prevent one case of diabetes,




1 0.703 ± 0.118 0.686 ± 0.121
2 0.695 ± 0.122 0.675 ± 0.122
3 0.692 ± 0.125 0.657 ± 0.125
Utility Scores
was $15,655.  The cost per QALY gained from the health system perspective was $31,512.
The following sensitivity analyses were performed: reducing personnel cost from 75%
to 25%; reducing intervention effectiveness from 20% to 10%; translating the intervention
from an individual counseling format to a group counseling format; and comparing dis-
counting costs and outcomes at 3% versus no discounting.  These results are given in
Table 3.4, and will help as a guide for sensitivity analyses required for the dissertation.
Table 3.4  Baseline Results and Sensitivity Analyses of the Cost of the Diabetes 
Prevention Program per Case of Diabetes Prevented and Quality of Life 
Year (QALY) Gained from a Health System Perspective a
a The Diabetes Prevention Program Research Group.  Within-trial cost-effectiveness of lifestyle interven-
tion or Metformin for the Primary Prevention of Type 2 Diabetes.  Diabetes Care. 2003;26:2518-2523. 
3.4.2.4  Summary
The DPPRG suggests that an intensive lifestyle intervention to delay or prevent T2DM
is cost-effective from a health system perspective. Cost savings could potentially occur in
each of the following direct medical cost categories: diabetes education; nutritional coun-
seling; glucose monitoring; treatment; surveillance of complications; and treatment of 
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Variable
Cost per Case of Diabetes 
Prevented (U.S $)
Cost per QALY Gained 
(U.S. $)
Lifestyle vs. Placebo 15,655 31,512
Personnel Cost
   25% Reduction 11,755 23,662
   50% Reduction 7,855 15,811
   75% Reduction 3,956 7,963
   Group Intervention 4,462 8,982
Intervention Effectiveness
   10% Reduction 17,243 35,013
   20% Reduction 18,831 39,389
Discounting
   3% Discount Rate 15,804 32,029
complications.165 The authors then reiterate the need for estimating the long-term cost-
effectiveness effects of intensive lifestyle intervention to prevent or delay T2DM using
modeling beyond the time horizon of the DPP itself.
3.4.3 SUMMARY OF THE ECONOMIC ANALYSES OF THE DIABETES 
PREVENTION PROGRAM
A summary of the economic analyses developed by the DPPRG is valuable as a prepa-
ration for creating a Markov model to estimate the long-term effects of a lifestyle program
to prevent T2DM.  The modeler is able to identify data for variables that may be impor-
tant to include in the dissertation model.  A discussion of additional variables needed for
a long-term Markov model follows.
3.5 The Numerator of a Diabetes Prevention Cost-Effectiveness 
Model: Cost-of-Illness (COI)
Collecting the information required to construct a Markov model can be thought of as
"building a database."  To model the numerator of a cost-effectiveness analysis beyond the
time horizon of the DPP, numerous variables are required.  These will first include ana-
lyzing the excess costs of IGT and T2DM.  In addition, simply using these long-term
excess costs of abnormal glucose homeostasis may not address the entire direct healthcare
cost requirements of the models, as they may not include additional costs due to the obese
nature of the cohort. Therefore, the long-term excess cost of obesity in relation to abnor-
mal glucose homeostasis will also be addressed.  
Subjects in the dissertation model also fall into the category of NGT.  Costs involved
with this population may be viewed in two possible ways.  Traditionally, patients in this
"normal" category are given no costs for health care outside of that for the intervention 
165  Ibid.
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because they are the control group to which the diabetic population is compared.  
Another view, which will also be used in this model is to incorporate the fact that this
NGT population is also a population with an average BMI of ≥ 30 kg/m2.  The average
BMI of the DPP subject at the start of the study was 34 kg/m2, a value that falls into the
WHO category of obese class I (BMI values of 30 kg/m2 to 34.9 kg/m2).  The 7% weight
loss goal places this average patient in a BMI category of 31 kg/m2, which still falls into
this obesity category.  Current literature supports the possibility that there may be an
excess cost of medical care in these obese NGT patients; therefore, these excess costs
should be incorporated into the model.  The literature review will therefore also address
the costs of obesity in subjects with NGT.
The perspective of this dissertation is that of the health care provider, so the values
emphasized in the discussion will be direct medical costs and in particular, those used in
the DPP.  These include hospital days, emergency room visits, urgent care visits, outpa-
tient visits, calls to providers, and prescription medications.  All pertinent cost variables
will be translated when possible into year 2000 dollars using the medical portion of the
Consumer Price Index. 166
This section of the dissertation will help to address the difficulty of using the cost of
care that was presented in Section 3.4.1.4, the summary of the usefulness of the DPP data.
As noted in Section 3.4.1.3 (Cost of Care Outside of the Diabetes Prevention Program),
cost of care outside of the DPP is given for the placebo group and the intensive lifestyle
intervention group.  The values derived are a combined cost for all subjects in each cohort:
those with NGT, those with IGT, and those with T2DM. For a Markov model approach, it
may be more efficacious to determine these data separately for each category (NGT, IGT, 
166  Labor Statistics Data. Consumer Price Index: Medical Care Services. U.S. Bureau of Labor
Statistics. Accessed April 2004.
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and T2DM) than in these combined states.  In addition, figures for cost of medical care
for a control group without abnormal glucose status will be examined. 
3.5.1   HOW TO ASSESS COI OF A SPECIFIC DISEASE
Analyses that quantify the long-range economic impact of a disease are commonly
called "cost-of-illness" (COI) studies.  The primary component of COI of a disease is costs
that are reported when the disease is listed as the primary diagnosis. Additional costs must
be included such as those that are related to chronic complications from the disease and
costs secondary to related comorbid conditions that have increased health care utiliza-
tion.167 The four basic methodologies to assess COI as described by Ettaro et al. will now
be discussed as well as some of the methodological approaches to capturing the addition-
al costs listed. 168
3.5.1.1  COI Based on Aggregated Population Data
One common method of assessing COI is to study aggregated population data based
on international classification of disease (ICD) codes related to the illness in question.
Early in the use of this methodology, the only costs analyzed were those that were direct-
ly attributed to a disease.  Therefore, the cost could not be included unless the disease in
question was listed as the primary diagnosis.  In the 1980s, the methodology began to
change to incorporate disease events that were recorded with the disease being analyzed
listed as a secondary or tertiary diagnosis.  The addition of these costs was performed to
address potential underestimation when calculating COI.  One example of the type of 
167  Hodgson TA, Cohen AJ. Medical care expenditures for diabetes, its chronic complications, and
its comorbidities. Preventive Medicine. 1999;29:173-186.
168  Ettaro L, Songer TJ, Zhang P, et al. Cost-of-illness studies in diabetes mellitus.
Pharmacoeconomics. 2004;22:149-164.
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problem that was frequently encountered when assessing COI of T2DM was the exclusion
of costs of complications such as retinopathy or end-stage renal disease from an analysis
because the diabetes diagnosis would be listed as a second or third diagnosis, or com-
monly, not at all.
Another method to address underestimation of costs using this methodology is to use
the concept of attributable risk (AR) in the analysis.  In the case of diabetes, AR seeks to
identify "the relative contribution of diabetes to the overall risk of a disorder such as heart
disease or renal failure."169 AR can be considered from the perspective of the general pop-
ulation or from the diseased population.  Using the general population perspective may
underestimate risk, but disease-specific AR rates are often not readily available.  One
problem that occurs when using AR in a COI study is that confounders present in the
analysis may lead to overstatement of the role of the disease. 
3.5.1.2  The Survey Approach to COI
Self-reported surveys are another method to analyze COI.  This methodology allows
for an analysis on an individual level instead of an aggregate level, and is therefore, con-
sidered to be more precise.  The downside of this precision is that it is more expensive,
and is often based on limited sample sizes.  Sampling variability due to small sample size
may influence results.
3.5.1.3  Analyzing Excess Medical Costs of the Disease in Question
Ettaro et al. define excess medical costs as "the incremental difference in medical




This methodology is quite helpful in an analysis of treatment interventions because the
technique allows for an estimation of costs avoided.  Most of the data that have been used
for this methodology are derived from large administrative data sets or national medical
expenditure surveys.  There are two general approaches to assessing excess costs.  The
first method is to compute the difference without an attempt to match population charac-
teristics.  The second technique allows for case-control matching.  
3.5.1.4  COI Analyses Based on Estimates of Previous Studies
Modeling techniques based on previous estimates of prevalence, healthcare use, and
mortality are used in this methodology to estimate COI.  The primary limitation of these
analyses is that the changes in the cost of the disease in question may not depend, or only
depend in part on the variables that are included in the model.  Unlike changes in preva-
lence in a disease or secondary to inflation, the studies show that one variable that is not
easily controlled for is a change in quantity or quality in health care practice related to the
disease in question.
3.5.2  AN ANALYSIS OF DIABETES COI STUDIES 
The following section includes a review of pertinent studies that will be used in the
dissertation model to analyze the COI of diabetes.  
3.5.2.1  COI Collected before 1998 171
In 2004, Ettaro et al. published a review article that analyzed the COI studies of dia-




of diabetes (of all diagnostic categories) in the U.S. was $2.6 billion in 1969,173 and rose
to $98.2 billion by 1997.174 Significant increases in costs were attributed to changes in
diabetes prevalence and inflation.  Another source of increased costs was the change in
methodology of calculating COI to allow for inclusion of costs related to diabetes when
the disease is listed as a secondary or tertiary diagnosis.  An interesting way to evaluate
the changes in COI of diabetes over the time period evaluated is to examine the ADA
reports from 1987,175 1992176 and 1997177 on this topic.
3.5.2.1.1  A Comparison of the ADA COI Studies from 1987, 1992, and 1997
Ettaro et al. compared the ADA studies of the COI of diabetes from 1987 to 1997 in their
review.  These studies estimate COI of diabetes of all diagnostic categories, and not just
T2DM.  These studies all used aggregated data and attributable risk procedures.   The COI
direct medical cost reported values adjusted for inflation in 1997, and the values adjusted
for inflation and diabetes prevalence in 1997 are reported in Table 3.5.  The adjustment
for inflation, as calculated by the authors of the study, used the change in gross domestic
product deflator over time, and did not use the specific medical Consumer Price Index.
173 Entamacher PS. Report of economic impact of diabetes. Washington, DC: US Government
Printing Office; 1976. NIH Publication No. 76-1022.
174  American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997.
Diabetes Care. 1998;21:296-309.
175  Pracon Inc. Direct and indirect costs of diabetes in the United States in 1987. Alexandria (VA):
American Diabetes Association; 1988.
176  American Diabetes Association. Direct and indirect costs of diabetes in the United States in
1992. Alexandria (VA): American Diabetes Association; 1993.
177  American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997.
Diabetes Care. 1998;21:296-309.
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Table 3.5 A Comparison of American Diabetes Studies of the Direct Cost of Illness 
of  Diabetes from 1987, 1992 and 1997 a
a Ettaro L, Songer TJ, Zhang P, et al.  Cost-of-illness studies in diabetes mellitus.  Pharmacoeconomics.
2004;22:149-64.
b Inflation adjustment using the gross domestic product deflator over time
3.5.2.1.1.1  Comparison of the 1987 ADA Study to the 1992 Study
At least part of the differences in direct costs which are noted when comparing the
ADA studies of 1987 to 1992 is thought to be related to the large increase in costs calcu-
lated for hospital services during this period.178 One factor contributing to the overall
increase was the increase in the cost of a hospital day increased by approximately three
times, from $572 to $1,706.179 Another factor was the increase in the total number of hos-
pital days related to diabetes during this period from 11.5 million to 20.2 million.180 This
large increase in hospital days may be secondary to increased diabetes prevalence or
changes in practice patterns.  Ettaro et al. suggested that the most important reasons for
the increase was the inclusion of diabetes as a secondary diagnosis in the methodology
used for cost collection.  (See Section 3.5.1.1)
3.5.2.1.1.2  Comparison of the 1992 ADA Study to the 1997 ADA Study
Direct medical costs of diabetes declined from 1992 to 1997 using reported and 










Inflation ($ Billion; 
1997 Valuesb)
Adjusted for Inflation 
and Diabetes Prevalence   
($ Billion; 1997 values b)
1987 9.60 13.05 20.24
1992 45.22 50.98 70.80
1997 44.14 44.14 44.14
adjusted data.181 This decline was thought to be secondary to a decrease in inpatient hos-
pital days from 20.2 million to 13 million.  Ettaro et al. felt that at least part of this decline
was due to the overall decrease in hospital admissions for all causes over this time peri-
od, as healthcare payers were seeking methods to contain costs by lowering inpatient hos-
pital treatment. 182
There was also a difference in methodology between these two studies.  The 1992
study used disease-specific ARs, while the 1997 study used general population ARs
(which is thought to underestimate risk).  A second methodological change that occurred
in 1997 was performed in an attempt to correct for the underestimation of secondary costs
of diabetes due to the fact that the diagnosis of diabetes is often not reported in patient
encounters that are related to complications of the disease.  In the 1992 ADA study, costs
from complications of diabetes were collected by using secondary diagnosis codes to
identify healthcare utilization.  In the 1997 study, primary diagnosis codes were combined
with a population AR coefficient to reflect utilization assumed to be due to diabetes to in
order to capture healthcare utilization secondary to diabetes complications.
3.5.2.1.2  Additional Studies of Interest using Data Collected Prior to 1998
The direct medical costs of diabetes changed dramatically over the 10-year period
from 1987 to 1997.  The ADA studies suggest that hospital use attributed to diabetes
showed dramatic shifts in both positive and negative directions during the period.  Any
value calculated for COI using data from this period must take these changes in utiliza-
tion into consideration.  Other changes noted during the 10-year period include those sec-




methodology used to calculate COI, as well as changes secondary to diabetes prevalence.
In order to place the most accurate values for COI of T2DM in the dissertation model, all
of these variables must be taken into account for both the initial cost periods, and all pro-
jected time periods.  
The following section contains short summaries of pertinent articles published with
data collected prior to 1998 that include COI data that may be helpful for the model.
These studies are included because data were collected in a time period similar to that of
the DPP, and similar direct medical costs were analyzed. Important cost variables will be
translated to year 2000 U.S. dollars when possible by use of the medical portion of the
Consumer Price Index.  
Of note, the first two of the articles summarized are analyzed using data collected by
the Kaiser Permanente health maintenance organization (HMO) system.  Kaiser
Permanente has been instrumental in collecting data on COI of diabetes, and also in
improving the methodology for calculations of COI.  The authors of the studies note that
their results are probably underestimations of those in most other health care settings due
to the probable lower cost of care provided in the Kaiser Permanente HMO setting.183
They suggest using the ratio of total costs to control costs to compare their findings to
those of other health care settings.
3.5.2.1.2.1  Excess Costs of Medical Care for Diabetes in the Kaiser Permanente System
A study by Selby et al. utilizes a case-controlled matching design of costs collected in
1994 to study excess costs of diabetes in the Kaiser Permanente system of Northern
183  Brown JB, Nichols GA, Glauber HS, et al. Type 2 diabetes: incremental medical care costs dur-
ing the first 8 years after diagnosis. Diabetes Care. 1999;22:1116-1124.
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California.184 Acute and long-term complications of diabetes were identified, and an
excess cost of $3,494 ($4,353 in 2000 dollar values) per age and sex-matched control was
determined, which translates into a ratio of 2.4 for total costs to control costs for the dia-
betes group versus the control group.  The largest proportion of excess costs was for hos-
pitalizations (38%).  This may reflect that these data were collected in the transition period
prior to a decrease in use of inpatient hospital services.  
3.5.2.1.2.2  Incremental Costs of T2DM in the First Eight Years after Diagnosis
A study by Brown et al. conducted at the Kaiser Permanente Northwest Division of
Portland, Oregon analyzed the incremental cost change that occurred in patients from the
time of diagnosis through the next eight-year period for patients with T2DM.185 The peri-
od studied was 1988 to 1995.  A matched-control design by sex and age was used.  The
average age at the year of diagnosis was 59.6 years.  Values were adjusted to 1993 dollars
using the U.S. medical price index, and a medical care insurer perspective was used.  The
direct costs utilized were for inpatient costs, outpatient costs, and pharmacy costs (includ-
ing supplies).  
These data were collected in the ten-year time period prior to the DPP, so it may not
fully reflect an accurate value of excess COI.  On the other hand, it serves as a check for
the value that is finally determined for the model.  It also allows for an analysis of the lon-
gitudinal trend in cost changes secondary to T2DM.  In addition, the early years of T2DM
may help in evaluation of COI of IGT.
184 Selby JV, Ray GT, Zhang D, et al. Excess costs of medical care for patients with diabetes in a
managed care population. Diabetes Care. 1997;20:1396-1402.
185 Brown JB, Nichols GA, Glauber HS, et al. Type 2 diabetes: incremental medical care costs dur-
ing the first 8 years after diagnosis. Diabetes Care. 1999;22:1116-1124.
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Table 3.6 has been constructed from data collected in this study to further aid in build-
ing COI variables for the dissertation model.  Total mean direct costs, mean excess direct
costs, and control costs, adjusted to year 2000 dollars, are given with the ratio of total
costs to control costs for subdivided periods of years 1 to 3, years 4 to 6, and years 7 to 8.
These periods were chosen to approximate the three-year time cycle used in the DPP eco-
nomic analyses.
Table 3.6 Direct Medical Costs per Person and Type of Cost in Years 1
through 8 after T2DM Diagnosis a
a Brown JB, Nichols GA, Glauber HS, et al.  Type 2 diabetes: incremental medical care costs during the
first 8 years after diagnosis.  Diabetes Care. 1999;22:1116-24.
b Adjusted to year 2000 dollars from 1993 dollars using the medical component of the Consumer Price
Index  
T2DM, type 2 diabetes mellitus
Total costs for subjects with diabetes were approximately double that of the matched
control group. The largest contributors to direct costs were hospitalizations (46%).
Pharmaceutical expenditures contributed 28% and outpatient costs contributed 26%.
3.5.2.1.3 Summary of Studies with Data Collected Prior to 1998
Summarizing the pertinent articles published with data collected prior to 1998 allows
for preliminary estimates of COI of diabetes values and ranges to use in the sensitivity





Control Costs  
($)b
Ratio of Total 




1 to 3 5,293 2,568 3,355 1.57
4 to 6 5,512 2,877 2,635 2.09
7 to 8 6,044 3,333 3,169 1.91
Average 5,563 2,875 2,688 2.07
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excess costs of T2DM for the dissertation model. With these preliminary data, more recent
publications will now be examined and discussed. 
3.5.2.2  Studies Published with Data Collected from 1998 to Present
A Pub Med literature search was performed using the Ettaro et al. study186 as a refer-
ence.  This article was chosen due to its 2004 publication date and the fact that the authors
reviewed all articles that had data collected prior to 1998.  The two major studies that ana-
lyze U.S. data on COI of diabetes after 1998 are now discussed. 
3.5.2.2.1   The 2002 ADA COI Study
The ADA published a fourth COI of diabetes study using 2002 estimates in 2003.187
The authors estimated that total costs of diabetes in 2002 were $132 billion, and total
direct costs were $92 billion. The 1997 respective costs were $98.2 billion and $44.1 bil-
lion.  The large increase in costs is thought to be due to both increased prevalence and
increased costs of health care services.
The methodology used in the study is similar to that of the previous ADA studies.  The
authors use an estimate of 12.1 million people in the U.S. with diabetes in 2002 (versus
12 million in 2000).  Prevalence rates by demographic group were projected onto the 2000
Census values.  These CDC-derived prevalence rates for these 12.1 million people with
diabetes by age group in 2000 were 18% for age 44 years and under, 43% for ages 45 to
64 years, 23% for ages 65 to 74 years, and 16% for ages 75 years and older.188
186  Ettaro L, Songer TJ, Zhang P, et al. Cost-of-illness studies in diabetes mellitus.
Pharmacoeconomics. 2004;22:149-164.
187  American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care.
2003;26:917-932.
188 Centers for Disease Control and Prevention. Prevalence of Diabetes and Impaired Fasting
Glucose in Adults - United States, 1999-2000. Morbidity and Mortality Weekly Report. 2003;52:833-837.
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Multiple sources of data were required to gather all of the information needed to derive
the cost estimates.  The authors combined the years of 1998 to 2000 for some data sources
to increase the sample size.  To calculate AR, odds ratios derived from Medical
Expenditure Panel Survey (MEPS) data were combined with National Health Information
Service (NHIS) prevalence data.  Etiological fractions, adjusted for race, sex and age
group were calculated for the following disease categories: neurological disease; periph-
eral vascular disease; cerebrovascular disease; renal disease; endocrine disease; oph-
thalmic disease; general medical conditions; and other medical conditions.
The authors defined health care expenditures attributable to diabetes as "those costs
incurred by the population with diabetes above what would be expected if this population
did not have diabetes."189 Table 3.7 presents a summary of health care expenditures attrib-
utable to diabetes by age in 2002.  The health care costs included are hospital inpatient
days, office-based physician encounters, emergency department encounters, hospital out-
patient and free-standing ambulatory surgical center encounters, outpatient medications,
oral agents, and insulin delivery supplies.  For the purpose of the dissertation model, these
values are presented in year 2000 dollars.
Table 3.7 Excess Health Care Expenditures for Diabetes in the U.S. by Age in 2002 
Adjusted to Year 2000 Dollars a,b
a American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care.2003;26:917-
932.
b Adjusted to year 2000 dollars using medical component of the Consumer Price Index
c Using a control cost of $3,968







Ratio of Total 
Costs to Control 
Costs
Age
Less than 45 Years 8,050 4,082 2.03
45 to 64 Years 8,379 4,411 2.11
Greater than or equal 65 years 11,212 7,244 2.83
Average 9,424 5,456 2.38
The total per capita health care expenditure for people with diabetes in this study is
$9,424 (year 2000 dollar adjustment) using the above health care cost inclusions.  The
value calculated for total annual per capita expenditure for health care for people without
diabetes is $3,968 (year 2000 dollar adjustment), and is age-adjusted to control for demo-
graphic differences between the populations with and without diabetes.  The ratio of total
costs to control costs for patients aged < 65 years is consistent with that derived in the
Brown et al. study in the eight years following diagnosis of T2DM with a range from 1.57
to 2.09 (Section 3.5.2.1.2.2)190 The increased ratio of 2.83 at an age of ≥ 65 years may be
helpful to include in the dissertation model to adjust for increased direct medical care
costs due to T2DM with age.
3.5.2.2.2 A Final Check Value: Diabetes in a Large Employer Population
A final paper by Ramsey et al. is included in the summary of publications with data
collected after 1998 as a check value.191 The authors used a large claims database for the
purpose of assessing the economic burden of diabetes from an employer’s perspective.
Claims were collected between 1996 and 1998.  Subjects with and without diabetes were
matched by age, sex, job, health plan, and location (by state) to determine excess health
care costs of having the condition.  The mean age of the diabetic population was 53 years,
and the prevalence of diabetes was 3.5%.  Forty-four percent of the subjects were female.
Diabetics in this study, as in all of the previously described, were more likely to use
all types of services and to have more utilization of these services.  As with the other serv-
ices, cost increased with age.  Table 3.8 gives the total direct costs for diabetics, non-
190  Brown JB, Nichols GA, Glauber HS, et al. Type 2 diabetes: incremental medical care costs dur-
ing the first 8 years after diagnosis. Diabetes Care. 1999;22:1116-1124.
191  Ramsey S, Summers K, Leong SA, et al. Productivity and medical costs of diabetes in a large
employer population. Diabetes Care. 2002;25:23-29.
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diabetics, excess costs, and percent of excess in year 2000 adjusted values.
Table 3.8 Total Direct Medical Costs for Diabetics and Controls in a Large
Employed Population a
a Ramsey S, Summers K, Leong SA, et al.  Productivity and medical costs of diabetes in a large employ-
er population. Diabetes Care. 2002;25:23-29.
b Adjusted to year 2000 dollars using the medical component of the Consumer Price Index
n, Sample size
3.5.2.2.3  Summary of COI of Diabetes
The articles summarized are helpful for the dissertation in many ways.  It becomes
apparent that total COI of T2DM can be addressed in the model as a multiplier of a con-
trol COI.  This multiplier (the ratio of total costs to control costs) appears to be in a range
from approximately 2.03 to 2.83 if the low value of 1.57 from the Brown et al. study192
that is calculated using values from years one to three after the diagnosis of T2DM
(Section 3.5.2.1.2.2) is eliminated.  It may be that this low value is more consistent with
excess COI values that will now be examined for IGT.
192 Brown JB, Nichols GA, Glauber HS, et al. Type 2 diabetes: incremental medical care costs dur-












46 to 55 Years 
(n=3,292)
6,426 2,446 3,980 2.63
56 to 64 Years 
(n=3,762)
8,071 3,432 4,639 2.35
Mean Payment per 
Person ($)b
3.5.3  THE COST OF ILLNESS OF IGT
The "database" for use in the Markov model is slowly being constructed, but is far
from complete.  The next section of the dissertation takes us back to the fact that our pop-
ulation does not start in NGT or as a type 2 diabetic, but in the state of IGT.  The addi-
tional problem that has been alluded to is that the cost data given for health care from the
DPP were given for a combined subject group that has NGT, IGT and T2DM.  These val-
ues cannot be "plugged" into the model without extracting the costs for the three groups
separately.  Finally, it is important to determine if the outside, direct health care costs
given by the DPP (over and above that for the intervention) are similar to what was seen
in the U.S. during the general time period of the study.  This evaluation may be warrant-
ed because the intervention costs are thought to be more expensive than what would be
seen in a clinical setting, and the same may be true for the care outside of the DPP.  This
section of the dissertation will begin to answer these questions by starting with an analy-
sis of the COI of IGT.
3.5.3.1 Does IGT Have a COI, and if so, Why?
The DPP states that the per capita direct medical costs over the three-year period of
the study were $5,011 for the placebo group and $4,579 for the lifestyle group.  Do these
values differ from those that would be found in a group of subjects with an average age
of 50.9 years and an average BMI of 34 kg/m2 who do not have IGT?  In other words, do
we need to calculate an excess cost of IGT to place into the Markov model?
Multiple studies have suggested that there is an increased risk of cardiovascular dis-
ease, stroke, and large-vessel occlusive disease in subjects with IGT. 193, 194, 195 While it
193  Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individ-
uals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? Journal of the
American Medical Association. 1990;263:2893-2898.
194  Meigs JB, Nathan DM, D'Agostino RB, et al. Fasting and postchallenge glycemia and cardiovascular
disease risk: the Framingham Offspring Study. Diabetes Care. 2002;25:1845-1850.
195  The DECODE Study Group. Glucose tolerance and cardiovascular mortality. Archives of Internal
Medicine. 2001;161:397-404. 72
is out of the realm of this dissertation to discuss the pathophysiologic mechanisms for this
increased risk, some proposed mechanisms of action include increased insulin resistance,
or increases in other inflammatory substances such as fibrinogen or C-reactive protein.196
In addition, patients with IGT are commonly found to be more obese, and have abnor-
malities of triglycerides, HDL cholesterol, and blood pressure, which may all lead to
increased macrovascular risk.
Microvascular complications are also associated with IGT.  These include retinopathy,
neuropathy, and renal microproteinuria.197 It has been suggested that the microvascular
changes noted in patients with IGT may be more difficult to reverse with lifestyle inter-
vention than the macrovascular reactive changes.198
Current literature suggests there is an excess health care risk associated with IGT, and
therefore a subsequent excess cost.  The next section of this chapter will discuss the cal-
culation of this excess COI of IGT.
3.5.3.2 An Analysis of the Literature of COI of IGT
A MEDLINE search on the subject of COI of IGT gives no results for any economic
analysis on this topic.  The following paper by Nichols et al. gives some direction toward
calculating a value of COI of IGT for the model.  The information obtained from these
studies will be examined in conjunction with the previous studies on COI of diabetes and
the costs generated by the DPP to help derive a value for the COI of IGT.
196  Haffner SM. Pre-diabetes, insulin resistance, inflammation, and CVD risk. Diabetes Research
and Clinical Practice. 2003;61:S9-S18.




3.5.3.2.1 Incremental Medical Care Costs in the Eight Years Preceding T2DM Diagnosis 
The Kaiser Permanente System Northwest Division expanded their COI of T2DM by
evaluating the medical cost of patients who were ultimately to receive the diagnosis of
T2DM in the eight years prior to diagnosis.199 These data may be the closest approxima-
tion that can currently be made for a value for COI of IGT.  Patients in this study were
newly diagnosed in the years between 1995 and 1998.  Excess costs were determined
using a matched-control design.  Patients were matched for year of birth, sex, and dura-
tion of health plan coverage.  Values were adjusted to 1998 dollars using the medical com-
ponent of the U.S. Consumer Price Index.  The perspective was that of the medical insurer.
The average age in the year prior to diagnosis was 60.1 years.
Table 3.9 gives the results of the data derived in this study in year 2000 dollars.  These
data have again been grouped to facilitate incorporation into the dissertation model.  Years
8 to 6 prior to diagnosis correspond to an average age of 53 years to 55 years.  Years 5 to
3 prior to diagnosis correspond to an average age of 56 years to 58 years.  Years 2 and 1
prior to diagnosis correspond to an average age of 59 years and 60 years.  
199  Nichols GA, Glauber HS, Brown JB. Type 2 diabetes: incremental medical care costs during the
8 years preceding diagnosis. Diabetes Care. 2000;23:1654-1659.
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Table 3.9 Direct Medical Costs per Person and Type of Cost in Years 1
through 8 Prior to T2DM Diagnosis a
a Nichols GA, Glauber HS, Brown JB. Type 2 diabetes: incremental medical care costs during the 8 years
preceding diagnosis.  Diabetes Care. 2000;23:1654-1659.
b Adjusted to year 2000 dollars from 1993 dollars using the medical component of the Consumer Price
Index  
T2DM, type 2 diabetes mellitus
Medical costs for prediabetic patients exceeded those of the control group for all years,
and these excess costs were substantial in the seven years prior to diagnosis.  The average
ratio of total costs to control costs was 1.48 and this ratio increased in the years immedi-
ately preceding the diagnosis of T2DM.
The largest difference in costs was noted in the two-year period prior to diagnosis of
T2DM.  The main driver of this cost increase was inpatient costs.  The authors also state
that "expenditures to prevent cardiovascular disease prominently contributed to health
care costs in the years leading up to recognition of type 2 diabetes," which is consistent
with the literature examined about morbidity secondary to IGT.
Of interest for this dissertation analysis, particularly the examination of COI of obesi-
ty that is to follow, is a statement the authors make as to other possible reasons for the high
excess costs noted prior to diagnosis of T2DM.  Nichols et al. state that an additional
















- 8 to - 6 53 to 55 3,149 2,326 823 1.35
- 5 to - 3 56 to 58 3,906 2,841 1,065 1.37
- 2 to - 1 59 to 60 5,380 3,006 2,374 1.79
Average of 
Years -8 to -1
3,991 2,689 1,301 1.48
prediabetic were also obese.200 They were unable to examine this more fully due to lack
of data on obesity status of the patients analyzed.
3.5.4  THE COST OF ILLNESS OF OBESITY
How does obesity factor into this dissertation model?  We have already noted that
increased BMI increases the risk of developing T2DM.  In addition, numerous studies
suggest that medical costs increase with increased BMI.201,202 There may be an additional
cost for obesity in the patient with T2DM.  This could also occur in patients with IGT. The
literature review will address the possibility that additional costs must be added to the
derived COI of subjects with abnormal glucose homeostasis to adjust for obesity. Another
more interesting possibility is that there is an excess COI for subjects with NGT second-
ary to obesity, and this possibility will also be examined.
3.5.4.1  Methodology of Determining the Cost of Obesity
Thompson et al. have pointed out that determining the cost of obesity is different than
estimating a cost of illness for a disease like T2DM because obesity is better characterized
as a risk factor for disease than as an actual disease itself.203 When evaluating the COI of
a disease such as T2DM, the researcher is able to derive actual cost figures attributable to
treatment of the disease process.  These same authors state that the cost of illness of obe-
sity "is measured in terms of attributable expenditures on other diseases for which excess 
200  Ibid.
201  Wolf AM, Colditz GA. Social and economic effects of body weight in the United States.
American Journal of Clinical Nutrition. 1996;63:466S-469S.
202  Thompson D, Brown JB, Nichols GA, et al. Body mass index and future healthcare costs: a 
retrospective cohort study. Obesity Research. 2001;9:210-218.
203 Thompson D, Wolf AM. The medical-care cost burden of obesity. Obesity Reviews. 2001;2:189-197.
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body weight plays an etiological role."204 One limitation of evaluating cost of obesity in
this fashion is that there is no consensus as to which diseases are related to obesity,
although the most commonly listed are coronary heart disease, T2DM, hypertension, gall-
bladder disease, endometrial cancer, and osteoarthritis of the knee.205 The cost of obesity
will, in part, be determined by the selection of and number of diseases included in the eco-
nomic evaluation.
A population-attributable risk (PAR) methodology is commonly used in database
evaluations of cost of obesity.  PAR evaluates the influence of a risk factor of the popula-
tion under study.  The resultant value is generally expressed as the proportion of disease
risk that is attributable to the risk factor in question. PAR can also be described as an esti-
mate of "the proportion of disease in a population that could have been prevented by elim-
inating obesity," or "the maximum proportion of disease in the population that was
attributed to a specific exposure."206 A common formula used to calculate PAR is the fol-
lowing where P represents prevalence of obesity, and RR represents relative risk of dis-
ease rate in exposed subjects versus that in subjects who are not exposed.
PAR= P(RR-1)/1 + P(RR-1)
Thompson et al. point out that a limitation of the PAR approach is the assumption that
"each obese person has some quantifiable potential of developing all of the obesity-relat-
ed diseases of interest." 207
204  Ibid.
205  Ibid.
206  Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States.
Obesity Research. 1998;6:97-106.
207  Thompson D, Wolf AM. The medical-care cost burden of obesity. Obesity Reviews. 2001;2:189-197.
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3.5.4.2  Is There an Excess Cost of Obesity in Patients with T2DM?
A MEDLINE search was completed using the MeSH headings of obesity, non-insulin
dependent diabetes and cost of illness to evaluate the current literature to answer the ques-
tion of the possibility that an excess cost of obesity should be added to the value for COI
of T2DM in the dissertation model.  The following articles suggest that there is little need
to include any adjustment to COI of T2DM.
Heithoff et al. used the 1987 National Medical Expenditure Survey (NMES) database,
a precursor of the MEPS database, to evaluate the association between body mass and
health care expenditures.208 While the presence of T2DM was highly collinear with body
mass when predicting health care expenditures, the authors found that when incorporating
T2DM in the regression model, no relationship was observed between BMI and health
care expenditures.  The authors stated that "the data offer no evidence that body mass has
an independent influence on health care expenditures apart from the fact that increased
body mass predisposes individuals to chronic and costly medical conditions."
Quesenberry et al. found similar results in an evaluation of the membership health sur-
vey completed by Kaiser Permanente subjects in 1993.209 The goal of this study was to
analyze the association of BMI and health care costs that could be explained by "diseases
that could be caused or influenced by obesity."  A strong association was noted between
BMI and total health care costs.  These authors also found that by controlling for diabetes,
hypertension and coronary heart disease, "the age-sex adjusted association between BMI
and total annual costs was to a large extent eliminated."
208  Heithoff K, Cuffel B, Kennedy S, et al. The association between body mass and health care expen-
ditures. Clinical Therapeutics. 1997;19:811-820.
209  Quesenberry CP, Caan B, Jacobson A. Obesity, health services use, and health care costs among
members of a health maintenance organization. Archives of Internal Medicine. 1998;158:466-472.
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A final study by Brandle et al. examined the possibility that there may be an addition-
al COI secondary to obesity in subjects with abnormal glucose tolerance.210 The authors
studied a Michigan HMO population of 1,364 T2DM subjects with an average age of 66
years and a median duration of diabetes of > 8 years.  More than 50% of the subjects had
a BMI of < 30 kg/m2.
The baseline, "control" median annual direct medical cost for a white male with diet-
controlled T2DM, a BMI of 30 kg/m2, and no diabetes-related complications was $1,684
(year 2000 dollars).  
Table 3.10 gives multipliers derived from a linear regression model developed from
the study data that examined variables that were positively associated with the direct cost
of illness in subjects with a diagnosis of T2DM.  Hispanic Americans were not analyzed
in the study.  African Americans had lower direct medical costs than whites, which was
thought to be because this group received less health care.  Increased BMI has a minimal
effect on direct healthcare costs in this analysis.
Table 3.10 Baseline Direct Cost and Multipliers for Additional Demographic 
Characteristics from a Michigan HMO a
a Brandle M, Zhou H, Smith BRK, et al.  The direct medical cost of type 2 diabetes.  Diabetes Care.
2003;26:2300-2304.






African American Race 0.82
Every Unit of BMI > 30 kg/m2 1.01
3.5.4.3  Obesity Adjustments for NGT Subjects
The question also arises as to whether the model should incorporate an excess cost of
obesity for subjects with NGT.  In order to incorporate a value in the model, studies that
have evaluated the cost of obesity in patients without T2DM must be examined.  The one
study that was found in the literature review was by Thompson et al. who examined data
gathered in a 1990 health survey completed by patients in the Kaiser Permanente
Northwest Division.211 Utilization and costs of health care then were evaluated retro-
spectively from 1990 to 1998 for the 1,286 respondents.  The age range of the subjects
was 35 years to 64 years, and more than half (n=741) had a BMI of ≥ 25 kg/m2.
For those patients who did not have T2DM, hypertension or hypercholesterolemia, the
ratio of total annual health care expenditures for the BMI categories of 25 kg/m2 to 29.9
kg/m2 and ≥ 30 kg/m2 were 0.99 (95% C.I. of 0.80 to 1.25) and 1.34 (95% C.I. of 1.02 to
1.74) respectively using a reference BMI category of 20 kg/m2 to 24.9 kg/m2.  
This is the only study found that directly examines subjects without T2DM to allow
for adjustment for COI due to obesity.  The study suggests that, at a minimum, the dis-
sertation models should allow for a sensitivity analysis that incorporates an excess COI
for obesity in NGT subjects over control direct healthcare costs.
3.6  The Denominator of the Cost-Effectiveness Equation: Mortality
As mentioned in Section 3.1, the denominator of the cost-effectiveness equation
requires a measurement of health benefit.  These benefits may be measured as single
measures such as number of life-years saved, or as combined measures such as a QALY
211  Thompson D, Brown JB, Nichols GA, et al. Body mass index and future healthcare costs: a 
retrospective cohort study. Obesity Research. 2001;9:210-218.
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measurement.212 The uses of each of these outcome measures have been explained by
Hunink in the following way: "Differences in survival in CEA capture the life-saving and
life-extending benefits of interventions, while in the QALY, the differences in weighted
life years capture the duration of health effects."213
Mortality for the U.S. population is most commonly derived using the United States
life tables published by the National Center for Health Statistics.214 Adjustments to these
numbers are often required to these numbers in a CEA to account for changes in mortali-
ty due to a disease condition, or the effects of a treatment intervention.  
The following terms, which are referred to by Kuntz et al. as "relative reduction
parameters," are commonly used in clinical literature when adjustments to mortality rates
are made.215 A hazard ratio (HR) is calculated by measuring the rate of an event with the
intervention or in a particular disease state versus the rate of the event without the inter-
vention or in a different disease state.  Survival analysis techniques such as Kaplan-Meier
methods or Cox proportional hazards models are used to estimate these ratios. 
Hazard ratios are often referred to as relative risk (RR) ratios in the literature.  The dif-
ference in the two terms is that RR depends on the time frame of the analysis, as one is
evaluating the probability of the event over the time frame of the analysis.  When one is
comparing the RRs of a one-year and five-year period, the five-year ratio will be larger
212  Hunink MGM, Glasziou PP, Siegel JE, et al. Ch. 9 - Constrained Resources. In: Huninck MGM,
Glasziou PP, Siegel JE, et al., eds. Decision Making in Health and Medicine: Integrating Evidence and
Values. Cambridge: Cambridge University Press; 2001.
213  Ibid.
214  Arias E. United States Life Tables, 2000. Hyattsville, MD: National Center for Health Statistics;
2002. vol. 51;3.
215  Kuntz K, Weinstein M. Ch. 7 - Modeling in Economic Evaluation. In: Drummond M, McGuire A,
eds. Economic Evaluation in Health Care: Merging Theory with Practice. New York: Oxford University
Press; 2001:141-171.
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when underlying rates are constant. 216
Several issues must be examined to adequately investigate the mortality variables
required for the dissertation model.  The effect of T2DM and IGT on mortality must be
evaluated.  In addition, the effect of obesity on mortality is also required.  This will help
to evaluate whether an adjustment must be made for obese patients who fall into all cate-
gories of glucose tolerance from NGT to T2DM. 
A final issue that will be discussed will be the actual mortality figures that were
derived from the DPP, and how these values compare to mortality figures from the U.S.
life expectancy tables.  The reasons for possible deviations will be discussed, as well as
the relevance of these deviations to the dissertation model.
A MEDLINE search was performed using the following MeSH headings: obesity; dia-
betes mellitus, type II; impaired glucose tolerance; and mortality.  The methods for study
selection are described in each section.  The following sections will describe the studies
that are pertinent to calculate variables to input into the dissertation model.  
3.6.1  THE EFFECT OF DIABETES ON MORTALITY
Multiple studies have suggested that premature mortality is a result of diabetes.217, 218
The literature review will first start with an examination of studies that evaluated the effect
of diabetes on mortality without incorporating the influence of obesity on hazard ratios.
216  Ibid.
217  The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose
tolerance and mortality: comparison of WHO and American diagnostic criteria. The Lancet.
1999;354:617-621.
218  Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burden of death attributable to diabetes
in the United States. American Journal of Epidemiology. 2002;156:714-719.
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3.6.1.1  The DECODE Study 
The Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe
(DECODE) study,219 published in 1999, is important in that it examined a large sample
size (18,048 men and 7,316 women) for a truncated follow-up of 10 years from 13
prospective European cohort studies that included a 2-hour post-challenge glucose meas-
urement as part of the study design.  The HR for death for subjects with a FPG ≥ 126
mg/dl and a 2-hour glucose level of ≥ 200 mg/dl was calculated as 2.27.  When examin-
ing these data, it is important to note that the majority of European diabetes-related stud-
ies include subjects with lower BMIs than the DPP average (34 kg/m2).
3.6.1.2  An Analysis Using NHANES II Data
Saydah et al. utilized NHANES II data from 1976 to 1980 linked to mortality status
from 1976 to 1992 using the National Death Index (NDI) and the Social Security
Administration’s Death Master File.220,221 Subjects included in the study were aged 30
years to 75 years, with a follow-up of 12 years to 16 years.  The sample size was 9,250.
A smaller subgroup of the cohort (n=3,262) received a FPG test, and 225 subjects (6.9%)
were considered to have undiagnosed diabetes.  The criteria for undiagnosed diabetes
were a FPG level of ≥ 126 mg/dL, or a 2-hour plasma glucose level ≥ 200 mg/dL.222 The
mean baseline BMI given in kg/m2 for subjects with diabetes aged 50 years to 64 years
was 28.2 versus 26.2 for those without.  For subjects aged 65 years to 75 years the BMI 
219  The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose
tolerance and mortality: comparison of WHO and American diagnostic criteria. The Lancet.
1999;354:617-621.
220  Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burden of death attributable to diabetes
in the United States. American Journal of Epidemiology. 2002;156:714-719.
221  Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of
death in the U.S. Diabetes Care. 2001;24:447-453.
222 Ibid.
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values were 27.6 and 26.0 for those subjects with and without diabetes, respectively.
Adjusting for age, sex, education, smoking, physical activity, total cholesterol level,
BMI, and systolic blood pressure, the HR for all-cause mortality for subjects aged 50
years to 64 years was 1.9 (CI: 1.4, 2.5).  For subjects aged 65 years to 74 years, this value
dropped to 1.8 (CI: 1.5, 2.3).  
3.6.1.3  The Interaction of T2DM, Obesity and Premature Mortality
One problem with the studies that have been examined addressing the effect of T2DM
on mortality is that they calculate the HR of premature mortality due to diabetes without
taking into account the BMI category of the subjects without diabetes, the comparison
group.  If obesity does have an independent effect on mortality, the HRs are, therefore,
potentially inaccurate for subjects with diabetes because obesity will also increase mor-
tality rates in the non-diabetic subjects.
Rogers et al. have recently published an observational study that evaluates the rela-
tionship of BMI and premature mortality for overall and diabetes-specific causes of
death.223 The authors used the NHIS data from 1987 to 1994 and linked it via the NDI to
the Multiple Cause of Death (MCD) files from 1987 to 1997.  The result of this linkage
provided a sample size of 647,015 with 47,271 deaths, 1,209 from diabetes.  This sample
size allowed the authors to better analyze smaller subgroups, such as those with differing
BMI obesity categories.
This is the only study found in the literature search of mortality that carefully delin-
eates the effects of obesity on diabetes-related mortality.  The HRs calculated by the
authors are presented in Table 3.11.  The derived figures were calculated using a model 
223  Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and
diabetes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
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that adjusted for age, sex, marital status, income, education, employment, and geograph-
ic local.  The authors suggested that their results were consistent with the possibility that
obesity significantly contributed to increased diabetes-specific mortality.  The risk of
death from diabetes increased from a HR of 1.63 for the BMI subcategory of 25.0 kg/m2
to 30.0 kg/m2 to 7.32 for those subjects with a BMI of ≥ 40 kg/m2.  
Table 3.11 The Hazard Ratios of Death by Underlying Cause of Diabetes in U.S. 
Adults, 1987-1997a
a Source: Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and
diabetes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
BMI, body-mass index
3.6.1.4   Summary of the Literature of the Effect of Diabetes on Mortality
Current literature suggests that there is an apparent increased HR of mortality of
approximately 2 in subjects with T2DM.  Both the DECODE and Saydah et al. HRs for
increased mortality for subjects with T2DM (2.27 and 1.9) are consistent with values cal-
culated by Rogers et al. for subjects in a BMI range of 25 kg/m2 to 35 kg/m2 (a range of
1.63 to 2.64).
3.6.2  DOES THE DIAGNOSIS OF IGT ALSO IMPACT MORTALITY?
Current research strongly supports the possibility that diabetes increases the risk of
premature mortality.  The question then arises of whether the mortality rate for subjects





18.5 to 25.0 Reference
25.0 to less than 30.0 1.63
30.0 to less than 35.0 2.64
35.0 to less than 40.0 4.15
Greater than or equal 40.0 7.32
following will address the literature evaluating this subject.
3.6.2.1  An Analysis of the Effect of IGT on Mortality Using NHANES II Data
Current researchers do suggest that IGT mortality is thought to be intermediate
between the mortality rates for subjects with NGT and those with T2DM.224 Saydah et al.
have also analyzed the NHANES II data on this subject in a fashion similar to their stud-
ies on the effect of diabetes on premature mortality (Section 3.6.1.2).
Patients in this study with a FPG < 126 mg/dl and a 2-hour plasma glucose of > 140
mg/dl to ≤ 200 mg/dl were found to have a hazard ratio of 1.1 (95% CI: 0.8, 1.6) when
adjusted for age, sex, race, education, smoking, physical activity, BMI, systolic blood
pressure, and the ratio of total cholesterol to HDL cholesterol.
3.6.2.2  Other European Studies
The DECODE study group found that patients diagnosed with IGT using the same cri-
teria as described in section 3.6.1.1 had an HR of increased mortality over control subjects
of 1.38 (95% CI: 1.09, 1.74).225 A similar value of 1.48 (95% CI: 0.88, 2.49) was calcu-
lated by de Vegt et al. using data from the Hoorn study.226 The study, initiated in 1989,
consisted of men and women aged 50 years to 75 years.  Follow up extended until 1995.
The sample size for this analysis was 2,363.  The average BMI for the study was < 30
kg/m2.  Known diabetics were excluded.
224  Saydah SH, Miret M, Sung J, et al. Postchallenge hyperglycemia and mortality in a national 
sample of U.S. adults. Diabetes Care. 2001;24:1397-1402.
225  The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose
tolerance and mortality: comparison of WHO and American diagnostic criteria. The Lancet.
1999;354:617-621.
226  de Vegt R, Dekker JM, Rhue HG, et al. Hyperglycemia is associated with all-cause and cardio-
vascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999;42:926-931.
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3.6.2.3  The Malmo Prevention Trial
One of the most interesting evaluations of the possible effect of IGT on mortality was
performed using data from the Malmo Prevention Trial, a precursor of the DPP described
in Section 2.3.2.1.227 This follow up study included 423 subjects, and the goal was to
ascertain if the program had a differential effect on involved subjects after 12 years of fol-
low up.  IGT subjects in the placebo/routine treatment arm of this study had a mortality
rate of 14 subjects per 1,000 patient-years (95% CI: 8.7, 21.4) at the end of the 12-year
follow up.  This was in comparison to the mortality for the NGT group of 6.2 per 1,000
patient-years (95% CI: 5.7, 6.8).    
The authors also found that overall mortality for the IGT intervention group was sig-
nificantly lower than that found for patients who had IGT but were in the placebo/routine
arm.  This is consistent with the normalization of glucose values that was found initially
at the six-year follow up, and continued to the twelve-year follow up.  The subjects in the
IGT intervention group at the time of the twelve-year follow up were found to have a total
mortality of 6.5 (95% CI: 4.1, 9.9).  The ratio of this value to the patients with NGT is
1.05.
The authors reported independent risk factors for death for the entire cohort of 1.02
(95% CI; 0.92, 1.09) for BMI, 1.19 (95% CI: 0.84, 1.70) for IGT, and 1.99 (95% CI: 1.05,
3.79) for diabetes. They also found that being in the IGT intervention group lowered the
risk factor of death by 0.49 (95% CI: 0.27, 0.96).
3.6.3  THE INDEPENDENT EFFECT OF OBESITY ON MORTALITY
There appears to be an increased effect of mortality due to diabetes, and this effect 
227  Eriksson K, Lindgarde F. No excess 12-year mortality in men with impaired glucose tolerance
who participated in the Malmo Prevention Trial with diet and exercise. Diabetologia. 1998;41:1010-1016.
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is exacerbated by obesity.  The Rogers et al. study also suggests that obesity increases the
risk of death over and above the risk associated with diabetes.228 Establishing the effect of
obesity on the risk of death for patients with NGT is also important for this dissertation
model in that patients with this status may require an adjustment to their mortality rates
due to increased BMI.  The following studies will examine the effect of obesity on mor-
tality, both positive and negative, and the factors that influence the results.  
3.6.3.1  The Rogers et al. Study Results
Rogers et al. suggest that obesity has a significant impact on general health and result-
ant risk of death in all subjects, and not just those with diabetes.229 Table 3.12 gives the
calculated HRs of the effects of body mass on overall mortality for U.S. adults from 1987
to 1997 using NHIS data.  The results show that while there is an increased risk of mor-
tality due to obesity, this effect is most pronounced in BMI subgroups ≥ 35 kg/m2.
Table 3.12 Hazard Ratios of the Effects of Body Mass on Overall Mortality for U.S. 
Adults from 1987-1997a
a Source: Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and
diabetes-specific mortality.  Journal of Biosocial Science. 2003;35;107-129.
128  Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and
diabetes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
129  Ibid.
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Ages 45 to 64 
Years Ages 65 and Over
BMI
18.5 to less than 25.0 Reference Reference
25.0 to less than 30.0 0.85 0.86
30.0 to less than 35.0 1.02 0.94
35.0 to less than 40 1.23 1.13
Greater than or equal 40 1.61 1.21
The HR associated with obesity decreases with age.  Of more importance, the over-
weight patients in this study aged 45 years and older (BMI 25 kg/m2 to < 30 kg/m2), and
obese class I patients aged 65 years and older (BMI 30 kg/m2 to < 35 kg/m2) appear to
have a decreased mortality risk compared to subjects in the normal BMI category (BMI
18.5 kg/m2 to 25 kg/2). The authors attribute this protective effect of being overweight to
"unmeasured factors" such as lower rates of smoking.  Other studies have also suggested
that the lowest mortality rates are found in subjects with BMI of 24 kg/m2 to 27 kg/m2.230
3.6.3.2  The Düsseldorf Obesity-Mortality Study (DOMS)
Bender et al. examined data from the DOMS, a 33-year study with a median follow up
of 14.8 years, and a sample size of 6,053.231 The average BMI for the study population
was 36.6 kg/m2, and this value decreased with age.  Mortality for all causes was evaluat-
ed for the 1,028 patients who died during the follow up period.  The data were reported as
standardized mortality ratios.  The reference group was the population of North Rhine
Westphalia.  The standardized mortality rates by body-mass index and age are given in
Table 3.13.
Age groups were divided into group I for ages 18 years to 29 years, group II for ages
30 years to 39 years, group III for ages 40 years to 49 years, and group IV for ages 50
years to 74 years.  BMI subgroups (all values given in kg/m2) were divided into group I,
with BMI values of 25 to < 32, group II, with BMI values of 32 to < 36, group III, with
BMI values of 36 to <40, and group IV, with BMI values of ≥ 40.  
230  Durazo-Arvizu RA, McGee DL, Cooper RS, et al. Mortality and optimal body mass in a sample
of the U.S. population. American Journal of Epidemiology. 1998;147:739-749.
231  Bender R, Jockel K, Trautner C, et al. Effect of age on excess mortality of obesity. JAMA.
1999;281:1498-1504.
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Table 3.13   Standardized Mortality Rates by Body-Mass Index and Agea
a Source: Bender R, Jockel, K, Trautner, C, et al. Effect of age on excess mortality on obesity. JAMA.
1999;281:1498-1504.
BMI, body-mass index; CI, 95% confidence interval; kg/m2, kilogram per meters-squared;  SMR, 
standardized mortality rate
No excess mortality was associated with a BMI of at least 25 kg/m2 but less than 32
kg/m2 for either women or men aged 50 years to 74 years, which is similar to the result
found for Rogers et al.  The model did not analyze the effects of risk factors such as ele-
vated blood pressure, cholesterol levels, impaired glucose tolerance, diabetes, or smoking,
but the regression coefficients for age and BMI did not show significant changes when any
one of these risk factors was added to the model.
3.6.3.3  The Nurses’ Health Study
Manson et al. evaluated the association of BMI with overall mortality and that from
specific causes using data from the 115,195 women enrolled in the Nurses’ Health
Study.232 The original age of the cohort was 30 years to 55 years, and the follow up peri-
od was 16 years.  Patients with cardiovascular disease at baseline were excluded from the
study. There were 4,726 deaths at follow up.
232 Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. New
England Journal of Medicine. 1995;333:677-685.
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The authors determined that 53% of deaths among women with a BMI of > 29 kg/m2
could be attributed to obesity.  After controlling for hypertension, diabetes and elevated
cholesterol, mortality was lowest for women with BMI < 19 kg/m2.  Table 3.14 gives the
corresponding multivariate risks of mortality for increasing BMI categories in the study.
There was no modifying effect of age on mortality in this study.
Table 3.14 Relative Risks for Mortality with Increasing Body-Mass Index Using
Nurses’ Health Study Data a
a Source: Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. New
England Journal of Medicine. 1995;333:677-685.
b Adjusted for age, smoking, hypertension, diabetes and cholesterol level
BMI, body-mass index; kg/m2, kilograms per meter squared
The relative risk values are higher in this analysis than in the previously cited studies.
One major difference between these two study populations is that the Nurses’ Health
Study excluded subjects with cardiovascular disease at baseline, while the NHIS data and
the DOMS data did not carry such exclusions. 
3.6.3.4  An Analysis of the Effect of Obesity Using Framingham Data  
Do the exclusion criteria of a study design have an impact on the calculated hazard
ratios for mortality?  The above studies seem to indicate that this may be a possibility.  The
following study produced an even higher ratio for premature mortality for obese subjects
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cular disease at baseline. 
Peeters et al. examined data collected on 3,607 subjects aged 30 years to 49 years at
baseline for a follow up period of 40 years.233 The study examined mortality rates for two
periods: period I extended from year 4 to year 28 of follow up, and period II extended
from year 29 to year 40.
The derived HRs for the study are given in Table 3.15.  For subjects with a BMI of 30
kg/m2 or greater who were non-smokers, the HR for mortality was 2.05 for period I of fol-
low up, and 2.27 for period II compared to subjects with a BMI of 18.5 kg/m2 to 24.9
kg/m2.  For subjects with a BMI of 25 kg/m2 to 29.9 kg/m2 these values were 1.47 and
1.53, respectively.  Adjustment for hypertension and diabetes lowered the HRs for mor-
tality secondary to obesity.  
Table 3.15 Mortality Hazard Ratios for Body-Mass Index Based on Framingham
Heart Study Dataa
a Source: Peeters A, Barendregt JJ, Willekens F, et al.  Obesity in adulthood and its consequences for life
expectancy: a life-table analysis. Annals of Internal Medicine. 2003;138:24-32.
b Given in values of kg/m2
kg/m2, kilograms per meter squared; CI, 95% confidence interval
These values are again higher than previous values reported by Rogers et al.  The
results may be secondary to the fact that HR values are increased in calculations that are 
233 Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life
expectancy: a life-table analysis. Annals of Internal Medicine. 2003;138:24-32.
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Period I            
(Year 4 to Year 28 
of Follow Up)
Period II          
(Year 29 to Year 
40 of Follow Up)
Body-Mass Index b
18.5 to 24.9 Reference Reference
 25 to 29.9
1.47               
(CI:1.06 to 2.04)
1.53             
(CI:1.19 to 1.97)
 Greater than or 
equal 30
2.05               
(CI: 1.38 to 3.05)
2.27             
(CI:1.67 to 3.1)
based on data derived from an initial cohort that excludes subjects with cardiovascular dis-
ease at enrollment. One final study will be presented to address the issue of the effect of
the exclusion of disease on enrollment on calculated hazard ratios secondary to obesity.
3.6.3.5  An Analysis Using Cancer Prevention Study II Data
Calle et al. analyzed the effect of obesity on mortality using data from the Cancer
Prevention Study II, a prospective study of 1,184,657 subjects with an average age at
enrollment of 57 years.234 In 1982, a survey was completed that provided baseline infor-
mation on demographics, family history, and "various aspects of behavior, environmental
and occupational exposures, and diet."  There were no exclusions due to health state for
participants. 
The authors analyzed the relative risk for death according to current or former smok-
ers versus subjects who had never smoked.  They further subdivided each of these cate-
gories into subjects who had a history of any of the following diseases: cancer, heart
disease, stroke, respiratory disease, current illness of any type, or a weight loss of at least
4.5 kg in the previous year versus subjects with no history of disease at enrollment.  
Table 3.16 gives the relative risk of death according to BMI category for non-smokers
with no history of disease at enrollment.  High BMI was associated with higher rates of
death from all causes.  Relative risk declined with age, but absolute risk increased sub-
stantially.   Most importantly, these relative risk values for these subjects with no disease
at baseline are larger than those given by Rogers et al. for similar BMI categories.
234  Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of
U.S. adults. New England Journal of Medicine. 1999;341:1097-1105.
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Table 3.16  The Relative Risk of Death by BMI Category in Non-Smokers 
With No History of  Disease at Enrollmenta
a Source: Calle EE, Thun MJ, Petrelli JM, et al.  Body-mass index and mortality in a prospective cohort
of U.S. adults.  New England Journal of Medicine.  1999;341:1097-1105.
b Adjusted for age, level of education, physical activity, alcohol use, marital status, aspirin use, fat con-
sumption, vegetable consumption, and use of estrogen replacement therapy (in women)
BMI, body-mass index; CI, confidence interval, kg/m2, kilograms per meter squared; RR, relative risk
Table 3.17 gives the relative risk death values for non-smoking subjects with a histo-
ry of disease at enrollment.  These values were derived from graphical data from the Calle
et al. article, so no confidence intervals are given.  The relative risk of death values per
BMI category for these patients with no exclusions are much closer in value to the Rogers
et al. values, which most likely reflects the fact that the Rogers et al. study is based on sub-
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Table 3.17  The Relative Risk of Death by BMI Category in Non-Smokers 
With a History of Disease at Enrollmenta,b
Source: Calle EE, Thun MJ, Petrelli JM, et al.  Body-mass index and mortality in a prospective cohort of
U.S. adults.  New England Journal of Medicine.  1999;341:1097-1105.
b Derived from graphical data.  No confidence intervals available
BMI, body-mass index;  kg/m2, kilograms per meter squared
3.6.3.6  A Summary of the Effect of Obesity on Mortality
The above studies help to determine whether an increased HR should be included for
obese patients with NGT in the dissertation model.  The studies suggest that there may or
may not be an effect of obesity on mortality depending on the initial status of the subjects
in the database that is being analyzed.  
3.6.4 DOES WEIGHT LOSS ACTUALLY REVERSE THE EFFECT OF 
OBESITY ON MORTALITY?
The Malmo Prevention Study suggests that weight loss in patients with IGT decreased
mortality rates.  This suggests that increased mortality rates secondary to abnormal glu-
cose homeostasis, obesity, or a combination of both conditions may approximate normal
rates as patients lose weight, and their glucose values return to a NGT status.  



















   White Men 
With A History 
of Disease
Relative Risk 1.00 1.04 1.09 1.10 1.20 1.30 1.40 1.64
White Women 
With A History 
of Disease
Relative Risk 1.00 1.05 1.05 1.10 1.10 1.18 1.30 1.50
BMI (kg/m 2)
studies.235, 236 Using NHIS data collected in 1989 linked to NDI data with follow up until
1997,  the authors found that 892 deaths were reported.  Intentional weight loss was asso-
ciated with a 24% lower mortality rate (HR 0.76; 95% CI: 0.6, 0.97).  When adjusted for
age, sex, race, smoking, education, and initial BMI, those who lost weight had a decreased
mortality of 15% (HR 0.85; 95% CI 0.66, 1.11).  These studies, along with the Malmo
Prevention Study, seem to suggest that the increased mortality risk that accompanies obe-
sity and abnormal glucose homeostasis can approach a more normal value with weight
loss.
3.6.5   THE DPP MORTALITY DATA
How does the above mortality data apply to the results derived from the DPP?  Over
the three-year study period the mortality rate was 0.0010 for the lifestyle group and 0.0017
for the placebo group.  The all-sex probability for mortality for a person aged 50 years in
the year 2001 was 0.0044.237 Why was there such a huge discrepancy in this cohort that
included subjects with IGT and T2DM?  The answer may lie in the design of the DPP
study.  Subjects were excluded from the study with significant ischemic heart disease, aor-
tic stenosis, uncontrolled hypertension, renal insufficiency, and congestive heart disease.
3.6.6  SUMMARY
Mortality rates and their adjustments introduce substantial uncertainty into the disser-
tation model.  The studies presented above suggest the following conclusions.  There 
235  Gregg E, Gerzoff R, Thompson T, et al. Intentional weight loss and death in overweight and
obese U.S. adults 35 years of age and older. Annals of Internal Medicine. 2003;138:383-389.
236  Gregg EW, Gerzoff RB, Thompson TJ, et al. Trying to lose weight, losing weight, and 9-year
mortality in overweight U.S. adults with diabetes. Diabetes Care. 2004;27:657-662.
237 Arias E. United States Life Tables, 2000. Hyattsville, MD: National Center for Health Statistics;
2002. vol. 51;3.
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appears to be an increased HR of mortality in subjects with diabetes, and there is further   
increase in HR secondary to increasing BMI.  IGT also appears to increase HRs for mor-
tality when compared to subjects with NGT at a level that is intermediate to that between
subjects with T2DM and NGT.
There appears to be little effect of obesity on mortality in subjects with BMI < 35
kg/m2 if the cohort being examined has no exclusions secondary to health state at enroll-
ment.  If there are exclusions secondary to health state, such as those secondary to car-
diovascular disease, a HR as high as 2.27 may need to be incorporated into mortality
figures for subjects with a BMI category of 30 kg/m2 to < 35 kg/m2.  Finally, weight loss
may allow for a decrease of the effect on mortality that is found in subjects with IGT and
T2DM.
3.7   The Denominator of the Cost-Effectiveness Equation: Utilities
As noted in Section 3.6, mortality figures are necessary for single measures of out-
comes such as life-years saved.  These single measures are usually considered adequate in
interventions that primarily extend life.  Mortality estimates are also needed to measure
combined effectiveness measures, the most common of which is the quality adjusted life
year or QALY.
What is a QALY, and why do we need to use it for our effectiveness measure?  A
QALY is an integrated summary score that incorporates mortality with morbidity and
patient preferences.238, 239 The underlying theory for using QALYs assumes that the illness
addressed may potentially affect life expectancy, and may also make quality of life less 
238  Coons SJ, Kaplan RM. Ch. 6- Cost-Utility Analysis. In: Bootman JL, Townsend RJ, McGhan WF,
eds. Principles of Pharmacoeconomics. Cincinnati: Harvey Whitney Books Company; 1996.
239  Ibid.
97
desirable prior to death.
Quality of life (QOL) may be important to measure in several situations.  Gold et al.
suggest that a measure of quality is important when: (1) the main effects of a single inter-
vention may cause potential differences among groups; (2) the side effects of an inter-
vention may be significant enough to have an effect on quality of life; and (3) the audience
that is examining the analysis requires an evaluation of quality of life as well as duration
of life.240 However, the main reason suggested for using a measure of quality in the
denominator of a cost-effectiveness analysis is when the intervention potentially has an
effect on both mortality and morbidity.241, 242
There are several very important things to note about a cost-effectiveness analysis
using quality of life.  The health outcomes measured for the denominator involve prefer-
ences, which are generally referred to as utilities.  A utility is the value that a subject places
on a particular health status.  Cost-effectiveness analyses that incorporate utilities are
often referred to as cost-utility analyses (CUAs), and are suggested by some authors to be
a subclass of CEAs.243, 244
3.7.1  COMMON MEASURES OF UTILITIES IN DIABETES STUDIES
As noted, a utility is a measure of a patient’s preference for an outcome.  There are
multiple methods of assigning utilities.  Common methods employed are the standard 
240 Gold MR, Patrick DL, Torrance GW, et al. Ch. 4 - Identifying and Valuing Outcomes. In: Gold
MR, Russell LB, Siegel JE, et al., eds. Cost-Effectiveness in Health and Medicine. New York: Oxford
University Press; 1996.
241  Coons SJ, Kaplan RM. Ch. 6- Cost-Utility Analysis. In: Bootman JL, Townsend RJ, McGhan
WF, eds. Principles of Pharmacoeconomics. Cincinnati: Harvey Whitney Books Company; 1996.
242  Ibid.
243  Ibid.
244  Sieber WJ, Groessl JJ, David KM, et al. Quality of Well-Being Self-Administered (QWB-SA)
Scale User's Manual: Health Outcomes Assessment Program, University of California, San Diego; 2004.
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gamble and time trade-off. Another common method involves a multi-attribute frame-
work.  This technique breaks health states into domains, assigns a value for each domain,
and then collates these values into a single value.245
Visual analog scales (VASs) are also employed to measure utilities.  VASs fall under
the category of psychological scaling methods called rating scales.  While used for CUAs,
they are controversial because some authors feel they do not reflect preferences under
uncertainty. 246
Scores generated for rating scales are generally lower than those generated by other
methods of measuring utilities.  Hunink et al. make the statement that this is due to the
fact that "there is no penalty associated with assigning a health state a rating scale value
lower than that of perfect health."247 The following have been suggested by these same
authors as rating scale – utility transformation formulas.248 Utility is represented by u and
rating scale is represented by r in these formulas.
Torrance: (1-u) = (1-r)1.6
Weeks: u = 1 (for r > 0.85)
u = 1.18 X r (for r < 0.85)
The scales used for measurement of utilities in diabetes may be generic or disease spe-
cific, although most of the large prospective diabetic studies incorporate generic scales as
will be described in the following sections.  
One very common generic scale used in diabetes studies in the U.S. is the Quality of
Well Being – Self Administered (QWB-SA) scale.  This preference-based measure of util- 
245  Coons SJ, Kaplan RM. Ch. 6- Cost-Utility Analysis. In: Bootman JL, Townsend RJ, McGhan
WF, eds. Principles of Pharmacoeconomics. Cincinnati: Harvey Whitney Books Company; 1996.
246  Hunink M, Glasziou PP, Siegel JE, et al. Ch. 4 - Valuing Outcomes. Decision Making in Health




ity is the scale that was used in the cost-effectiveness analysis performed by the DPP com-
paring metformin, extensive lifestyle intervention, and placebo.249
The QWB-SA was derived from the Quality of Well Being (QWB) scale.  The QWB
instrument includes four dimensions: mobility, physical activity, social activity, and symp-
tom/problem complexes.250 It requires administration by a trained interviewer.  The more
newly designed self-administered scale (QWB-SA) includes several mental health items,
and the symptom assessment follows a review of systems format which is thought to be
more clinically useful to the researcher.251 General equivalence has been found when the
two scales are compared, although lower scores are found with the QWB-SA.252
The EuroQol EQ-5D is the most common generic scale used in diabetes studies in
Europe.253 Developed by the EuroQoL Group, it has two parts.  First, the EQ-5D asks
questions about the domains of the five dimensions of social relations, mobility, physical
activity, and symptoms/impairment. The second part, the EuroQol VAS, has been
described as a single measure that asks subjects to rate their health between the "worst
imaginable state" which is rated as a value of 0, and the "best imaginable state" that is
rated as a value of 1.
It important to note that neither of the two major sets of scales that will primarily be
discussed, the QWB-SA or the EuroQoL EQ-5D and VAS, have been officially cross-val-
249  Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle inter-
vention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
250  Sieber WJ, Groessl JJ, David KM, et al. Quality of Well-Being Self-Administered (QWB-SA)
Scale User's Manual: Health Outcomes Assessment Program, University of California, San Diego; 2004.
251  Ibid.
252  Sieber WJ, Ganiats T, Kaplan R. Validation of a self-administered quality of well-being (QWB)
scale. Medical Outcomes Trust Bulletin. 1997;5:2-4.
253  Redekop WK, Koopmanschap MA, Stolk RP, et al. Health-related quality of life and treatment
satisfaction in Dutch patients with type 2 diabetes. Diabetes Care. 2002;25:458-463.
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idated with each other for diabetic U.S. subjects, although the research is currently under-
way. 254
3.7.2   VALUES TO USE FOR THE DISSERTATION MODEL
Evaluation of the abstracts that have been presented dealing with long-term projec-
tions of cost-effectiveness of diabetes prevention in Sections 3.3.1 and 3.3.2 shows that
current researchers have not included a utility measure in their cost-effectiveness analy-
sis.255, 256
There are no standardized values for utility for obese subjects with T2DM or IGT, nor
are there standardized values for obese subjects with NGT.  One option to use for this
analysis is also to simply leave out any cost utility evaluation.  Another option is to
attempt to incorporate patient preference values into the model using the data generated
by the DPP.  The utility values used in the DPP cost-effectiveness analysis comparing met-
formin, extensive lifestyle intervention and placebo are again listed in Table 3.18.
Table 3.18  Utility Scores of the Diabetes Prevention Programa
a The Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle interven-
tion or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.  
254  Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes
Care. 2002;25:2238-2243.
255 Palmer AJ, Roze S, Cabrieres L, et al. Long-term projection of the costs of the Diabetes
Prevention Program in the USA using the CORE diabetes prevention model: intensive lifestyle changes
and metformin are both cost-effective. Paper presented at: 18th International Diabetes Federation
Congress, 2003; Paris.
256  Palmer AJ, Roze S, Valentine WJ, et al. Intensive lifestyle changes or metformin in patients with
impaired glucose tolerance: modeling the long-term health economic implications of the Diabetes




0.703 ± 0.118 0.686 ± 0.121
0.695 ± 0.122 0.675 ± 0.122
0.692 ± 0.125 0.657 ± 0.125
Utility Scores
The utility scores given are the mean scores of the entire cohort that participated in
either the lifestyle or placebo arms of the study collectively.  There is no way to differen-
tiate the utility score that was derived for subjects in each of the states of NGT, IGT or
T2DM, nor is there a way to determine the effect that obesity had on the score.  
In spite of this lack of information, can these values be used in our model, and for what
groups?  The following literature review will discuss the possibility that these values may
be appropriate to incorporate into the model for all categories of impaired glucose home-
ostasis, at least as an initial value to use prior to performing sensitivity analyses. Articles
selected for this literature review were found in a MEDLINE search using the following
MeSH headings: quality of life; diabetes mellitus, type II; impaired glucose tolerance; and
obesity.  
3.7.2.1 Health Related Quality of Life in Diabetics using the QWB-SA
Coffey et al., in an effort to address the lack of standardized and consistent health util-
ity scores for diabetics, set out to "describe the health utilities associated with diabetes and
its treatments, complications, and comorbidities."257 They used the QWB-SA in a group
of T2DM subjects who were drawn from diabetic tertiary care clinics.  The average age
was 57.6 years (range of 49.9 years to 67.3 years) and the average BMI was 30.4 kg/m2
(26.2 kg/m2 to 36.0 kg/m2).  The average duration in years of diabetes was 10.4 years
(range of 4.0 years to 17.2 years).  The mean health utility score for diet controlled non-
obese diabetic men without complications (microvascular, neuropathic, or cardiovascular)
was 0.689 (S.E. 0.014).  This score is very similar to the score of 0.686 obtained on the
QWB-SA in year 1 of the placebo arm of the DPP.
257  Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes
Care. 2002;25:2238-2243.
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Subjects with a BMI category classified as obese (not defined by the author, but
assumed to be ≥ 30 kg/m2) received a "penalty" of -0.021 (S.E. 0.007) derived using a
multiple linear regression model.  The actual value of 0.665 that is calculated for obese
subjects is intermediate to the utility scores derived in years 2 and 3 of the DPP study.
Subjects on oral antidiabetic agents received a penalty of -0.023 (S.E. 0.013), and those
on insulin received a penalty of -0.034 (S.E. 0.013).  More severe microvascular and
macrovascular complications were accompanied by lower utility scores.  Age, race, and
duration of diabetes were not associated with significant reductions in scores.  
3.7.2.2 Assessing Weight-Related Quality of Life in Obese Persons with T2DM
Another potentially useful study that specifically evaluates the effect of obesity on
quality of life in persons both with and without diabetes was published by Kolotkin et al.
in 2003.258 The instrument used was the Impact of Weight on Quality of Life-Lite
(IWQOL-Lite) questionnaire.  This instrument has five domains including physical func-
tion, self-esteem, sexual life, public distress, and work.  The scores are given in a range
from 0 to 100.  Obese persons with (n=225) and without (n=972) diabetes were enrolled
in a clinical trial comparing obesity medication to gastric bypass surgery.  The average age
of diabetics was 54.1 ± 10.1 years and for non-diabetics was 49.2 ± 10.6 years.  The aver-
age BMI was 34.2 ± 4.6 kg/m2 for diabetics, and 34.6 ± 4.8 kg/m2 for non-diabetics.
While this study did not use a utility instrument, the results are very useful to the dis-
sertation model.  The authors first make the statement that they chose to evaluate the rela-
tionship between obesity and T2DM on quality of life due to the fact that approximately 
258  Kolotkin RL, Crosby RD, Williams GR. Assessing weight-related quality of life in obese persons
with type 2 diabetes. Diabetes Research and Clinical Practice. 2003;61:125-132.
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80% of patients with T2DM are obese.  They hypothesized that obesity might be a con-
tributor to impairment in QOL scores in addition to the impairment found secondary to
T2DM.
Using ANCOVA analysis, the authors found that when controlled for age, gender, and  
BMI, there were no differences between obese diabetic and non-diabetic subjects on any
IWQOL-Lite scale.  They also found that there was a greater impairment for both diabet-
ics and non-diabetic subjects seeking treatment for obesity versus those obese subjects in
each category who were not seeking treatment.  They stressed the great importance of
determining whether obese subjects in a study were seeking treatment for obesity when
analyzing quality of life scores due to this increased impairment.
Therefore, in this population of obese subjects seeking treatment, diabetes status did
not further influence impairment in QOL score, but obese subjects seeking treatment did
have lower QOL than those subjects who were not seeking treatment.
3.7.2.3 Utility Scores in Diabetics using the EQ5D and the EuroQoL VAS
Redekop et al. examined health-related QOL in Dutch patients who were enrolled in
the Cost of Diabetes in Europe – Type 2 (CODE-2) study using the EQ5D and the
EuroQoL VAS.259 The values derived in the study are given in Table 3.19. 
259  Redekop WK, Koopmanschap MA, Stolk RP, et al. Health-related quality of life and treatment
satisfaction in Dutch patients with type 2 diabetes. Diabetes Care. 2002;25:458-463.
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Table 3.19 Quality of Life Reported by Dutch Type 2 Diabetic Patients Enrolled 
in the CODE-2 Studya
a: Source: Redekop WK, Koopmanschap MA, Stolk RP,  et al. Health-related quality of life and treatment
satisfaction in Dutch patients with type 2 diabetes. Diabetes Care. 2002.;25:458-463.
b: Utility scores given in means and standard deviations
CODE-2, Cost of Diabetes in Europe-Type 2; EQ5D, EuroQoL 5D; VAS, visual analog score; n, sample
size
Diabetics reported an EQ5D mean score of 0.74 (SD 0.27), which was only slightly
lower than the utility score reported by the general population (United Kingdom popula-
tion aged 60 years to 69 years: women = 0.81 and men = 0.78).  Obesity, defined in this
population as a BMI of > 30 kg/m2, was associated with a penalty of -0.007 units.  
The VAS score was strikingly similar to the score generated using the QWB-SA by the
DPP placebo group.  As noted above, these two scales have not been cross-validated.
Koopmanschap also used the EQ5D to perform a more generalized study on 4,189
T2DM subjects from five European countries.260 The average utility score in these sub-
jects with an average age of 66 years was 0.69 (compared to a score of 0.74 for the over-








Overall 0.74 (0.27) 0.68 (0.18)
Age (in Years)
   Less than 50 0.79 (0.26) 0.69 (0.18)
   50 to 59 0.75 (0.26) 0.69 (0.18)
   60 to 69 0.78 (0.25) 0.70 (0.18)
   Greater than or equal 70 0.70 (0.28) 0.67 (0.18)
Obesity 0.70 (0.28) 0.66 (0.19)
No Obesity 0.77 (0.26) 069 (0.1)
Duration of Diabetes (in 
Years)
   Less than 5 0.77 (0.25) 0.70 (0.17)
   5 to 10 0.73 (0.29) 0.67 (0.19)
   Greater than or equal 10 0.70 (0.28) 0.66 (0.18)
all score in the Redekop study).  Diabetic patients without complications had a utility
score of 0.76.  There was also no variation in score according to treatment with oral antidi-
abetic drugs versus treatment with diet and exercise (0.71 for both groups).  In this model,
independent predictors of poor quality of life included age, sex (female) and BMI.  The
poor quality of life associated with BMI occurred at a cut point of 27 kg/m2.  The VAS
scale was not evaluated in this study.
3.7.2.4 How to Explain the Differences between the Lifestyle and Placebo Arm
Rubin et al. reviewed the published literature on quality of life in diabetics in 1999.261
Their literature review helps to answer the question of whether there is a legitimate rea-
son for a difference between the utility values of the two arms of the DPP.  
The first hypothesis that might come to mind is that the difference may be secondary
to improved glycemic control.  This relationship is equivocal in the literature that was pre-
sented up to the point of the publication, but the authors felt that overall "the benefits of
good glycemic control more than offset the increased burden it may involve, at least for
the majority of patients." In addition, it was suggested that medical interventions includ-
ing counseling and educational interventions improved QOL, but the basis for this
improvement is unknown.  The options might include factors such as better glycemic con-
trol, increased activity, or increased weight loss.
It may be possible that the combination of diet and exercise used in the intensive
lifestyle intervention arm of the study has an influence on the improved utility scores
found in these subjects. In general, obese subjects in general who use diet and exercise to
attempt weight loss have been found to experience better health related quality of life 
261  Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes/Metabolism Research and Reviews.
1999;15:205-218.
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(HRQL) than those using diet alone, or those subjects not attempting to lose weight.262
This study used CDC and Prevention’s Behavioral Risk Factor Surveillance Survey
(BRFSS) data.  Exercise was defined as participating in physical activity for 30 minutes
or more, five times a week, and dieting was defined as any attempt at eating less.  The
authors of this study pointed out that the improved HRQL might be an antecedent event,
as subjects with higher HRQL scores at baseline might be more able to exercise than those
with lower scores.
3.7.2.5  The Effect of Obesity on Health Utilities
If the decision is made to use the DPP utility data for all obese subjects, regardless of
glucose homeostasis, the literature must be investigated to confirm that obesity is thought
to have a negative effect of health utility in subjects with NGT.  The one study that specif-
ically addresses the topic of the effect of obesity using a generic utility measurement was
performed by Groessl et al. on 1,326 adults from the Rancho Bernardo longitudinal study
using the QWB scale.263 The characteristics of the BMI groups are given in Table 3.20.
Table 3.20 Underlying Characteristics and Utility Scores of the Rancho Bernardo
Longitudinal Studya
a Groessl EJ, Kaplan RM, Barrett-Connor E, et al.  Body mass index and quality of well-being in a community
of older adults.  American Journal of Preventive Medicine. 2004;26:126-129.
b Adjusted for gender, age, smoking, and exerciseBMI, body-mass index; kg/m2, kilograms per meter squared;
n, sample size; QWB, quality of well being
262  Hassan MK, Joshi AV, Madhavan SS, et al. Obesity and health-related quality of life: a cross-sectional
analysis of the US population. International Journal of Obesity and Related Metabolic Disorders.
2003;27:1227-1232.
263  Groesl EJ, Kaplan RM, Barrett-Connor E, et al. Body mass index and quality of well-being in a com-
munity of older adults. American Journal of Preventive Medicine. 2004;26:126-129.
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Variable
20 to 24.9 
(n = 618)
25 to 29.9 
(n = 491)
Grater than or 
equal 30        
(n = 148)
p value
% Female 67.6 50.1 57.4 p < 0.001
% Exercise 74.6 75.4 58.9 p < 0.001
% With Diabetes 5 5.3 11.6 p = 0.019
Age 72.8 71.6 69.1 p < 0.001
Adjusted QWB Scoreb 0.709 0.695 0.663 p < 0.001
BMI (in kg/m 2)
Obese subjects, with a mean age of 69.1 years in this study had significantly lower
adjusted QWB scores than those subjects who had normal or overweight BMI scores.  The
percentage of diabetes in this subgroup was almost twice that of those subjects with nor-
mal or overweight BMI subcategories.  
Significant decreases in quality of life with increasing levels of obesity were also
found using the Health Utility Index Mark III in a study involving 38,151 Canadian sub-
jects, aged 20 years to 64 years (52.4% male).264 Significant decreases were found in each
of the eight attributes measured in the instrument (vision, hearing, speech, mobility, dex-
terity, cognition, emotion, and pain), with the most significant changes noted in the
domains of mobility, cognition, and pain. 
Similar findings were also found using CDC and Prevention’s 2000 BRFSS data on
182,372 subjects.265 Significant decreases in limitations were noted for each of the three
domains measured (physical, mental and activity).
3.7.2.6 Summary
The review of the literature suggests several important points.  There are little stan-
dardized data on health utilities for obese subjects regardless of glucose status.  It is sug-
gested that increasing levels of obesity have a negative effect on health utilities.  The
diagnosis of diabetes may have little effect on the already diminished QOL status of an
obese subject.  Finally, lifestyle interventions such as exercise may improve QOL status.
With these points in mind, it may be appropriate to use the DPP utility data as a starting
point for a sensitivity analysis to use in the dissertation model.
264  Trakas K, Oh PI, Singh S, et al. The health status of obese individuals in Canada. International
Journal of Obesity. 2001;25:662-668.
265  Hassan MK, Joshi AV, Madhavan SS, et al. Obesity and health-related quality of life: a cross-sec-
tional analysis of the US population. International Journal of Obesity and Related Metabolic Disorders.
2003;27:1227-1232.
108
3.8 Weight Loss Maintenance
A final variable to examine for the dissertation model is the rate of weight loss main-
tenance that can be expected by subjects who participate in intensive lifestyle interven-
tions to prevent progression from IGT to T2DM.  This is important if we assume that
diabetes prevention is caused, at least in part, by the modest reductions in body weight that
have been found in the studies described in Section 2.3. 
As a summary, the goal of the lifestyle intervention in the DPP was a 7% weight loss,
which was achieved by 50% of the subjects in this arm of the study at the end of the twen-
ty-four week curriculum.266 At the time of the most recent visit, 38% had a 7% weight
loss.  The lifestyle group lost an average of 5% of their body weight at the end of two years
(an average of 5.45 kg), and an average of 3.5% of their body weight at the end of three
years (an average of 4.1 kg).267
Studies examining weight loss maintenance in diabetics support the weight loss find-
ings of the DPP.268 Hensrud et al. found that diabetic subjects enrolled in comprehensive
weight loss programs of ten weeks to twenty weeks duration generally lost an average of
2 kg to 10 kg.  By the end of one year, most patients were found to regain one-third to
one-half of the original weight that was lost, regardless of the weight loss approach.  They
found that weight loss from baseline rarely exceeded 5 kg.
The DPP may actually have a higher rate of weight loss maintenance than is seen in
the general U.S. population.  Wing et al., who define weight loss maintenance as a sus-
tained maintenance of at least 10% of initial body weight for at least one year, have found 
266  Teutsch S. The cost of preventing diabetes: what do we know and what do we need to know?
Diabetes Care. 2003;26:238-239.
267  Ibid.
268  Hensrud DD. Dietary treatment and long-term weight loss and maintenance in type 2 diabetics.
Obesity Research. 2001;9:348S-353S.
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that approximately 20% of overweight/obese subjects are able to achieve this goal.  If a
criterion of 5 kg or greater weight loss for at least one year is used, a range of successful
maintenance from 13%269 to 22%270 has been reported.
In a meta-analysis of long-term weight loss maintenance observational studies in sub-
jects who completed structured weight-loss programs, it was found that at the end of five
years the average obese individual maintained an approximate 3 kg weight loss.  This rep-
resented an average of approximately 3.2% below initial body weight.271
Weight loss maintenance seems to stabilize at two years to five years, as it has been
found that maintaining weight for this period seems to decrease subsequent weight regain
by approximately 50%.272 This stabilization is more likely to occur in subjects who have
participated in very low-energy diets than in those who participate in hypoenergetic bal-
anced diets.273 Stabilization also appears to improve with age.274
3.9   Proposed Hypotheses
The literature review suggests that while there is evidence that intensive lifestyle
intervention appears to help prevent the progression of IGT to T2DM, there is little
research into the long-term cost-effectiveness of such treatment.  Obesity appears to play 
269  Wadden TA, Sternberg JA, Letizia KA, et al. Treatment of obesity by very low calorie diet,
behavior therapy, and their combination: a five-year perspective. International Journal of Obesity.
1989;13:39-46.
270  Stalonas PM, Kirschenbaum DS. Behavioral treatment for obesity: eating habits revisited.
Behavior Research and Therapy. 1985;16:1-14.
271  Anderson JW, Konz EC, Frederich RC, et al. Long-term weight-loss maintenance: a 
meta-analysis of US studies. American Journal of Clinical Nutrition. 2001;74:579-584.
272  McGuire MT, Wing RR, Klem ML, et al. What predicts weight regain among a group of 
successful weight losers? Journal of Consulting and Clinical Psychology. 1999;67:177-185.
273  Anderson JW, Konz EC, Frederich RC, et al. Long-term weight-loss maintenance: a 
meta-analysis of US studies. American Journal of Clinical Nutrition. 2001;74:579-584.
274  Ibid.
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a major role in any evaluation that is used to determine this cost-effectiveness.  Therefore,
the following hypotheses are proposed for this dissertation.
H1: In a population similar to that studied by the DPP that is diagnosed with IGT and
no other disease-state abnormalities, long-term intensive lifestyle intervention to 
prevent progression to T2DM is cost-effective.
Rationale: 
Current short-term cost-effectiveness analysis of the DPP results275 and projected
long-term cost-effectiveness evaluations of T2DM prevention276, 277 suggest that 
intensive lifestyle intervention is cost-effective.  The DPP study group had a BMI 
range of approximately 27 kg/m2 to 41 kg/m2, with an average of 34 kg/m2.278
H2: In a population that is diagnosed with IGT and no other disease-state abnormali-
ties that fall into a specific BMI classification of 30 kg/m2 to < 35 kg/m2, long-
term intensive lifestyle intervention to prevent progression to T2DM is cost-effec-
tive.
275  Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle inter-
vention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
276  Palmer AJ, Roze S, Cabrieres L, et al. Long-term projection of the costs of the Diabetes
Prevention Program in the USA using the CORE diabetes prevention model: intensive lifestyle changes
and metformin are both cost-effective. Paper presented at: 18th International Diabetes Federation
Congress, 2003; Paris.
277  Palmer AJ, Roze S, Valentine WJ, et al. Intensive lifestyle changes or metformin in patients with
impaired glucose tolerance: modeling the long-term health economic implications of the Diabetes
Prevention Program in Australia, France, Germany, Switzerland, and the United Kingdom. Clinical
Therapeutics. 2004;26:304-321.
278  Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes
with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
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H3:  In a population that is diagnosed with IGT and no other disease-state abnormali
ties that falls into a BMI classification of > 35 kg/m2, long-term intensive lifestyle 
intervention to prevent progression to T2DM is cost-effective.
Rationale:
The DPP results suggest that the use of intensive lifestyle intervention to prevent 
T2DM may be more efficacious in subjects with a BMI < 35 kg/m2 (see Table 
2.6).279 These hypotheses allow for a division into BMI subgroups to examine the 
effect of increasing levels of obesity on the cost-effectiveness of the intervention.
H4: If adjustments to mortality hazard rates and direct healthcare costs that are sug-
gested by current literature are made for the exclusion of baseline disease-state 
abnormalities as well as obesity in an evaluation of a population similar to that 
studied by the DPP (average BMI classification of obese class I, and diagnosis of 
IGT), long-term intensive lifestyle intervention to prevent progression to T2DM is 
cost-effective.
Rationale:
This hypothesis includes the following modifications to H1 that are discussed in 
the literature review:
(1) the need for an increased mortality hazard rate for obese subjects with NGT 
reflecting this finding in studies of mortality in cohorts that have baseline 
exclusions of disease abnormalities, and in particular, cardiovascular 
disease,in their design (Section 3.6.3),280, 281
279  Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle inter-
vention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
280  Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. New
England Journal of Medicine. 1995;333:677-685.
281  Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life
expectancy: a life-table analysis. Annals of Internal Medicine. 2003;138:24-32.
112
(2) the need for an increased mortality hazard rate for obese subjects with 
T2DM with increasing BMI (Section 3.6.1.3) ,282
(3) the need for the possible inclusion of an increased cost of illness for obese 
subjects with NGT (Section 3.5.4.3). 283
H5: In a population with IGT and an average BMI category of obese class I that is 
drawn from a hypothetical cohort that has no disease-state exclusions in the base
line study design criteria, and in which no adjustments are made for obesity, long-
term intensive lifestyle intervention to prevent progression to T2DM is cost-effective. 
Rationale:
The rationale for this hypothesis again follows that outlined in H1, except that it 
allows for a more generalizable population, i.e. one with multiple beginning dis-
ease state abnormalities in addition to IGT.  This beginning health status appears 
to be more representative of an obese population. 284
H6:  In a population with IGT and an average BMI category of obese class I that is 
drawn from a hypothetical cohort that has no disease-state exclusions in the base
line study design criteria, and in which adjustments are made for obesity, long-
term intensive lifestyle intervention to prevent progression to T2DM is cost-effective.
Rationale:
This hypothesis (in similar fashion to H4) includes the following modifications to H5 
that were discussed in the literature review:
282 Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and
diabetes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
283  Thompson D, Brown JB, Nichols GA, et al. Body mass index and future healthcare costs: a 
retrospective cohort study. Obesity Research. 2001;9:210-218.
284  Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States.
Obesity Research. 1998;6:97-106.
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(1) the need for an increased mortality hazard rate for obese subjects with 
T2DM with increasing BMI (Section 3.6.1.3), 285
(2) the need for the possible inclusion of an increased cost of illness for obese 
subjects with NGT (Section 3.5.4.3). 286
On the other hand, unlike H4, where mortality hazard rates for obese subjects with 
NGT were adjusted due to exclusion of disease-state abnormalities at baseline, 
there is no need to make these adjustments due to the inclusion of all possible 
health states in the analysis.
285  Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and
diabetes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
286  Thompson D, Brown JB, Nichols GA, et al. Body mass index and future healthcare costs: a 
retrospective cohort study. Obesity Research. 2001;9:210-218.
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CHAPTER 4 – METHODOLOGY
The major problem identified in this dissertation is that while current research sug-
gests that lifestyle intervention to prevent progression from IGT to T2DM is effective over
a three-year period, it is not currently known whether this method of intervention is cost-
effective over the lifetime of a subject.  Modeling techniques, therefore, were required to
extrapolate the DPP three-year data over the long-term.
A healthcare model has been described as "any mathematical structure that represents
the health and economic outcomes of patients, or populations under a variety of scenar-
ios."287 Kuntz and Weinstein have suggested that in some cases, the only approach that
may be available to address a research problem may be constructing a model that is based
entirely on data acquired from literature sources and existing databases.288 Using avail-
able data to construct a model allows for simulation of a clinical trial that can attempt to
answer questions not answered directly by current data, such as those required for this dis-
sertation.  
Another advantage of modeling, described by Kuntz and Weinstein, is that treatment
effects derived from clinical studies based on cohorts that are not particularly representa-
tive of the general population can be extrapolated to attempt to make the results more gen-
eralizable.289 As noted, the DPP subjects started in a state of IGT.  At least some of these
subjects started the study with both clinically defined IFG and IGT, which is not as com-
mon in the general population as either of these abnormalities alone (see Section 
287  Kuntz K, Weinstein M. Ch. 7 - Modeling in Economic Evaluation. In: Drummond M, McGuire





2.1.2.2.1).  In addition, the health care exclusions that are part of the study criteria are not
reflective of most obese subjects, in general, or of obese subjects with abnormal glucose
homeostasis, in particular (see Section 2.3.3 for exclusion criteria).
Along with the possible improvement in generalizability afforded by modeling, these
mathematical techniques allow us to incorporate differing scenarios into the baseline
analyses.  The major scenario that modeling allows us to examine is the effect of obesity
on costs, mortality, and healthcare utility in subjects at various stages of glucose home-
ostasis.  Modeling also allows for incorporation of sensitivity analyses to test the major
effects of all variables and transition probabilities, and the possible interactions of these
various factors. 
Modeling, therefore, allows us to extrapolate the data from the literature review and
the DPP study to a time horizon beyond the trial, attempting to answer the question of
long-term cost effectiveness of lifestyle intervention to prevent T2DM.  Modeling also
allows us to attempt to make the DPP data more generalizable.  In addition, modeling
allows for incorporation of the effects of factors such as obesity and weight loss on gen-
eralized health states, costs, mortality, and healthcare utilities.
Finally, the results of the modeling analyses used in this dissertation and other evalu-
ations of extensive lifestyle intervention to prevent T2DM may aid in the design of future
research.290 In the most general way, this particular set of dissertation models allows the
researcher to ask the question, "Should this intervention even be undertaken?"  If the
answer is affirmative, the investigator can progress to more specific research questions.
Examples in this case would be determining subgroups to most effectively target for treat-
ment, or establishing cost ranges for the intervention.
290  Briggs A, Goeree MA, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models:




Frequently cited articles describing the use of Markov modeling for healthcare
research are those by Beck and Pauker, published in 1983,291 and Sonnenberg and Beck,
published in 1993.292 The later article describes Markov models as "analytical structures
that represent key elements of a disease and are commonly used in economic evalua-
tions."293 The models have found particular use when evaluating the progression of chron-
ic diseases such as T2DM, where input data, such as transition probabilities, costs or
utilities, change over time because they are based on "transitions between defined health
states."294, 295
To construct a Markov model, several steps are required.296, 297, 298 The disease states
required for the model must first be specified.  Kuntz and Weinstein emphasize the impor-
tance that each of these states must reflect "the relevant states of health associated with
the disease and treatment over time."299 Other authors have stated that the states must 
291  Beck JR, Pauker SG. The Markov process in medical prognosis. Medical Decision Making.
1983;3:419-458.
292  Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Medical
Decision Making. 1993;13:322-338.
293  Ibid.
294  Kuntz K, Weinstein M. Ch. 7 - Modeling in Economic Evaluation. In: Drummond M, McGuire
A, eds. Economic Evaluation in Health Care: Merging Theory with Practice. New York: Oxford
University Press; 2001:141-171.
295  Kahn J. Lecture 6 - Portraying disease progression: Markov modeling. San Francisco: UCSF
Department of Epidemiology and Biostatistics; 2003.
296  Glick H. Introduction to Markov Models. Available at:
www.uphs.upenn.edu/dgimhsr/MARK0303.pdf. Accessed July 2004.
297  Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation.
Pharmacoeconomics. 1998;13:397-409.
298  Kuntz K, Weinstein M. Ch. 7 - Modeling in Economic Evaluation. In: Drummond M, McGuire




represent "clinically and economically important events in the disease process to be mod-
eled."300 Each state must be mutually exclusive, and the subject cannot be in more than
one state at a time.  
Markov cycle lengths are then assigned.  These are chosen to best approximate the
stages of the disease or treatment in question.
The next step is to assign transition probabilities to the model.  Markov models are dif-
ferentiated into two distinct types by the transition probabilities that are incorporated into
the analysis.301 Markov chain models use constant transition probabilities over time, while
time-dependent Markov processes allow transition probabilities to vary over time.
The model is then populated with estimates of transition probabilities that have been
derived from current literature or trial data.  The initial distribution in the Markov states
is then assigned.  All subjects may start in one state, or the cohort may be divided among
the states. Generally, the assumption is made that subjects all start in a "well" state, or in
this case the "IGT" state.  Estimates of health costs and utilities (which are referred to in
the model as "variables") are then inserted into the model.
There are two major methods of evaluating Markov models.302 Cohort simulation is a
method that takes each "hypothetical cohort" through the model simultaneously.  The
results of this type of evaluation give "average" results for the hypothetical cohort.  The
alternative method of evaluation is a first-order Monte Carlo simulation, which allows for
the random selection of subjects to each go through the model individually.  Briggs sug-
gests that using this technique is similar to adjusting for population variability in a cohort, 
300 Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation.
Pharmacoeconomics. 1998;13:397-409.
301  Ibid.
302 Glick H. Introduction to Markov Models. Available at:
www.uphs.upenn.edu/dgimhsr/MARK0303.pdf. Accessed July 2004.
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or stated in another way, adjusting for alternative pathways through the model.303 It is
important to note that variability is due to differences in the patient’s progress through the
disease state, and is not due to variation in parameter values in this evaluation method.  In
other words, each subject is allowed to have his or her own "history" throughout the
model.  The major advantage of this method is that past information can be tracked
through the model, allowing for increased complexity of the health state descriptions.  
The major outputs that are generally reported after a Markov analysis are lifetime costs,
life expectancy, percentage of subjects in each Markov stage, and incremental cost effec-
tiveness in terms of costs per life-year gained and costs per QALY.
4.2 Sensitivity Analyses
One of the most important uses of modeling is to manage uncertainty.304 This is espe-
cially pertinent in early stages of research about the applicability of a treatment such as
lifestyle intervention to prevent T2DM, as there is a substantial amount of uncertainty
associated with almost all of the transition probabilities and cost and utility variables used.
It has been suggested that analysts using Markov modeling should include "assessment of
the implications of uncertainty for their result" for any analyses performed.305
In a study with substantial uncertainty, sensitivity analyses are important for two
major reasons.306 Sensitivity analyses suggest that the modeler knows the potential effect
of variation of the input data.  In addition, sensitivity analyses allow for an evaluation of 
303  Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 
2000;17:479-500.
304  Sculpher M. The Role and Potential of Probabilistic Modeling. Paper presented at: Society for
Medical Decision Making, 2003; Chicago.
305  Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 
2000;17:479-500.
306  Marseille E. Lecture 5: Cost-effectiveness analysis: sensitivity analysis. San Francisco: UCSF
Department of Epidemiology and Biostatistics; 2003.
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the effect of variation of input data on the final results of the study.  The most important
result of the later, as previously noted, is to aid in design of further research studies.
Briggs identified several major divisions of parameter uncertainty that are found in
healthcare modeling.307 Uncertainty surrounding analytic methods may include the actual
method of modeling, the methods involved in evaluating costs or utilities, or how to
include discount rates in the model.  In addition, as previously discussed, first-order uncer-
tainty is that which is associated with "variability in the underlying population from which
the model is drawn."308
The input data used in the model are an additional source of uncertainty.  This is com-
monly referred to as second-order uncertainty.309 The common method of evaluating this
second-order uncertainty is referred to as deterministic sensitivity analyses, or more com-
monly seen in the literature as one-way, two-way, or multi-way sensitivity analyses.  A
more recently introduced method of evaluating parameter uncertainty is referred to as
probabilistic sensitivity analysis.
4.2.1   DETERMINISTIC SENSITIVITY ANALYSES
Deterministic sensitivity analyses are a standard in healthcare economic analyses.  In
a one-way sensitivity analysis, all other input is held constant as one variable at a time is
altered over a predetermined range by the modeler.  This allows for an evaluation of the
dependence of the results on that particular input.310 Another important use of one-way
sensitivity analyses is to "identify errors in the formulas that link inputs to outcomes," 




310  Marseille E. Lecture 5: Cost-effectiveness analysis: sensitivity analysis. San Francisco: UCSF
Department of Epidemiology and Biostatistics; 2003.
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which is more commonly known as debugging.311 A final important use of one-way sen-
sitivity analyses is to substantiate results.  This step can ultimately allow for identification
of further research needs.
The problem with one-way sensitivity analyses is that uncertainty may be underesti-
mated, as it is unlikely that there will be no variation of other input parameters in the
model.312 It has also been suggested that bias is introduced when using deterministic sen-
sitivity analysis.  There are two major reasons for this bias:  interpretation of the sensitiv-
ity analysis may be arbitrary depending on the modeler; and interaction between
parameters may be ignored.313, 314
4.2.2 PROBABLISTIC SENSITIVITY ANALYSIS
Probabilistic sensitivity analysis is a method that has been introduced to address the
problem of failing to recognize the interaction between variables in a model.  As originally
introduced by Critchfield et al., the first step for a probabilistic sensitivity analysis is to
choose a probability density function for each variable that is to be evaluated using this
technique.315 These distribution functions relate to the nature of each variable.316
The following are current common recommendations for distributions of major classes
311  Ibid.
312  Briggs A, Goeree MA, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models:
choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making.
2002;22:290-308.
313  O'Brien BJ, Drummond MF, Labelle RJ, et al. In search of power and significance: issues in the
design and analysis of stochastic and cost-effectiveness studies in health care. Medical Care.
1994;1994:150-163.
314  Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479-
500.
315  Critchfield GC, Willard KE, Connelly DP. Probabilistic sensitivity analysis methods for general
decision models. Computers and Biomedical Research. 1986;19:254-265.
316  Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479-
500.
121
of parameters used in Markov models.  Cost data may be normally distributed,  but if data
are skewed, a gamma distribution may be more appropriate.318 A gamma distribution is
constrained to be positive and is fully continuous.319
The beta distribution is a continuous distribution which is conjugate to the binomial
distribution.320 Transition probabilities are bounded by 0-1 intervals and are commonly
given a beta distribution.321 When the original data are not available, it is suggested that
the method of moment’s estimation be utilized to determine the beta input parameters.
Utilities may also be represented by beta distributions if they are far from zero.322 On the
other hand, it is suggested that relative risks be represented by log-normal distributions.
The above distributions assume that the modeler has actual statistical data or meta-
analysis results to work with.  When these data options are not available, and a theoreti-
cal foundation is not available for the distribution in question, two distributions are
available to insert into the probabilistic sensitivity analysis. The first is the triangular dis-
tribution, which allows input of the data using a lower limit value, a most likely value (the
mode), and an upper limit value.323 A second distribution method to use in this situation
is the uniform distribution, or rectangular distribution.324 In this distribution, the probability 
318  Briggs A. Probabilistic cost-effectiveness modeling: practical aspects of modeling: fitting distri-
butions and drawing simulations. Paper presented at: Society of Medical Decision Making, 2003;
Chicago.
319  Briggs A, Goeree MA, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models:
choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making.
2002;22:290-308.
320  Ibid.
321  Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479-
500.
322  Briggs A. Probabilistic cost-effectiveness modeling: practical aspects of modeling: fitting distri-
butions and drawing simulations. Paper presented at: Society of Medical Decision Making, 2003;
Chicago.
323 Triangular Distribution. Vanguard Software Corporation. Available at:
http://www.vanguardsw.com/dphelp4/dph00121.htm. Accessed July 2004.
324 Uniform Distribution. Available at: davidmlane.com/hyperstat/A12237.html. Accessed July 2004.
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of occurrence is the same for all values of X.
4.3 Models Required for this Dissertation
Figure 4.1 shows the prototype for all models used to extrapolate long-term cost-effec-
tiveness of intensive lifestyle intervention to prevent T2DM. The models used were
designed using DATA 4.0 software (TreeAge Software, Inc., Williamstown,
Massachusetts).325
The following are the basic models that were used to test the study hypotheses.
Appendix 1 contains an overview table of the models and the hypotheses.  Appendix 2
includes complete tables of input data for Models 1A and 1B, and Appendix 3 includes the
same for Models 2A and 2B.  Appendix 4 includes a list of assumptions used in this
methodology section.
Model 1A: A population similar to that studied by the DPP is assumed.  This population 
has no major disease-state abnormalities except for IGT at baseline.  The 
population has an average BMI that falls into the category of obese class I.  
No adjustments were made to cost or mortality variables secondary to obesi-
ty or the healthcare exclusions.  This model was used to address H1, H2, and 
H3 by adjusting transition probabilities between the Markov states to reflect 
the efficacy of the DPP intervention at different BMI classifications.
Model 1B: A population similar to that studied by the DPP is assumed.  This population 
has no major disease-state abnormalities except for IGT at baseline.  The 
population has an average BMI that falls into the category of obese class I.  
Adjustments were made to cost and mortality variables secondary to obesity 
and healthcare exclusions.  This model addresses H4. 
325  TreeAge Software, Inc. Available at: http://www.treeage.com/.
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Model 2A: An IGT population that has no disease state exclusions at baseline with aver-
age BMI category of obese class I is assumed in order to make the analysis 
more generalizable.  No additional adjustments were made for obesity.  This 
model addresses H5.
Model 2B: An IGT population that has no disease state exclusions at baseline with an 
average BMI category of obese class I is assumed in order to make the analy-
sis more generalizable.  Adjustments for obesity were made to mortality and 
cost variables.  This model addresses H6.
Figure 4.1  Prototype Model for Dissertation Models























































The two arms from the first choice node are those corresponding to the placebo and
intensive lifestyle intervention arms of the study.  The four Markov states included are
NGT, IGT, T2DM and Death.  All subjects start in the IGT state; they may remain in the
IGT state or move to any of the other three states.  From the state of NGT a subject may
remain in the state of NGT, or progress to the states of IGT or Death.  The assumption was
made that progression from NGT to T2DM without progressing through the state of IGT
is sufficiently unlikely to not include this as an option in the model.  The assumption was
also made that a subject will not spontaneously revert back to IGT from T2DM.  A sensi-
tivity analysis based on the possibility that a newly diagnosed T2DM subject may revert
back to the IGT state (see section 2.1.2.3.5) was conducted for Models 2A and 2B.
The Markov cycle length is one year.  The term "stage" is used synonymously with the
term "cycle" throughout the following discussions.  All subjects in the model started at a
baseline age of 50 years.  The model is designed to run until subjects reach the age of 85
years.  All patients started at a BMI of 34 kg/m2 (except for the subgroups of Model 1A).
Probabilities for progression from IGT to T2DM, and reversion from IGT to NGT, as well
as utility values were taken from the DPP results.326
The probability variables that were used in the placebo arm of all models for progres-
sion through the states of glucose homeostasis are listed in Table 4.1.  The one-year prob-
abilities of progression from IGT to T2DM and reversion to NGT from the state of IGT
were taken from DPP results.327
A one-year probability for progression from NGT to IGT of 0.0767 was chosen for the
placebo arm of the study.  This value, derived from the Pima Indian Study discussed in 
326  Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes
with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
327  Ibid.
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Section 2.1.2.3.3.2, was chosen using the following reasoning.328 The DPP subjects’ rate
of one-year transition probability from IGT to T2DM in the placebo group of 0.1075 was
much higher than the value of 0.0676 that was expected (Sections 2.1.2.3.2 and 2.3.3).329, 330
This higher value was attributed to the "selection of patients at higher risk" (i.e. with a
combined state of IFG and IGT), or more frequent glucose testing.331
The Pima Indians had the highest rate of progression from IGT to T2DM of all stud-
ies evaluated by Edelstein et al. (one-year transition probability of 0.0836).332 Therefore,
the assumption was made for this study that the transition probability from NGT to IGT
for this cohort would also reflect this high progression rate, and the value might be real-
istic for the DPP model.
The literature review also noted a high transition probability of progression from NGT
to IGT in the Miegs et al. study discussed in Section 2.1.2.3.3.1 (a one-year transition
probability of 0.0624 based on a ten-year follow-up, which is 18.6% less than the Pima
Indian Study value).333 These higher values might be a reflection of the use of an abnor-
mal OGTT to define IGT, as this test is considered more sensitive for the diagnosis.   A
sensitivity analysis was conducted for this transition probability (using the Pima Indian
value of 0.0767) using values 20% greater.
328 Weyer C, Tataranni P, Bogardus C, et al. Insulin resistance and insulin secretory dysfunction are
independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes develop-
ment. Diabetes Care. 2001;24(1):89-94.
329  Diabetes Prevention Program Research Group. The Diabetes Prevention Program: design and
methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22:623-634.
330  Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes
with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
331  Ibid.
332  Edelstein SI, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose toler-
ance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701-710.
333  Meigs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose
tolerance to type 2 diabetes in the Baltimore Longitudinal Study of the Aging. Diabetes. 2003;52:1475-
1484.
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Table 4.1 Transition Probabilities Used in the Placebo Arm of All Models
Sources:
a: Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
b: Weyer C, Tataranni PA, Bogardus C, et al.  Insulin resistance and insulin secretory dysfunction are
independent predictors of worsening glucose tolerance during each stage of type 2 diabetes development.
Diabetes Care. 2001;24:89-94.
The transition probabilities used in the intensive lifestyle arm of all models are listed
in Table 4.2.  Once again, the one-year probabilities of change from IGT to NGT or T2DM
were taken directly from the DPP study.  The probability of progression from NGT to IGT
was calculated using the Pima Indian Study value of 0.0767 and lowering it by the same
rate of decrease as that found from IGT to T2DM between the placebo and lifestyle arms
of the DPP study (53% using probability rates), resulting in a value of 0.0406.334 A sensi-
tivity analysis was also conducted for this variable, using a 20% greater value (0.0487).
Table 4.2  Transition Probabilities Used in the Intensive Lifestyle Arm of All Models
Sources:
a: Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
b: Weyer C, Tataranni PA, Bogardus C, et al.  Insulin resistance and insulin secretory dysfunction are
independent predictors of worsening glucose tolerance during each stage of type 2 diabetes development.
Diabetes Care. 2001;24:89-94.
334  Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes
with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
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Variable One-Year Probability Source
Progression from IGT to T2DM 0.1075 a
Reversion from IGT to NGT 0.0678 a
Progression from NGT to IGT 0.0767 b
Variable One-Year Probability Source
Progression from IGT to T2DM 0.0505 a
Reversion from IGT to NGT 0.1121 a
Progression from NGT to IGT 0.0406 b
The transition probabilities used for progression to the Death stage in each model will
be described in detail below, but the baseline mortality rates were derived from U.S. Life
Table statistics for the year 2000.335 The year 2000 was used because costs in this model
were adjusted to the year 2000 using the Medical Consumer Price Index.336
No specific values are given in the models for the probability of staying in a specific
Markov state from cycle to cycle (i.e. starting in the NGT state and ending in the NGT
state in the next cycle).  TreeAge DATA 4.0 software includes a built-in complementary
probability expression that "automatically calculates 1.0 minus the sum of probabilities at
the other branches." 337
Table 4.3 lists cost variables for screening and intervention that were used in all mod-
els in the dissertation.  These cost values were derived from the cost analysis performed
by the DPP for the study as discussed in 3.4.1.338 All costs are in year 2000 dollars.
Table 4.3 Costs of Screening and Intervention in Years One through Three of the 
Diabetes Prevention Programa
a Source: The Diabetes Prevention Program Research Group. Costs associated with the primary prevention
of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36-47.
335  Arias E. United States Life Tables, 2000. Hyattsville, MD: National Center for Health Statistics;
2002. vol. 51;3.
336 Labor Statistics Data. Consumer Price Index: Medical Care Services. U.S. Bureau of Labor
Statistics. Accessed April 2004.
337  DATA Healthcare User's Manual. Williamstown, MA: TreeAge Software, Inc.; 2002.
338 Diabetes Prevention Program Research Group. Costs associated with the primary prevention of






Screening (1st Year) $139 $139 
Intervention
      Year 1 $43 $1,399 
      Year 2 $18 $679 
      Year 3 $18 $702 
Utility values also do not vary between the models.  As discussed in Section 3.7, the
values given in Table 3.18 were used for all three groups of NGT, IGT and T2DM for the
first three years.  The value of 0.692 was used for the NGT, IGT and T2DM groups of the
lifestyle group for years four and higher of the model, and the value of 0.657 was used for
the NGT, IGT and T2DM for the placebo arm.339
The treatment intervention was modeled to occur over the first three Markov cycles to
mimic the three-year duration of the program.  Two scenarios will be reported for dura-
tion of treatment effect. The first scenario made the assumption that the treatment effect
will last for a subject’s lifetime.  This scenario was based on the assumption that the effi-
cacy of the program is due, at least in part, to weight loss maintenance, and that weight
loss is maintained in the lifestyle intervention program at the rate that was attained at the
end of the third year of the study, or 38%.340 While this value is higher than the 20% value
of sustained weight loss maintenance reported by Wing et al.,341 it reflects the stabilization
at two years to five years of weight loss maintenance reported by McGuire et al.342 The
models were also analyzed assuming that duration of efficacy of the lifestyle duration only
occurs for the initial three years of the program, and at the fourth year, lifestyle interven-
tion probabilities will revert back to the placebo values.
All base-case models were first run without using discount rates, and then discount
rates of 3% and 5% were incorporated for both costs and health consequences. This is in
accordance to current frequently cited recommendations in Gold’s Cost-Effectiveness in
Health and Medicine.343
339  Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle interven-
tion or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
340 Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes
with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
341  Wing RR, Hill JO. Successful Weight Loss Maintenance. Annual Review of Nutrition. 
2001;21:323-341.
342  McGuire MT, Wing RR, Klem ML, et al. What predicts weight regain among a group of successful
weight losers? Journal of Consulting and Clinical Psychology. 1999;67:177-185.
343  Lipscomb J, Weinstein MC, Torrance GW. Ch. 7- Time Preference. In: Gold MR, Russell LB,
Siegel JE, et al., eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
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The following sections will describe in greater detail each of these models.  The vari-
ables included for each model will be given, with the rationale behind their choice.
Sensitivity analyses will also be described.
4.3.1 MODEL 1A: A MODEL BASED ON THE DPP COHORT
Model 1A was designed to most closely approximate the cohort that was studied by
the DPP.  As previously noted, the DPP study criteria excluded patients who had health-
care abnormalities other than IGT.  As discussed in the literature review, the major areas
affected by the exclusion criteria are costs and mortality.  The following will include a
description of all input parameters not included in Tables 4.1, 4.2, and 4.3 necessary to
populate Model 1A.  The discussion will also include assumptions required to select this
data.  Any possible effect that the exclusion of healthcare states in design criteria of stud-
ies has on input data will also be emphasized to reflect the healthcare exclusions used in
the design criteria of the DPP.  As noted, a complete table of input data for the model is
contained in Appendix 2.
4.3.1.1 Model 1A: Cost of Direct Medical Care Outside of the Intervention
The average yearly direct medical costs for each of the first three years of all subjects
in the placebo arm of the DPP study was $1,670 and in the lifestyle arm was $1,526
(Section 3.4.1.3).344 The major problem with using these values is there is no breakdown
for costs for each specific group of NGT, IGT or T2DM subjects, and this type of cost
adjustment is required for all of the models used in this dissertation.
344 Diabetes Prevention Program Research Group. Costs associated with the primary prevention of
type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36-47.
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In addition, direct medical cost values for the DPP are even lower than control values
found for patients with NGT in all studies examined in Section 3.5.  One hypothesis for
these low costs is that they reflect the exclusion of healthcare abnormalities other than
IGT as a selection criterion for the DPP.  Therefore, the following steps have been taken
to incorporate direct healthcare costs for the states into the dissertation model.  
4.3.1.1.1 Control Cost of Illness for NGT Subjects
Due to the extreme difference between the DPP direct healthcare cost values and those
reported in the reviewed literature, the decision was made to use two different control fig-
ures for subjects with NGT in this model (the basic "control" cost).  For the first three
years of the study, the approximate control direct cost of healthcare found in the DPP was
used.  For the subsequent years after year three, a second, higher and possibly more rep-
resentative, direct healthcare cost was used.  The derivation of both of these values will
now be discussed.
The literature review suggests that a subject with IGT has an increase in outside costs
of healthcare of approximately 1.5 times control costs (Section 3.5.3.2.1).345 The approx-
imate increased cost of care for a subject with diabetes is 2 times the control cost (Section
3.5.2).346,347 Using the three-year, per capita direct medical costs for the placebo group
derived from the cost-analysis of the DPP ($5,011),348 these increased cost of care ratios
noted above, the approximate three-year cumulative incidences of progressing through 
345  Nichols GA, Glauber HS, Brown JB. Type 2 diabetes: incremental medical care costs during the
8 years preceding diagnosis. Diabetes Care. 2000;23:1654-1659.
346  Brown JB, Nichols GA, Glauber HS, et al. Type 2 diabetes: incremental medical care costs dur-
ing the first 8 years after diagnosis. Diabetes Care. 1999;22:1116-1124.
347  American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care.
2003;26:917-932.
348  Diabetes Prevention Program Research Group. Costs associated with the primary prevention of
type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36-47.
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the states of glucose homeostasis given in Section 2.3.3 (NGT = 19%, IGT = 52%, and
T2DM = 29%),349 and basic algebraic manipulation gives an approximate per capita con-
trol cost of NGT patients for the first three years of the study.  The algebraic formula for
this calculation is given below:
The average three-year direct cost per patient for the entire placebo group (all 
groups of glucose homeostasis) = 
The cumulative incidence of NGT status at the end of three years X 
(Control Cost) 
+
The cumulative incidence of IGT status at the end of three years X 1.5 X 
(Control Cost)
+
The cumulative incidence of T2DM status at the end of three years X 2.0 X
(Control Cost)
OR
$5,011 = 0.19 (Control Cost) + 0.52(1.5) (Control Cost) + 0.29(2.0) (Control 
Cost)
Solving for Control Cost for three years gives a value of $3,233.  Therefore, the one-year
per capita direct control cost is approximately $1,078.  
For the control cost value used for the subsequent years after year three, the assump-
tion was made that medical costs should more closely approximate those which were
found in the literature review.  A control cost for subjects with NGT of $2,688 was chosen
349 Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes
with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
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to use for years four to the completion of the model (subject age of 85 years).  This figure
was taken from the Kaiser Permanente control cost figures350, 351 because these figures were
thought to be lower than average direct healthcare costs that were generated at the time by
non-managed care systems.  The reasoning behind increasing healthcare costs and using
this specific value is that in spite of dramatically lower direct healthcare costs seen in the
first three years of the DPP, which is assumed to be, in part, secondary to design criteria
of healthcare exclusions, healthcare costs will ultimately increase in this cohort.  The
assumption is made, however, that this increase will not be as high as those reported in
Section 3.5.
4.3.1.1.2 Cost of Abnormal Glucose Homeostasis
The decision was made to multiply control costs of illness by the ratio of total health-
care costs to control costs for T2DM and IGT to derive values for cost of illness for each
of these subgroups.
T2DM multipliers can be approached in several different ways for the model.  Using
the studies reported in Section 3.5 of the literature review, it is noted that the ratio of total
health care costs to control for T2DM ranges from approximately 2.03 to 2.83, with an
average approximate value of 2.27.352, 353, 354  The low value of 1.57 for years one through
three after diagnosis of T2DM by Brown et al. was eliminated as an outlier, with the 
350 Brown JB, Nichols GA, Glauber HS, et al. Type 2 diabetes: incremental medical care costs 
during the first 8 years after diagnosis. Diabetes Care. 1999;22:1116-1124.
351  Nichols GA, Glauber HS, Brown JB. Type 2 diabetes: incremental medical care costs during the
8 years preceding diagnosis. Diabetes Care. 2000;23:1654-1659.
352  Brown JB, Nichols GA, Glauber HS, et al. Type 2 diabetes: incremental medical care costs 
during the first 8 years after diagnosis. Diabetes Care. 1999;22:1116-1124.
353  Ramsey S, Summers K, Leong SA, et al. Productivity and medical costs of diabetes in a large
employer population. Diabetes Care. 2002;25:23-29.
354  American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care.
2003;26:917-932.
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assumption that this value might be more indicative of the excess cost values found for
subjects with IGT (section 3.5.3.2.1).  A triangular distribution was used, with the most
likely value being 2.27, and upper and lower ranges of 2.03 and 2.83. 
A multiplier for IGT excess cost was based on the Nichols et al. study (Section
3.5.3.2.1).356 A triangular distribution was applied using the values of 1.35, 1.48, and
1.79, with 1.48 being the most likely value.
Subjects with NGT were given the control cost for each cycle of the model for direct
medical care outside of the healthcare system.  These cost multipliers are summarized in
Table 4.4.
Table 4.4 Cost Multipliers for Markov States of Glucose Homeostasis for Model 1A
Sources:
a: Nichols GA, Glauber HS, Brown JB.  Type 2 diabetes: incremental medical care costs during the 8
years preceding diagnosis.  Diabetes Care. 2000;23:1654-1659.
b: Brown JB, Nichols GA, Glauber HS, et al.  Type 2 diabetes: incremental medical care costs during the
first eight years after diagnosis.  Diabetes Care. 1999;22:1116-1124.
c: American Diabetes Association. Economic costs of diabetes in the US. in 2002. Diabetes Care. 
2003;26:917-932.
d: Ramsey S, Summers K, Leong SA, et al.  Productivity and medical costs of diabetes in a large 
employer population.  Diabetes Care. 2002;25:23-29.
4.3.1.2 Mortality Rates for the Model
Mortality rates in the DPP study may reflect the exclusion of healthcare abnormalities
other than IGT as part of the study design.  The one-year mortality rate of 0.0017 found
in the placebo group and 0.0010 for the lifestyle group for the first three years of the 
356  Nichols GA, Glauber HS, Brown JB. Type 2 diabetes: incremental medical care costs during the
8 years preceding diagnosis. Diabetes Care. 2000;23:1654-1659.
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Markov State Planned Ajustments to Control Cost Source
NGT None
IGT




Use a Multiplier with Triangular Distribution of 
2.03, 2.27, 2.83
b,c,d
study is much lower than the value of 0.0044 found in the U.S. Life Tables for a subject
aged 50 years (Section 3.6.5).357, 358 The decision was again made to use the DPP values as
listed above for the first three years of the study.
For subsequent years, the standard life table mortality figures were incorporated using
the data from the year 2001, which was the year of the termination of the study.359
NHANES II data suggest that diabetes increases the mortality rate by a multiplier of
approximately 1.9.360, 361 A hazard ratio multiplier using a triangular distribution of 1.4,
1.9, and 2.5 was used to increase the standard mortality rate for diabetics in this model
(Section 3.6.1).
There also appears to be a possible increase in mortality rate due to IGT as noted in
the literature review.  A triangular distribution was used for this multiplier, with the val-
ues of 0.8, 1.1, and 1.6 being used as derived from NHANES II data (Section 3.6.2).362
No adjustment to mortality rates was given to subjects who pass into the Death stage
from the NGT stage.  A summary of the hazard ratios used for Model 1A for the years sub-
sequent to cycle year three are given in Table 4.5.
357  Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle inter-
vention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
358  Arias E. United States Life Tables, 2000. Hyattsville, MD: National Center for Health Statistics;
2002. vol. 51;3.
359  Ibid.
360  Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of
death in the U.S. Diabetes Care. 2001;24:447-453.
361  Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burden of death attributable to diabetes
in the United States. American Journal of Epidemiology. 2002;156:714-719.
362  Saydah SH, Miret M, Sung J, et al. Postchallenge hyperglycemia and mortality in a national sam-
ple of U.S. adults. Diabetes Care. 2001;24:1397-1402.
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Table 4.5 Hazard Ratio Multipliers for Mortality in Model 1A
a: Saydah SH, Miret M, Sung J, et al.  Postchallenge hyperglycemia and mortality in a national sample of
U.S. adults.  Diabetes Care. 2001;24:1397-1402.
b: Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of death
in the U.S.  Diabetes Care. 2001;24:447-453.
c: Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burdens of death attributable to diabetes in the
United States.  American Journal of Epidemiology. 2002;156:714-719.
4.3.1.3 Model 1A Specifications
Figure 4.2 shows the Markov model required for Model 1A.  The first information
shown in a TreeAge generated Markov model (when examining from left to right) is a
"variable box" that is found under the first choice node (the node from which the placebo
and lifestyle arms emanate).  The variable box contains variable input that is used as
default through the tree.   There are no specific rules for nomenclature for the variables
used in a model, and therefore variable names are subject to the preference of the model-
er.  Figure 4.3 shows the variable box information for Model 1A.  The names and defini-
tions of variables are given in Table 4.6 (as well as Appendix 2), and will be described in
detail through the next sections.
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Markov State
Adjustments to Mortality Rates 




Use a Hazard Ratio Multiplier of 
0.8, 1.1, and 1.6
a
T2DM
Use a Hazard Ratio Multiplier of 
1.4, 1.9, and 2.5
b,c
















































































pDie_L_I_ 1A=1-exp(-mo rt_L_1A[Age+_stage ]*HRI_mort_1A)
pDie_L_NGT_ 1A=1-exp(-mort_L_1A[Age+_ stage])






















Table 4.6 Variable Information for Model 1A
(mort_Pl_1A) refers to the mortality table for the placebo arm of 1A
(mort_L_1A) refers to the mortality table for the lifestyle arm of 1A
[Age+_stage] refers to the number of the cycle under evaluation in an imported table
DistSamp, distribution sample; exp, exponential
4.3.1.3.1 Transition Probabilities for Model 1A: Lifetime Duration of Effect
The following section describes the required transition probabilities for the subset of
Model 1A that assumes lifetime duration of the effect of the intensive lifestyle interven-
tion.  Figure 4.4 illustrates the specific transition probabilities for the placebo arm of
Model 1A.  All subjects started in the IGT state, so the number 1 was placed under IGT
as an initial state probability, while all other initial state probabilities were given a 0 value.
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Variable Definition Formula or Distribution
Age 50 years
CM_I_1A Cost multiplier of IGT in 1A
Triangular distribution of 1.35, 1.48, 
and 1.79 (DistSamp3)
CM_T_1A Cost multiplier of T2DM in 1A
Triangular distribution of 2.03, 2.27, 
and 2.83 (DistSamp4)
cSC_1A Cost of screening in 1A $139 
HRI_mort_1A
Hazard ratio of mortality for 
IGT in 1A 
Triangular distribution of 0.8, 1.1, 
and 1.6 (DistSamp1)
HRT_mort_1A
Hazard ratio of mortality for 
T2DM in 1A 
Triangular distribution of 1.4, 1.9, 
and 2.5 (DistSamp2)
pDie_Pl_NGT_1A
Probability of death for a NGT 
subject in the placebo arm
1-exp(-mort_Pl_1A[Age+_stage])
pDie_Pl_IGT_1A
Probability of death for an IGT 
subject in the placebo arm
1-exp(-mort_Pl_1A[Age+_stage]       
*HR_I_mort_1A)
pDie_Pl_T_1A
Probability of death for a T2DM 
subject in the placebo arm
1-exp(-mort_Pl_1A[Age+_stage]       
*HR_T_mort_1A)
pDie_L_NGT_1A
Probability of death for a NGT 
subject in the lifestyle arm
1-exp(-mort_L_1A[Age+_stage])      
pDie_L_I_1A
Probability of death for an IGT 
subject in the placebo arm
1-exp(-mort_L_1A[Age+_stage]        
*HR_I_mort_1A)
pDie_L_T_1A
Probability of death for a T2DM 
subject in the lifestyle arm
1-exp(-mort_L_1A[Age+_stage]        
*HR_T_mort_1A 
Specific values for progression from IGT to T2DM, reversion from IGT to NGT, and
progression from NGT to IGT as noted in Table 4.1 (and Appendix 2) were inserted into
appropriate transition probabilities for the model.  The # symbol represents the built-in
complimentary probability expression. 
Figure 4.4 Placebo Arm of Model 1A
Variable Definitions:
pDie_Pl_NGT_1A: The probability of a NGT subject in the placebo arm dying in Model 1A
pDie_Pl_IGT_1A: The probability of an IGT subject in the placebo arm dying in Model 1A
pDie_Pl_T_1A: The probability of a T2DM subject in the placebo arm dying in Model 1A
IGT, impaired glucose tolerance; NGT, normal glucose tolerance; p, probability; Pl, placebo; T2DM, type
2 diabetes mellitus
The mortality transition probabilities require the input of data that varies in the first
three-years to reflect the DPP mortality rates as described in section 4.3.1.2.  The mortal-





































therefore increase with age.363 The baseline table required for Model 1A, which is also the
mortality per age for a NGT placebo subject is given in table 4.7.  These data will be
referred to in the model equations as "mort_Pl_1A."  
Table 4.7  Mortality Rates for Placebo Arm of Model 1A (mort_Pl_1A)a,b
Sources:
a: Diabetes Prevention Program Research  Group. Within-trial cost-effectiveness of lifestyle intervention
or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
b: Arias E. United States Life Tables, 2000.  Hyattsville, MD: National Center for Health Statistics; 2002.
vol. 51;3.
Italicized values reflect DPP mortality figures.
The model also requires adjustments for increased HRs for mortality for the IGT and
T2DM subjects as outlined in Table 4.5 (and Appendix 2).  It is apparent that no single
number can reflect all of the transitions required for a model that varies transition proba-
bilities according to cycle, so the mortality transition probabilities equations must reflect
both the changes in mortality rates as well as adjustments for HRs.  
Using the methodology described by Kuntz et al., the following basic formula was 












50 0.0017 62 0.0125 74 0.0346
51 0.0017 63 0.0136 75 0.0377
52 0.0017 64 0.0148 76 0.0409
53 0.0056 65 0.0161 77 0.0444
54 0.0061 66 0.0174 78 0.0485
55 0.0067 67 0.0189 79 0.0533
56 0.0073 68 0.0207 80 0.0588
57 0.0080 69 0.0227 81 0.0651
58 0.0088 70 0.0247 82 0.0721
59 0.0096 71 0.0267 83 0.0797
60 0.0104 72 0.0290 84 0.0882
61 0.0114 73 0.0317 85 0.0968
developed for the required mortality transition probabilities.364 The example given is for
a subject with NGT from the placebo arm.  The label in the model, pDie_Pl_NGT_1A rep-
resents the following formula used in the model: 1-exp(-mort_Pl_1A[Age +_stage]).  
The equation, pDie_Pl_NGT_1A converts annual rates to annual probabilities as required
by the TreeAge software.  This mathematic conversion is described in Section 2.1.2.3.2
and requires the following basic formula:  probability = 1-exp(-rate).  
As can be seen, the values found in Table 4.7 have been inserted into the equation for
the NGT subject as reflected by the insertion of the "mort_Pl_1A" value.  The multiplica-
tion variable "[Age+_stage]" is required in the software to insert the appropriate value for
mortality per age of subject in each Markov stage (or cycle, remembering that these terms
may be used interchangeably).  Age is defined as 50 years for this model.
The following formulas are those which were inserted into the model to define the
mortality transition probabilities:
pDie_Pl_NGT_1A = 1-exp(-mort_Pl_1A[Age +_stage])
pDie_Pl_IGT_1A = 1-exp(-mort_Pl_1A[Age +_stage]*HRI_mort_1A)
pDie_Pl_T_1A= 1-exp(-mort_Pl_1A[Age +_stage]*HRT_mort_1A).
The latter two formulas reflect the increased HRs of mortality described in Table 4.5.
These hazard ratio formulas are defined as the following:
HRI_mort_1A = hazard ratio of mortality for IGT subjects = a triangular 
distribution of 0.8, 1.1, and 1.6
364  Kuntz KM, Kim JJ, Heijenbrok-Ka. M, et al. Methods for Decision Analysis in Public Health
and Medicine. Boston: Harvard University; 2003.
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HRT_mort_1A = hazard ration of mortality for T2DM subjects = a triangular 
distribution of 1.4, 1.9, and 2.5.
The same procedure, as illustrated in Figure 4.5, was followed for the lifestyle arm of
Model 1A.  Transition probabilities for NGT to IGT, IGT to T2DM, and IGT to T2DM
were directly inserted from Table 4.2 (and seen in Appendix 2). 
Figure 4.5 Intensive Lifestyle Arm of Model 1A
Variable Definitions:
pDie_L_NGT_1A: The probability of a NGT subject in the lifestyle arm dying in 1A
pDie_L_IGT_1A: The probability of an IGT subject in the lifestyle arm dying in 1A
pDie_L_T_1A: The probability of a T2DM subject in the lifestyle arm dying in 1A
IGT, impaired glucose tolerance; L, lifestyle
Once again, mortality transition probabilities require input of data that vary to reflect






































mortality found with age in the U.S. Life Tables.  The mortality table required for the
lifestyle arm is labeled "mort_L_1A."  This table is essentially the same as Table 4.7
("mort_Pl_1A") but the values for the first three Markov cycles (Ages 50 years, 51 years,
and 52 years) are 0.0010, the mortality rate for the intensive lifestyle arm found by the
DPP.
The probability formulas for death found in the lifestyle arm use the same hazard
ratios for mortality for the IGT and T2DM state (HRI_mort_1A and HRT_mort_1A
respectively).  Therefore, the only difference for the death transition probabilities for this
arm is the mortality table information.
4.3.1.3.2 Transition Probabilities for Model 1A: Three-Year Duration of Effect
Model 1A requires the following modifications (as illustrated in Figure 4.6) to adjust
for an outcome measurement that assumes a three-year duration of the intensive lifestyle
intervention effect.  The transition probabilities of progression from NGT to IGT and IGT
to T2DM, as well as the reversion from IGT to NGT in the lifestyle arm were assumed to
revert back to the placebo values in the fourth stage of the model.  This change required
the substitution of the following formulas for the previously fixed transition probabilities.
In addition, these formulas required the values outlined in Table 4.8 to allow for the
changes of the transition probabilities with each cycle.
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Figure 4.6 Lifestyle Arm of Model 1A Adjusted for Three-Year Duration of 
Treatment Effect
Variable Definitions:
pDie_L_NGT_1A: The probability of a NGT subject in the lifestyle arm dying in 1A
pDie_L_IGT_1A: The probability of an IGT subject in the lifestyle arm dying in 1A
pDie_L_T_1A: The probability of a T2DM subject in the lifestyle arm dying in 1A
pNGT_IGT_L_1A: The probability of progressing from NGT to IGT in 1A (three-year duration of effect)
pIGT_NGT_L_1A: The probability of reverting from IGT to NGT in 1A (three-year duration of effect)
pIGT_T_L_1A: The probability of progressing from IGT to T2DM in 1A (three-year duration of effect) 




The three tables required for these formulas are found in Table 4.8.  These tables give the
values for the first ten stages.  It is again important to note that the reader can determine
that these equations require the insertion of tables by the inclusion in the equation of the






































cycle values are those that were used in the intensive lifestyle arm of Model 1A with a life-
time treatment duration effect.  At cycle 4, the transition probabilities revert back to the
placebo rates.
Table 4.8 Transition Probability Tables Required for Model 1A: Three-Year 
Duration of Treatment Effect
Italicized values represent original values from the DPP
pNGT_IGT_Life_1A: the table required to represent transition probabilities from NGT to IGT for the
lifestyle arm of 1A (treatment effect duration of three years)
pIGT_N_Life_1A: the table required to represent transition probabilities from IGT to NGT for the
lifestyle arm of 1A (treatment effect duration of three years)
pIGT_T_Life_1A: the table required to represent transition probabilities from IGT to T2DM for the
lifestyle arm of 1A (treatment effect duration of three years)
4.3.1.3.3 Markov State Rewards for Model 1A
Using the TreeAge Data program, additional assignment of the values of costs, utili-
ties, and life expectancy are all termed state rewards.  These specific values will now be
illustrated.  
4.3.1.3.3.1 Markov State Rewards for Costs









50 0.0406 0.11221 0.0505
51 0.0406 0.11221 0.0505
52 0.0406 0.11221 0.0505
53 0.0767 0.0678 0.1075
54 0.0767 0.0678 0.1075
55 0.0767 0.0678 0.1075
56 0.0767 0.0678 0.1075
57 0.0767 0.0678 0.1075
58 0.0767 0.0678 0.1075
59 0.0767 0.0678 0.1075
ing variables have been described in Table 4.6 (and Appendix 2): CM_I_1A (the cost mul-
tiplier of IGT for IA); CM_T_1A (the cost multiplier for T2DM for 1A); and cSC_1A (the
cost of screening for 1A).
Figure 4.7 Markov State Rewards for Costs for the Placebo Arm of Model 1A
Two additional variables are required for the cost input, and these values were insert-
ed as tables.  As a reminder, tables in the model include the function [Age+_stage] to
allow for matching the stage (or cycle) to the age for each Markov cycle.  The additional
variables are cINT_pl_1A, which represents the cost of the intervention for the placebo
for model 1A, and cNGT_1A, which represents the cost of a NGT subject (for both the
placebo and lifestyle arm).  The cNGT_1A values may also be considered the direct med-






Init Rwd : 0
Incr R wd: (cINT_ pl_1A[ Age+_stage]+cNGT_ 1A[Age+_stage] )





Init Rwd : (cSC_1A)+(cINT_pl_1A[Age+_s tage]+cNGT_1A[Age+_stage]*CM_I_1A)/2
Incr R wd: cINT_pl_1A[Age+_stage]+cNGT_1A[Age+_stage]*C M_I_1A





Init Rwd : 0
Incr R wd: cINT_pl_1A[Age+_stage]+cNGT_1A[Age+_stage]*C M_T_1 A





Init Rwd : 0
Incr R wd: 0




Table 4.9 Cost Tables for Placebo Arm of Model 1A for the First-Ten Stages
cINT_pl_1A: cost of intervention for the placebo arm for model 1A
cNGT_pl_1A: direct medical costs for a normal glucose tolerance subject in the placebo arm
The cost of the intervention directly reflects the costs from the DPP for the placebo
arm.  The direct medical costs for NGT are those derived in section 4.3.1.1.1 for the first
three-years of the study.  The costs then increase to reflect the more probable increase in
direct medical costs for the cohort as described in the same section.
The specific formulas used for the Markov state rewards for the placebo arm of the
model involve knowledge of the initial state probabilities of the cohort and of the concept
behind the half-cycle correction.  As the entire cohort starts in the IGT stage, this cost
information will be described first.
The Markov reward box for the IGT arm as seen in Figure 4.7 contains the following
equation:
InitRwd: (cSc_1A) + (cINT_pl_1A[Age+_stage]  + cNGT_1A[Age+_stage]
* CM_I_1A)/2.
InitRwd is the abbreviation for the initial reward, which occurs during the first stage,
which is referred to as stage zero.  The cost event that occurs during the first stage only













The equation starts with the following formula: (cSc_1A) +
(cINT_pl_1A[Age+_stage].  From Table 4.6 (and Appendix 2) the reader is aware that the
variable cSc_1A represents the cost of screening for the IGT cohort, a cost applied to all
subjects in this arm.  Table 4.9 gives the first ten values for cINT_pl_1A, the cost of inter-
vention for the placebo arm.  For all cycles not given, the cost of the intervention is zero.
The intervention value is also given to all subjects for the first-three years, but this entry
only inserts the first stage value of $43.  
The final part of the equation, cNGT_1A[Age+_stage] * CM_I_1A/2, allows for the
insertion of the direct medical control costs of the IGT subject.  The function,
cNGT_1A[Age+_stage], as given in Table 4.8 is multiplied by the cost multiplier for an
IGT subject, CM_I_1A.  The equation is divided by 1/2 to account for the half-cycle cor-
rection (HCC).  This correction allows for the direct medical costs of an IGT subject to
occur at the middle of the Markov cycle.  It has been found that if all rewards (costs, util-
ities, and life expectancy) accrue at the beginning of the cycle, they are overestimated.  If
rewards occur at the end of the cycle, they are underestimated.365 Therefore this type of
HCC was inserted for utilities and life expectancy in a similar fashion.
The IGT Markov reward box in Figure 4.7 then lists the next equation: 
IncrRwd: cINT_pl_1A[Age+_stage] + (cNGT_1A[Age+_stage]) * CMI_1A.
IncrRwd is the abbreviation for incremental reward, or that which occurs for the stages
that occur after stage zero.  This formula does not include the cost of screening, but does
include the cost of the intervention and the direct medical costs for an IGT subject (direct
medical costs for a NGT subject multiplied by the cost multiplier for IGT).  
FinalRwd is the abbreviation for final reward.  As this model is an absorbing process
defined as a Markov model in which almost the entire cohort is dead at the termination of
the model, no final entry is required.366
365  DATA Healthcare User's Manual. Williamstown, MA: TreeAge Software, Inc.; 2002.
366  Ibid.
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No initial or final rewards are required for the NGT or T2DM states (because all sub-
jects start in the IGT state), and therefore, no HCC are required.  The incremental reward
for the NGT subjects is the following:
cINT_pl_1A[Age+_stage] + cNGT_1A[Age+_stage].
The subject receives the costs of the intervention as well as direct medical costs as listed
in Table 4.8.  
The incremental cost for the T2DM subject is the following:
cINT_pl_1A[Age+_stage] + cNGT_1A[Age+_stage] * CM_T_1A.
This equation again allows for intervention cost inclusion as well as direct medical costs
for the subject with T2DM.
Figure 4.8 illustrates the Markov state rewards for costs for the lifestyle arm of model
1A, and Table 4.10 gives the required cost tables for the model.

























































 --- Markov Information
Term: Age+_stage=86
 
Table 4.10 Cost Tables for Lifestyle Arm of Model 1A for the First-Ten Stages
cInt_L_1A: cost of intervention for the lifestyle arm for model 1A
The cost reward formulas for the lifestyle arm of Model 1A follow the same format as
that described for the placebo arm, except that the cost of the lifestyle intervention is
inserted (cINT_L_1A).
4.3.1.3.3.2  Markov State Rewards for Life Expectancy 
Figure 4.9 illustrates the state rewards for life expectancy for the placebo arm of
Model 1A.  These state rewards are identical for both the placebo and lifestyle arms.  An
HCC was used for the IGT node of the model.  These cost rewards were used for the cost-
effectiveness calculations for the model.  When an actual life expectancy value is calcu-
lated, the HCC is removed according to the protocol outlined in the TreeAge training
course.367













Figure 4.9 Markov State Rewards for Life in the Placebo Arm of Model 1A
4.3.1.3.3.3 Markov State Rewards for Utilities
Figure 4.10 illustrates the Markov state rewards for utilities for the placebo arm for
Model 1A.  The lifestyle arm contains similar formulas, except the variable,
uPl_1A[Age+_stage] is replaced with uLife_1A[Age+_stage].  These values are those
derived from the DPP as described in section 3.7.  The first ten cycles of the tables for






















































 --- Markov Information
Term: Age+_stage=86
 
Figure 4.10 Markov State Rewards for Utilities for the Placebo Arm of Model 1A
Table 4.11 Utility Values for the First-Ten Cycles of Model 1A 
uPl_1A: utility of the placebo arm of model 1A































 --- Markov  Information




































The initial reward (IntRwd) arm of the IGT arm of the placebo in Figure 4.10 contains
the first utility cycle reward, 0.686/2, which is the initial reward corrected by the HCC.
The cycle-specific rewards were then inserted for the incremental rewards (IncRwd) for
all-three nodes (NGT, IGT, and T2DM) of the placebo arm.  The same format was used
for the lifestyle arm, except that the uLife-1A values were inserted.
4.3.1.4 Model 1A Submodels Based on Baseline BMI 
A sensitivity analysis was conducted for Model 1A based on the differences of effica-
cy of intensive lifestyle intervention to prevent T2DM by baseline BMI category in the
DPP as outlined in Table 2.6.  A complete table of input data for the submodels is includ-
ed in Appendix 2.  These submodels were based on the finding that subjects in both the
intervention arm and the placebo arm with a BMI ≥ 35 kg/m2 were more likely to progress
to T2DM from the IGT state than subjects with a BMI less than this value.368
4.3.1.4.1 Submodel of 1A: BMI of 30 kg/m2 to < 35 kg/m2
For the submodel that evaluates long-term cost-effectiveness for the subgroup with a
BMI of 30 kg/m2 to < 35 kg/m2, the following input parameters changed to reflect the
DPP results.  As noted in Table 2.6, the placebo group in this BMI category had a one-year
transition probability form IGT to T2DM of 0.0851 (based on a progression of 8.9 cases
per 100 person-years).369 This transition probability is a 26% improvement over that found
for the overall DPP cohort (11 cases per 100 person-years, or a one-year transition prob-
ability of 0.1075).  The assumption was made that this same improvement will be found
for reversion to IGT to NGT.  The overall DPP cohort had a one-year transition probabil-
368 Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes
with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
369 Ibid.
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ity of 0.0702 for this progression, and the assumption was made that the DPP subcatego-
ry of BMI from 30 kg/m2 to < 35 kg/m2 will improve their reversion rate by the same
26% to 0.0885. The lower rate of transition from NGT to IGT of 0.0602 found in the
Meigs et al. data was used for the model.  These values are shown in Table 4.12.  
Table 4.12 Probability Variables Used in the Placebo Arm of the DPP Submodel 
Based on a BMI Category of 30 kg/m2 to < 35 kg/m2
Sources:
a: Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
b: Meigs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose 
tolerance to type 2 diabetes in the Baltimore Longitudinal Study of the Aging. Diabetes. 2003;52:1475-
1484.
The one-year transition probability from IGT to T2DM for the lifestyle arm of the
BMI subcategory of 30 kg/m2 to < 35 kg/m2 is 0.0363.  This is a 39% improvement over
the overall cohort transition probability of 0.0505.  Once again, using the above method-
ology, the one-year transition probability for reversion from IGT to NGT becomes 0.1653
(reflecting a 39% improvement over the 0.1189 value found in the overall group).  This
39% improvement is also reflected in the assumption of a decreased transition from NGT
to IGT, calculated from the Meigs et al. value of 0.0602 to a value of 0.0433.  These val-
ues are given in Table 4.13.  All other values for variables remained as in Model 1A.  
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Variable One-Year Probability Source
Progression from IGT to T2DM 0.0851 a
Reversion from IGT to NGT 0.0885 a
Progression from NGT to IGT 0.0602 b
Table 4.13  Probability Variables Used in the Intensive Lifestyle Arm of the DPP 
Submodel Based on a BMI Category of 30 kg/m2 to < 35 kg/m2
Sources:
a: Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
b: Meigs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose 
tolerance to type 2 diabetes in the Baltimore Longitudinal Study of the Aging. .Diabetes. 2003;52:1475-
1484.
4.3.1.4.1.1  Model Specifications
Figure 4.11 illustrates the changes required for transition probabilities as outlined in
Tables 4.11 and 4.12.  Appendix 2 contains a table with all input data for this model.   The
submodel of BMI of 30 kg/m2 to < 35 kg/m2 that evaluates a three-year effect of the inter-
vention required the transition probability changes for cycles 1 through 3 for NGT to IGT,
IGT to NGT, and IGT to T2DM, and then the lifestyle arm transition probabilities revert-
ed back to those of the placebo.  The methodology required for this analysis is outlined in
section 4.3.1.3.2.
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Variable One-Year Probability Source
Progression from IGT to T2DM 0.0363 a
Reversion from IGT to NGT 0.1653 a
Progression from NGT to IGT 0.0433 b
Figure 4.11 Submodel of 1A for BMI Subcategory of 30 kg/m2 to < 35 kg/m2
Variable Definitions:
pDie_Pl_NGT_1A: The probability of a NGT subject in the placebo arm dying in Model 1A
pDie_Pl_IGT_1A: The probability of an IGT subject in the placebo arm dying in Model 1A
pDie_Pl_T_1A: The probability of a T2DM subject in the placebo arm dying in Model 1A
pDie_L_NGT_1A: The probability of a NGT subject in the lifestyle arm dying in 1A
pDie_L_IGT_1A: The probability of an IGT subject in the lifestyle arm dying in 1A
pDie_L_T_1A: The probability of a T2DM subject in the lifestyle arm dying in 1A
IGT, impaired glucose tolerance; NGT, normal glucose tolerance; p, probability; Pl, placebo; 











































































4.3.1.4.2  Submodel of 1A: BMI ≥ 35 kg/m2
As a comparator, the model was again evaluated using the progression rates from IGT
to T2DM found in the DPP results for subjects with a BMI ≥ 35 kg/m2.  Table 4.14 gives
the values that were used for the placebo arm of the subgroup.
Table 4.14 Probability Variables Used in the Placebo Arm of the DPP Submodel 
Based on a BMI Category of ≥ 35 kg/m2
Sources:
a: Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
b: Weyer C, Tataranni PA, Bogardus C, et al.  Insulin resistance and insulin secretory dysfunction are
independent predictors of worsening glucose tolerance during each stage of type 2 diabetes development.
Diabetes Care. 2001:24:89-94.
The placebo arm had an increase in progression from IGT to T2DM over the overall
placebo arm of the cohort of 23.9% (a one-year transition probability of 0.1332 versus
0.1075, respectively).  The assumption was made that reversion from IGT to NGT is
reduced by this same amount.  The one-year transition probability from the Pima Indian
Study for progression from NGT to IGT was used for the submodel, as this group has the
highest rate of progression from both NGT to IGT, and IGT to T2DM.370
Table 4.15 lists the values used for the intensive lifestyle arm of the submodel of the
subgroup of BMI ≥ 35 kg/m2.  This subgroup had a 39.4% increase in progression to
T2DM from IGT when compared to the overall lifestyle arm of the cohort (a one-year
transition probability of 0.0704 and 0.0505, respectively).
370  Weyer C, Tataranni P, Bogardus C, et al. Insulin resistance and insulin secretory dysfunction are
independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes develop-
ment. Diabetes Care. 2001;24(1):89-94.
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Variable One-Year Probability Source
Progression from IGT to T2DM 0.1332 a
Reversion from IGT to NGT 0.0567 a
Progression from NGT to IGT 0.0767 b
Table 4.15 Probability Variables Used in the Intensive Lifestyle Arm of the DPP 
Submodel Based on a BMI Category of ≥ 35 kg/m2
Sources:
a: Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
b: Weyer C, Tataranni PA, Bogardus C, et al.  Insulin resistance and insulin secretory dysfunction are
independent predictors of worsening glucose tolerance during each stage of type 2 diabetes development.
Diabetes Care. 2001:24:89-94.
The reversion from IGT to NGT reflects a 39.4% decrease from the overall cohort.
The Pima Indian Study progression from NGT to IGT was increased by this same value.  
All other input variables remained the same for these models as Model 1A.  The tran-
sition probabilities from NGT to IGT, IGT to NGT, and IGT to T2DM reverted back to
placebo values for the model based on three-year duration effect as outlined in section
4.3.1.3.2. 
Figure 4.12 illustrates the required model, and Appendix 2 contains a table with all
required input data.
160
Variable One-Year Probability Source
Progression from IGT to T2DM 0.0704 a
Reversion from IGT to NGT 0.0853 a
Progression from NGT to IGT 0.0465 b
Figure 4.12 Submodel of 1A for BMI Subcategory ≥ 35 kg/m2
Variable Definitions:
pDie_Pl_NGT_1A: The probability of a NGT subject in the placebo arm dying in Model 1A
pDie_Pl_IGT_1A: The probability of an IGT subject in the placebo arm dying in Model 1A
pDie_Pl_T_1A: The probability of a T2DM subject in the placebo arm dying in Model 1A
pDie_L_NGT_1A: The probability of a NGT subject in the lifestyle arm dying in 1A
pDie_L_IGT_1A: The probability of an IGT subject in the lifestyle arm dying in 1A
pDie_L_T_1A: The probability of a T2DM subject in the lifestyle arm dying in 1A
IGT, impaired glucose tolerance; NGT, normal glucose tolerance; p, probability; Pl, placebo; 











































































4.3.2 MODEL 1B: THE MODEL BASED ON THE DPP ADJUSTED FOR 
OBESITY
4.3.2.1 Changes in Adjustments to Direct Medical Care Cost Variables
The literature review suggests that the direct healthcare cost variable for obese sub-
jects with NGT should be adjusted secondary to obesity.  The Thompson et al. study
reviewed in Section 3.5.4.3 suggests that a multiplier of 1.34 should be used to increase
the cost of NGT in subjects who are obese (BMI ≥ 30 kg/m2) and do not have abnormal
glucose homeostasis, hypertension or hypercholesterolemia.371 Therefore, the cost vari-
able for NGT subjects was increased by a triangular distribution variable of 1.02, 1.34, and
1.74, with the most likely value being 1.34. 
No further adjustments were made to the subjects in the IGT and T2DM states, and
direct health care cost multipliers were the same as for Model 1A as listed in Table 4.4.
4.3.2.2 Changes to Hazard Ratios for Mortality
The second set of variables to be modified in Model 1B were the multipliers for mor-
tality rates.  The T2DM mortality hazard ratio were increased to 2.64 and used as a con-
stant.  This was based on the Rogers et al. study that incorporates BMI levels with
calculations of hazard ratios secondary to T2DM (Section 3.6.3.1).372
As also noted in the literature review, mortality rates appear to increase secondary to
obesity, but this increase occurs primarily in studies that exclude cardiovascular disease
from their baseline cohort, such as the studies using data from the Nurses’ Health Study,  373
371  Thompson D, Brown JB, Nichols GA, et al. Body mass index and future healthcare costs: a retro-
spective cohort study. Obesity Research. 2001;9:210-218.
372  Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and
diabetes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
373  Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. New
England Journal of Medicine. 1995;333:677-685.
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Framingham Heart Study Data,374 and subjects with no history of disease at baseline from
the Cancer Prevention Study II.375 Hazard ratio values for increased mortality for subjects
with a BMI ≥ 30 kg/m2 ranged from 1.3 to 2.05.  As there were no specific studies on this
topic for IGT subjects, the decision was made to adjust mortality rates by an increased
hazard ratio of 1.7 for this subgroup.  Subjects with NGT had an increased hazard ratio of
1.3.  This was based on the assumption that IGT subjects may have a slightly higher mor-
tality hazard ratio than those with NGT.  A summary of the adjustments to mortality rates
for the Markov Cycle years > 3 is given in Table 4.16.
Table 4.16 Adjustments to Hazard Ratios for Mortality for Model 1B
Source:
a: Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and dia-
betes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
b: Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women.  New England
Journal of Medicine. 1995;333:677-685.
c: Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life
expectancy: a life-table analysis. Annals of Internal Medicine. 2003;138:24-32.
d: Calle EE, Thun MJ, Petrelli JM, et al.  Body-mass index and mortality in a prospective cohort of U.S.
adults. New England Journal of Medicine. 1999;341:1097-1105.
4.3.2.3  Model Specifications
The Markov model for Model 1B is essentially the same as that illustrated in Figure
4.2 except for the required variable adjustments.  The Model 1B variable box is illustrat-
ed in Figure 4.13, and definitions are given in Table 4.17.  A complete input table is given
in Appendix 2.
374  Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life
expectancy: a life-table analysis. Annals of Internal Medicine. 2003;138:24-32.
375  Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of
U.S. adults. New England Journal of Medicine. 1999;341:1097-1105.
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Markov State
Adjustments to Mortality Rates 
After Cycle Year 3
Source
T2DM Use a Hazard Ratio Multiplier of 2.64 a
IGT Use a Hazard Ratio Multiplier of 1.7 b,c,d
NGT Use a Hazard Ratio Multiplier of 1.3 b,c,d




















Table 4.17 Variable Information for Model 1B
(mort_pl_1B) refers to the mortality table for the placebo arm of 1B
(mort_L_1B) refers to the mortality table for the lifestyle arm of 1B
[Age+_stage] refers to the number of the cycle under evaluation in an imported table
DistSamp, distribution sample; exp, exponential
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Variable Definition Formula or Distribution
Age 50 years
CM_N_1B Cost Multiplier of  NGT in 1B
Triangular distribution of 1.02, 1.34, and 
1.74 (DistSamp 1)
CM_I_1B Cost Multiplier of  IGT in 1B
Triangular distribution of 1.35, 1.48, and 
1.79 (DistSamp 2)
CM_T_1B
Cost Multiplier of T2DM in 
1B
Triangular distribution of 2.03, 2.27, and 
2.83 (DistSamp 3)
cSC_1B Cost of Screening in 1B $139 
HRM_N_1B












Probability of death for a NGT 
subject in the placebo arm
1-exp(-mort_pl_1B[Age+_stage]             
*HRM_N_1B)
pDie_Pl_I_1B
Probability of death for an 
IGT subject in the placebo arm
1-exp(-mort_pl_1B[Age+_stage]           
*HRM_I_1B
pDie_Pl_T_1B
Probability of death for a 
T2DM subject in the placebo 
arm
1-exp(-mort_pl_1B[Age+_stage]          
*HRM_T_1B
pDie_L_N_1B
Probability of death for a NGT 
subject in the lifestyle arm
1-exp(-mort_L_1B[Age+_stage]             
*HRM_N_1B)
pDie_L_I_1B
Probability of death for an 
IGT subject in the lifestyle 
arm 
1-exp(-mort_L_1B[Age+_stage]           
*HRM_I_1B
pDie_L_T_1B
Probability of death for a 
T2DM subject in the lifestyle 
arm
1-exp(-mort_L_1B[Age+_stage]          
*HRM_T_1B
The mortality table for the placebo arm for 1B (mort_pl_1B) is the same as Table 4.6
(Mortality Rates for the Placebo Arm of Model 1A).  The mortality table for the lifestyle
arm for 1B (mort_L_1B) is the same as mort_Pl_1A that is described in section  4.3.1.3.1.
4.3.3 MODEL 2A AND 2B: MORE GENERALIZABLE MODELS
Modeling is one method that can be used to predict cost-effectiveness of clinical stud-
ies for populations that are more likely to be found in "real-world" situations.  Two final
models were planned to attempt to apply the DPP data to a more generalized, hypotheti-
cal cohort of subjects.  
In both of these models, the assumption was made that the starting cohort of subjects
does not have exclusion of other healthcare states at the beginning of the study.  The most
important assumption that must be made in these models is that there is no change in prob-
abilities of moving from the Markov states of IGT to T2DM, IGT to NGT, or NGT to IGT
for the placebo group and the lifestyle group (as detailed in Section 4.3).  This assumption
may not be a totally accurate assumption, but currently there are no data to refute it.  Due
to the uncertainty of these assumptions, extensive sensitivity analyses were conducted for
these transition probabilities.
Mortality transition rates changed in Models 2A and 2B.  The values derived for mor-
tality by the DPP were no longer incorporated.  Instead, U.S. Life Table values were used
for all Markov cycles, with appropriate HR adjustments as specified.376
Another change that occurred in these models was that for control costs.  In Models
2A and 2B the DPP control cost is no longer used for the first three years of the study.  The
assumption was made that control costs will be higher because subjects have other health
conditions besides IGT.  Two figures were used for the models.  The first was the control 
376  Arias E. United States Life Tables, 2000. Hyattsville, MD: National Center for Health Statistics;
2002. vol. 51;3.
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cost figure generated by the Kaiser Permanent studies of $2,699.377, 378 A second control
cost value of $3,968 derived from the ADA 2002 data was also used as a sensitivity analy-
sis.379
Utility values also changed in this model.   The third-year value from each arm of the
study was used for all Markov cycles.  This was done with the assumption that with added
healthcare abnormalities, utilities for each arm of the study more closely approximate the
year-three value.
A sensitivity analysis was conducted for Model 2A and Model 2B based on the possi-
bility that a newly diagnosed T2DM subject may revert to IGT for a short period due to
caloric restriction (as discussed in section 2.1.2.3.5).  These models included an addition-
al arm off of the T2DM node that allowed for a transition from diabetes to IGT.  The first
cycle transition probability was 0.20, and all subsequent cycles were 0.00.
4.3.3.1 Additional Model 2A Adjustments
Model 2A allows for adjustments due to inclusion of additional healthcare abnormal-
ities at baseline but does not include specific adjustments for obesity.  Therefore the model
used the adjustments for costs that were outlined for Model 1A in Table 4.4 and the mor-
tality adjustments in Table 4.5.
4.3.3.1.1 Model Specifications
The variable information for Model 2A (lifetime duration of effect) is illustrated in
377  Brown JB, Nichols GA, Glauber HS, et al. Type 2 diabetes: incremental medical care costs dur-
ing the first 8 years after diagnosis. Diabetes Care. 1999;22:1116-1124.
378  Nichols GA, Glauber HS, Brown JB. Type 2 diabetes: incremental medical care costs during the
8 years preceding diagnosis. Diabetes Care. 2000;23:1654-1659.
379  American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care.
2003;26:917-932.
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Figure 4.14, and definitions are given in Table 4.18.  A complete input table is given in 
Appendix 3.


















Table 4.18 Variable Information for Model 2A
(mort_2A) refers to the mortality table for 2A
[Age+_stage] refers to the number of the cycle under evaluation in an imported table
DistSamp, distribution sample; exp, exponential
The mortality table for Model 2A (mort_2A) was taken from the U.S. Life Tables.380
There was no need to have separate formulas for the probability of dying of NGT, IGT,
and T2DM for each arm, as the mortality table was now the same for both the placebo and
lifestyle arms.  The difference in the arms depends on the intervention effect, duration of
380  Arias E. United States Life Tables, 2000. Hyattsville, MD: National Center for Health Statistics;
2002. vol. 51;3.
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Variable Definition Formula or Distribution
Age 50 years
CM_I_2A Cost multiplier of IGT in 2A
Triangular distribution of 1.35, 1.48 and 
1.79
CM_T_2A
Cost multiplier of T2DM in 
2A
Triangular distribution of 2.03, 2.27, 
and 2.83
cNGT Cost of NGT $2,688 or $3,966
cSC-2A Cost of screening in 2A $139 
HRI_mort_2A
Hazard ratio of mortality for 
IGT in 2A
Triangular distribution of 0.8, 1.1, and 
1.6 (DistSamp 3)
HRT_mort_2A
Hazard ratio of mortality for 
T2DM in 2A
Triangular distribution of 1.4, 1.9, and 
2.5 (DistSamp 4)
pDie_NGT_2A
Probability of death for a 




Probability of death for an 
IGT subject in the lifestyle 
and placebo arms
1-exp(-mort_l2A[Age+_stage]             
*HRI_mort_2A)
pDie_T_2A
Probability of death for a 
T2DM subject in the lifestyle 
and placebo arms
1-exp(-mort_2A[Age+_stage]             
*HRT_mort_2A_
uLife_2A




Utility score in the placebo 
arm
0.657
effect, and hazard ratio of mortality (in this case, an increase for the IGT and T2DM arms).
4.3.3.2 Adjustments Made to Model 2B
Model 2B allows for inclusion of additional healthcare states and also makes any
potential adjustments necessary for obesity.  The cost adjustment to NGT that was out-
lined in Section 4.3.2.1 used for Model 1B was applied to Model 2B.  This adjustment was
the use of a triangular distribution multiplier of 1.02, 1.34, and 1.74 to the NGT control
cost.
The hazard ratios for mortality for NGT and IGT subjects remained those which were
used in Model 1A, Table 4.5.  Therefore, there was no increased hazard ratio for NGT, and
a triangular distribution hazard ratio of 0.8, 1.1, and 1.6 was used for IGT subjects.  The
hazard ratio multiplier for T2DM was adjusted for obesity in this model. The previously
used triangular distribution of 1.4, 1.9, and 2.5 was changed to 2.64. This change was
made to reflect the increased hazard ratio found by Rogers et al. for increased levels of
BMI in T2DM subjects (section 3.6.3.1).381
No adjustment was made to mortality for obese subjects with NGT because as noted
in the literature review, there appears to be little effect on mortality secondary to obesity
in subjects with normal glucose homeostasis in studies that have no exclusions for car-
diovascular disease at baseline.382
The sensitivity analysis to incorporate the possibility of a reversion from T2DM to
IGT was also conducted for this model.
381  Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and
diabetes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
382 Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of
U.S. adults. New England Journal of Medicine. 1999;341:1097-1105.
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4.3.3.2. Model Specifications
The variable information for Model 2B (lifetime duration of effect) is illustrated in
Figure 4.15, and definitions are given in Table 4.19.  A complete input table is given in
Appendix 3.  The mortality table for this model was taken directly from the year 2000 U.S.
Life Table.383
Figure 4.15 Variable Information for Model 2B





















Table 4.19 Variable Information for Model 2B
(mort_2B) refers to the mortality table for 2B
[Age+_stage] refers to the number of the cycle under evaluation in an imported table
DistSamp, distribution sample; exp, exponential
4.4 Data Analysis
A healthcare system perspective, using direct medical costs, was assumed for all
models.  The models were run using Data 4.0 software (TreeAge Software, Inc.,
Williamstown, Massachusetts).384 A Markov process technique was utilized, which allows
for varying transition probabilities with time.  This technique is required due to 
384  Suzuki H, Fukushima M, Usami M, et al. Factors responsible for development from normal glu-
cose tolerance to isolated postchallenge hyperglycemia. Diabetes Care. 2003;26(4):1211-1215.
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Variable Definition Formula or Distribution
Age 50 years
CM_N_2B Cost multiplier of NGT in 2B
Triangular distributioin of1.02, 1.34, 
and 1.74 (DistSamp 5)
CM_I_2B Cost multiplier of IGT in 2B
Triangular distribution of 1.35, 1.48 and 
1.79 (DistSamp 1)
CM_T_2B
Cost multiplier of T2DM in 
2B
Triangular distribution of 2.03, 2.27, 
and 2.83 (DistSamp 2)
cNGT Cost of NGT $2,688 or $3,966
cSC-2B Cost of screening in 2B $139 
HRI_mort_2B
Hazard ratio of mortality for 
IGT in 2B
Triangular distribution of 0.8, 1.1, and 
1.6 (DistSamp 3)
HRT_mort_2B




Probability of death for a 




Probability of death for an 
IGT subject in the lifestyle 
and placebo arms
1-exp(-mort_2B[Age+_stage]             
*HRI_mort_2B)
pDie_T_2B
Probability of death for a 
T2DM subject in the lifestyle 
and placebo arms
1-exp(-mort_2B[Age+_stage]             
*HRT_mort_2B
uLife_2B




Utility score in the placebo 
arm
0.657
changes in mortality rates over the lifespan of the subjects calculated from the U.S. life
tables.385
Half-cycle corrections were incorporated for costs and rewards.  This correction
allows for transitions to occur at the mid-point of a Markov cycle.  Therefore, this cor-
rection was also used in both the cost per life-year and cost per QALY analyses.
Monte Carlo simulation was used for the probabilistic sensitivity analyses.  The sim-
ulation was run 10,000 times.
The following outcomes were assessed for each arm of the study: (1) number of years
free of T2DM; (2) number of years free of both IGT and T2DM; (3) life expectancy; and
(4) total costs.  Incremental costs, utilities, and life expectancy were calculated in
between-arm analyses.  Finally, incremental cost-effectiveness ratios for costs per life-
year gained and cost per QALY were calculated.  These ratios were compared to the U.S.
accepted standards for cost effectiveness given in section 3.3.
385  Arias E. United States Life Tables, 2000. Hyattsville, MD: National Center for Health Statistics;
2002. vol. 51;3.
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CHAPTER 5 – RESULTS
The results of this dissertation are presented in four major sections, and then summa-
rized.  The first section directly addresses the three major questions of the research proj-
ect: (1) What is the long-term cost-effectiveness of the use of intensive lifestyle
intervention to prevent progression from IGT to T2DM? (2) What is the effect of obesity
on this evaluation? and (3) How does the evaluation change if an attempt is made to make
the analysis more generalizable using a hypothetical population that may be more repre-
sentative of that which is currently found in the U.S. rather than the cohort studied by the
DPP?  This last question specifically relates to the baseline, exclusion criteria for the DPP
study cohort.  
A base-case result is presented for each of the proposed models (Model 1A, 1B, 2A,
and 2B), and the submodels of Model 1A (those that address the different effects of the
lifestyle intervention according to BMI subcategories). An overview of the models and
hypotheses is given in Appendix 1.  These models were analyzed as both a Monte Carlo
simulation and a Markov analysis.  The results are given for: (1) a three-year duration of
effect of the intervention given a three-year duration of intervention; and (2) a lifetime
duration of effect of the intervention given a three-year duration of the intervention.  
As a reminder, Model 1A is the model most similar to the DPP cohort.  In this model,
DPP results were used for the morality, utility, and cost values for the first three cycles.
The first submodel of 1A used DPP data to analyze cost-effectiveness for the BMI sub-
category of 30 kg/m2 to < 35 kg/m2.  The second submodel of 1A used DPP data to ana-
lyze cost-effectiveness for the BMI subcategory of ≥ 35 kg/m2.  Model 1B made
adjustments for obesity by increasing the hazard ratio for mortality for NGT, IGT and
T2DM subjects, and adding a cost-multiplier for obesity for NGT subjects.  DPP data for 
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mortality, utility and costs were used for the first-three years for all of the models
described above. 
Model 2A is similar to Model 1A, but the DPP data for the first-three years were not
used, and data that are potentially more representative of current U.S. values for mortali-
ty, utilities and costs were inserted.  Model 2B attempted to adjust Model 2A for obesity
by adding a cost-multiplier for NGT subjects and increasing the hazard ratio for mortali-
ty for T2DM subjects.  As noted, the models and hypotheses are listed in table form in
Appendix 1.
The results of analyses of determinates of the range of cost-effectiveness (as defined
by incremental cost-effectiveness ratios) are then reported.  These analyses include com-
parisons of the least and most cost-effective models.  Additional analyses reported include
the effect of "control cost of illness" (as defined as the direct medical costs of a non-obese,
NGT subject) on incremental cost-effectiveness ratios, as well as the effect of varying the
range of the cost of the intervention on this same output. 
A comparison of the obesity-adjusted models to unadjusted models is then given.  This
entails comparing Model 1B to Model 1A, and Model 2B to Model 2A.  The lifestyle and
placebo arms of each of the obesity-adjusted models (the B Models) are compared to the
unadjusted models (the A Models) in terms of total lifetime costs, total life-years, cost per
life-year differences, QALYs, cost per QALY differences, and overallincremental cost-
effectiveness ratio differences for both cost per life-year and cost per QALY.
The section concludes with a comparison of Model 1A and the submodels of 1A for a
BMI subcategory of 30 kg/m2 to < 35 kg/m2 and a BMI subcategory of ≥ 35 kg/m2.
These models are also compared in terms of differences in total lifetime costs, total life-
years, cost per life-year, QALYs, cost per QALY, and over-all incremental cost-effective-
ness ratio differences for life-year and QALY outcomes.
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A second major section addresses the maximum acceptable cost of the intervention for
Models 1A and 1B and Models 2A and 2B for the following scenarios: (1) a three-year
cost of treatment intervention with a three-year effect of the intervention; and (2) a three-
year cost of the treatment intervention with a lifetime effect of the intervention.
"Maximum acceptable cost of intervention" is defined as the maximum cost of the inter-
vention that is allowed in order to maintain domination of the lifestyle intervention arm
over the placebo arm in each of the models.  As a sensitivity analysis for the scenario in
which a lifetime effect is achieved from the intervention, results are presented examining
cost-effectiveness if the treatment is continued for the lifetime of the subject. This section
also examines the separate influences of the adjustments made for obesity and baseline
exclusions in the DPP study cohort on maximum acceptable cost of intervention. 
A maximum acceptable cost of intervention comparison is then reported for Model 1A
and the submodels of 1A based on BMI subcategories.  These models are run for: (1) a
three-year cost of treatment intervention with a three-year effect of the intervention; (2) a
three-year cost of treatment intervention with a lifetime effect; and (3) a lifetime cost of
treatment intervention with a lifetime effect.   A final discussion examines the effect of
changing the control cost of illness of a non-obese NGT subject from $3,968 to $2,688 on
the maximum acceptable cost of the intervention for Models 2A and 2B.  
A third major section first gives the time free of T2DM for each model.  The section
also provides an analysis of the cost per Markov healthcare state using the same Markov
cohort methodology.  
The final section addresses the sensitivity analyses performed in this dissertation.  The
analyses examine the effect of the following changes on the incremental cost-effective-
ness ratios for life-years:
(1) Altering the duration of effect of the three-year intervention (comparing a 
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three-year duration to a lifetime-duration);
(2) Changing the discount rate from 0% to both 3% and 5%;
(3) Decreasing the treatment effect by 20% (by increasing the progression from 
IGT to T2DM by 20% in the lifestyle arm and decreasing the rate of reversion 
from IGT to NGT by the same percentage in the same arm);
(4) Increasing the progression from NGT to IGT in both arms by 20%; and
(5) Inserting a possible reversion from T2DM to IGT in the intervention (in mod-
els 2A and 2B only).
All sensitivity analyses are performed on cost per life-year results only due to the
uncertainty surrounding the QALY measurement in this dissertation.
5.1 Results and Comparisons of Models with Hypothesis Testing
The following section gives base-case results for each proposed model, followed by
hypotheses testing.  Comparisons of obesity-adjusted models (Model 1B and 2B) to non-
adjusted models (1A and 1B) are first provided, followed by comparisons of Model 1A to
the 1A submodels based on BMI subcategories (30 kg/m2 to < 35 kg/m2 and ≥ 35 kg/m2.
5.1.1 BASE-CASE RESULTS
The following tables give the base-case results for cost per life-year and cost per
QALY for a three-year effect of the three-year intervention and a lifetime effect of the
three-year intervention for each of the models and submodels of the dissertation: 
Table 5.1 – Model 1A;
Table 5.2 – Submodel 1A (BMI 30 kg/m2 to < 35 kg/m2);
Table 5.3 – Submodel 1A (BMI ≥ 35 kg/m2 );
Table 5.4 – Model 1B; 
Table 5.5 – Model 2A; and
Table 5.6 – Model 2B.
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These results are given using the Monte Carlo simulation technique and the Markov
process technique.  All values for Models 2A and 2B are given with a direct medical con-
trol cost of illness of $3,968.
Table 5.1 Monte Carlo and Markov Results for Three-Year and Lifetime 
Effects of a Three-Year Intervention for Model 1A
a: Cost-Effectiveness for Life-Years and QALYs for Monte Carlo simulation reflects program output 
variation
b: Monte Carlo results given in mean values with standard deviations in parenthesis





























































Pl $121,728 25.10 $4,850/LY 16.52 $7,369/QALY




























Table 5.2 Monte Carlo and Markov Results for Three-Year and Lifetime 
Effects of a Three-Year Intervention for Submodel 1A: BMI 30 
kg/m2 to < 35 kg/m2
a: Cost-Effectiveness for Life-Years and QALYs for Monte Carlo simulation reflects program output 
variation
b: Monte Carlo results given in mean values with standard deviations in parenthesis





























































Pl $114,409 25.60 $4,468/LY 16.85 $6,788/QALY




























Table 5.3 Monte Carlo and Markov Results for Three-Year and Lifetime 
Effects of A Three-Year Intervention for Submodel 1A: ≥ 35 kg/m2
a: Cost-Effectiveness for Life-Years and QALYs for Monte Carlo simulation reflects program output 
variation
b: Monte Carlo results given in mean values with standard deviations in parenthesis





























































Pl $125,973 24.79 $5,083/LY 16.32 $7,721/QALY




























Table 5.4 Monte Carlo and Markov Results for Three-Year and Lifetime 
Effects of a Three-Year Intervention for Model 1B
a: There is no variation in the model for life-years, so standard deviations are calculate as a zero value.
b: Cost-Effectiveness for Life-Years and QALYs for Monte Carlo simulation reflects program output 
variation
c:  Monte Carlo results given in mean values with standard deviations in parenthesis





























































Pl $113,235 22.86 $4,953LY 15.06 $7,524/QALY




























Table 5.5 Monte Carlo and Markov Results for Three-Year and Lifetime 
Effects of a Three-Year Intervention for Model 2A
a: Cost-Effectiveness for Life-Years and QALYs for Monte Carlo simulation reflects program output 
variation
b: Monte Carlo results given in mean values with standard deviations in parenthesis


























































Pl $186,897 24.83 $7,527LY 16.31 $11,457/QALY


























Table 5.6 Monte Carlo and Markov Results for Three-Year and Lifetime 
Effects of a Three-Year Intervention for Model 2B
a: Cost-Effectiveness for Life-Years and QALYs for Monte Carlo simulation reflects program output 
variation
b: Monte Carlo results given in mean values with standard deviations in parenthesis





























































Pl $179,297 23.30 $7,694/LY 15.31 $11,711/QALY




























5.1.2  HYPOTHESES TESTING
Individual hypotheses were tested using the cost-effectiveness findings in Tables 5.1
through 5.6 (reported with Monte Carlo simulation values).  Intensive lifestyle interven-
tion dominated placebo for every model analyzed (both three-year effect and lifetime
effect) as indicated by negative incremental cost-effectiveness ratios.  The specific
hypotheses and supporting results are now discussed.  
H1: In a population similar to that studied by the DPP that is diagnosed with IGT 
and no other disease-state abnormalities, long-term intensive lifestyle inter-
vention to prevent progression to T2DM is cost-effective.
This hypothesis was tested using Model 1A (Table 5.1), which is the model that most
closely resembles that studied by the DPP.  The incremental cost-effectiveness ratios using
the Monte Carlo simulation results for the three-year effect of the three-year intervention
are -$6,941/LY (S.D. $3,671/LY), and -$2,384/QALY (S.D. $985/QALY).  The incremen-
tal cost-effectiveness ratios using the same methodology for the lifetime effect of the
three-year intervention are -$12,815/LY (S.D. $4,860/LY) and -$9,336/QALY (S.D.
$2,524/QALY).  Therefore, lifestyle dominates placebo for all scenarios, and H1 is not
rejected.
H2: In a population that is diagnosed with IGT and no other disease-state abnor-
malities that falls into a specific BMI classification of 30 kg/m2 to < 35 kg/m2, 
long-term intensive lifestyle intervention to prevent progression to T2DM is 
cost-effective.
This hypothesis was tested using the submodel of Model 1A that addresses the BMI sub-
category of 30 kg/m2 to < 35 kg/m2 (Table 5.2), which is the model that most closely
approximates the DPP cohort in this BMI subcategory.  The incremental cost-effectiveness
ratios using the Monte Carlo simulation results for the three-year effect of the three-year 
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intervention are -$9,070/LY (S.D. $3,893/LY), and -$3,590/QALY (S.D. $1,121/QALY).
The incremental cost-effectiveness ratios using the same methodology for the lifetime
effect of the three-year intervention are -$13,270/LY (S.D. $4,665/LY) and -$9,749/QALY
(S.D. $2,487/QALY).  Therefore, lifestyle dominates placebo for all scenarios, and H2 is
not rejected.
H3:  In a population that is diagnosed with IGT and no other disease-state abnor-
malities that falls into a BMI classification of > 35 kg/m2, long-term intensive 
lifestyle intervention to prevent progression to T2DM is cost-effective.
This hypothesis was tested using the submodel of Model 1A that addresses the BMI sub-
category of ≥ 35 kg/m2 (Table 5.3), which is the model that most closely approximates the
DPP cohort in this BMI subcategory.  The incremental cost-effectiveness ratios using the
Monte Carlo simulation results for the three-year effect of the three-year intervention are
-$5,110/LY (S.D. $3,479/LY), and -$1,502/QALY (S.D. $53/QALY).  The incremental
cost-effectiveness ratios using the same methodology for the lifetime effect of the three-
year intervention are -$11,745/LY (S.D. $4,882/LY) and -$7,706/QALY (S.D.
$2,249/QALY).  Therefore, lifestyle dominates placebo for all scenarios, and H3 is not
rejected.
H4: If adjustments to mortality hazard rates and direct healthcare costs that are 
suggested by current literature are made for the exclusion of baseline disease-
state abnormalities as well as obesity in an evaluation of a population similar 
to that studied by the DPP (average BMI classification of obese class I, and 
diagnosis of IGT), long-term intensive lifestyle intervention to prevent pro-
gression to T2DM is cost-effective.
This hypothesis was tested using Model 1B (Table 5.4), which is the model that most
closely resembles a population similar to that studied by the DPP that is adjusted for obe-
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sity as it relates to baseline disease-state abnormalities.  The incremental cost-effective-
ness ratios using the Monte Carlo simulation results for the three-year effect of the three-
year intervention are -$573/LY (S.D. $2,198/LY), and -$245/QALY (S.D. $964/QALY).
The incremental cost-effectiveness ratios using the same methodology for the lifetime
effect of the three-year intervention are -$4,168/LY (S.D. $2,279/LY) and  -$3,561/QALY
(S.D. $1,959/QALY).  Therefore, lifestyle dominates placebo for all scenarios, and H4 is
not rejected.
H5: In a population with IGT and an average BMI category of obese class I that 
is drawn from a hypothetical cohort that has no disease-state exclusions in the 
baseline study design criteria, and in which no adjustments are made for obe-
sity, long-term intensive lifestyle intervention to prevent progression to T2DM 
is cost-effective.
This hypothesis was tested using Model 2A (Table 5.5), which is the model that attempts
to apply the DPP study results to a more generalized population.  The incremental cost-
effectiveness ratios using the Monte Carlo simulation results for the three-year effect of
the three-year intervention are -$17,631/LY (S.D. $8,444/LY), and -$5,341/QALY (S.D.
$1,574/QALY).  The incremental cost-effectiveness ratios using the same methodology
for the lifetime effect of the three-year intervention are -$21,093/LY (S.D. $8,053/LY) and
-$12,548/QALY (S.D. $3,101/QALY).  Therefore, lifestyle dominates placebo for all sce-
narios, and H5 is not rejected.
H6:  In a population with IGT and an average BMI category of obese class I that 
is drawn from a hypothetical cohort that has no disease-state exclusions in the 
baseline study design criteria, and in which adjustments are made for obesi-
ty, long-term intensive lifestyle intervention to prevent progression to T2DM 
is cost-effective.
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This hypothesis was tested using Model 2B (Table 5.6), which is the obesity-adjusted
model that attempts to apply the DPP results to a more generalized population.  The incre-
mental cost-effectiveness ratios using the Monte Carlo simulation results for the three-
year effect of the three-year intervention are -$2,231/LY (S.D. $2,845/LY), and 
-$862/QALY (S.D. $1,072/QALY).  The incremental cost-effectiveness ratios using the
same methodology for the lifetime effect of the three-year intervention are -$4,307/LY
(S.D. $2,752/LY) and -$3,416/QALY (S.D. $2,196/QALY).  Therefore, lifestyle domi-
nates placebo for all scenarios, and H6 is not rejected.
5.1.3 A COMPARISON OF THE LEAST AND MOST COST-EFFECTIVE 
MODELS
While all models generated an outcome of "lifestyle dominates," there are substantial
differences in cost-effectiveness ratios across the scenarios presented.  When comparing
Models 1A, 1B, 2A, and 2B (using the values generated by the Markov technique due to
consistency of numbers) the following ranges are found:
Three-Year Intervention with Three-Year Duration of Effect:
Life-Years: -$551/LY to -$16,064/LY
QALYs: -$243/QALY to -$5,260/QALY
Three-Year Intervention with Lifetime Duration of Effect:
Life-Years: -$4,132/LY to -$19,496/LY
QALYs: -$3,444/QALY to -$14,540/QALY
The lower values are generated in all cases by Model 1B, three-year intervention with
three-year duration of effect, and the highest values are generated by Model 1A, three-
year intervention, lifetime duration of effect.  A comparison of the two models is illus-
trated in Table 5.7 (using the Markov technique values).
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Table 5.7 A Comparison of Model 1B and Model 2A
L, lifestyle; LY, life-year; Pl, placebo
5.1.4 THE EFFECT OF CONTROL COST OF ILLNESS
The incremental cost-effectiveness ratios of both Models 2A and 2B are lower than
those found for Models 1A and 1B, making the more generalized models appear to be
more cost-effective.  One potential explanation is the higher control cost of illness found
in the more generalized models ($3,968 for Models 2A and 2B versus $1,100 for the first-
three Markov cycles, and then $2,688 per cycle for Models 1A and 1B).   
To examine this possibility more closely, the following analyses were performed using
the Markov technique.  Starting with Model 1A and 1B, control cost of illness was varied
from $2,000 to $5,000.  The results presented in Table 5.8 show that by increasing control
cost of illness in each model (for each duration of effect) total incremental costs increase,
and subsequently incremental cost-effectiveness ratios also increase.  Table 5.9 shows the














L $112.9K $106.5K $180.9K $160.6K
Incremental 
Costs
$270 $6,694 $5,944 $26,319
Life-Years Pl 22.86 24.83
L 23.35 24.48 25.20 26.18
Incremental 
Life-Years
-0.49 -1.62 -0.37 -1.35
Incremental 
C/E 
-$551/LY -$4,132/LY -$16,064/LY -$19,496/LY
Time Free of 
Diabetes
Pl
L 56.24% 75.20% 53.89% 73.24%
$113.2K $186.9K
46.54% 44.35%
Table 5.8 The Effect of Varying Control Cost of Illness on Model 1A and  
a:   Calculated by subtracting lifestyle from placebo                   






























1B: Lifetime Duration of 
Effect
 
Table 5.9 The Effect of Varying Control Cost of Illness on Model 2A and 
Model 2Ba
a:   Calculated by subtracting lifestyle from placebo                   
C/E, cost-effectiveness; K, thousands; LY, life-year
The results suggest that the one reason that the more generalized models appear more
cost-effective is their higher control direct medical costs.
5.1.5  THE EFFECT OF INCREASING THE COST OF INTERVENTION 
Using algebraic reasoning, incremental cost-effectiveness ratios will obviously
increase with increasing incremental costs if the effect of the intervention is held constant.
The other variable that is held constant in the analysis described in 5.1.4 is the cost of the
intervention.  The model that appears to be the most "cost-effective" (having the lowest



























$2,000 $3,197 -2.1 -$1.5K/LY
$3,500 $7,614 -$3.6K/LY
$5,000 $12,000 -$5.7K/LY
approximately 1.5 times higher ($3,968 vs. $2,698) than in Model 1B.  The following
analysis evaluates the effect of increasing the cost of intervention for both the placebo and
lifestyle arms in Model 2A by 1.5 times, while holding all other variables constant to eval-
uate the effect of this change on incremental cost-effectiveness ratios.  The results are
given in Table 5.10.
Table 5.10 The Effect of Increasing the Cost of Intervention on Model 2A
L, lifestyle; LY, life-year; Pl, placebo.
Increasing the cost of intervention increases total costs for the intervention arms, and
therefore decreases the incremental cost difference (as compared to the results in Table
5.5).  Life-years do not change; therefore, the incremental cost-effectiveness ratio decreas-
es.
5.1.6 OBESITY- ADUSTED MODELS VS. UNADJUSTED MODELS
The following section compares the obesity-adjusted models versus the unadjusted
models (Model 1B versus 1A, and Model 2B versus 2A).  This comparison includes the
following differences between the models: total lifetime costs; total life-years; cost per
life-year; QALYs; cost per QALY; and the incremental cost-effectiveness ratios.  The
results are derived by subtracting the unadjusted model results (1A and 2A) from the obe-
sity-adjusted models (1B and 2B).  This section was designed to examine the influence of
the obesity-adjusted modifications on cost-effectiveness.


















1A (unadjusted) for life-years.  Table 5.12 does the same for QALYs.  Table 5.13 and
Table 5.14 illustrate these results for Models 2B (obesity-adjusted) and 2A (unadjusted)
for life-years and QALYs, respectively.  All values used for these calculations are taken
from the Markov Technique values found in Tables 5.1, 5.4, 5.5, and 5.6.  A negative value
in a column means that the obesity-adjusted model values (the B models) are lower than
the unadjusted model values (the A models), and vice-versa for a positive value.  
Table 5.11 Comparisons between Model 1B (Obesity-Adjusted) and Model 1A
(Unadjusted) for Life-Yearsa
a: Calculated by subtracting the Model 1A values from the Model 1B values
Negative values indicate that Model 1B values are lower than those for Model 1A, and vice-versa for 
positive values.











Placebo -$8,493 -2.24 +$103/LY
Lifestyle -$6,109 -2.17 +$173/LY
Placebo - $8,493 -2.24 + $103/LY







Table 5.12 Comparisons between Model 1B (Obesity Adjusted) and Model 1A
(Unadjusted) for QALYsa
a: Calculated by subtracting the Model 1A values from the Model 1B values
Negative values indicate that Model 1B values are lower than those for Model 1A, and vice-versa for 
positive values.
C/E, cost-effectiveness ratio; LY, life-year; QALY, quality-adjusted life-year
Table 5.13 Comparisons between Model 2B (Obesity-Adjusted) and Model 2A
(Unadjusted) for Life-Yearsa
a: Calculated by subtracting the Model 2A values from the Model 2B values
Negative values indicate that Model 2B values are lower than those for Model 2A, and vice-versa for 
positive values.












Placebo -$7,600 -1.53 +$167/LY
Lifestyle -$3,000 -1.31 +$268/LY
Placebo - $7,600 -1.53 + $167/LY














Placebo -$8,493 -1.46 +$155/QALY
Lifestyle -$6,109 -1.50 +$250/QALY
Placebo - $8,493 -1.46 + $155/QALY





Table 5.14 Comparisons between Model 2B (Obesity Adjusted) and Model 2A
(Unadjusted) for QALYsa
a: Calculated by subtracting the Model 2A values from the Model 2B values
Negative values indicate that Model 2B values are lower than those for Model 2A, andvice-versa for 
positive values.
C/E, cost-effectiveness  ratio; LY, life-year; QALY, quality-adjusted life-year
5.1.7 MODEL 1A COMPARED TO THE SUBMODELS
To complete the examination of the base-case results, the following section is pre-
sented to compare Model 1A to the submodels of BMI 30 to < 35 kg/m2 and ≥ 35 kg/m2.
This comparison includes the following differences between the models: total lifetime
costs; total life-years; cost per life-year; total QALYs; cost per QALY; and the incremen-
tal cost-effectiveness ratio differences.  The results were derived by subtracting the Model
1A results from the individual submodel results.  Negative values indicate that submodel
values are lower than those for Model 1A, and vice-versa for positive values.
Table 5.15 illustrates the differences between Model 1A and the submodels for a three-
year duration of intervention and a three-year effect of intervention for life-years.  Table
5.16 does the same for QALYs.  Table 5.17 gives the differences between Model 1A and
the submodels for a three-year duration of intervention and a lifetime effect of interven-











Placebo -$7,600 -1.00 $254/QALY
Lifestyle -$3,000 -0.56 $168/QALY
Placebo - $7,600 -1.00 +$254/QALY





the Markov technique values given in Tables 5.1, 5.2, and 5.3.
Table 5.15  Comparison of Model 1A and the Submodels (Based on BMI 
subgroups) for a Three-Year Duration of Intervention and a 
Three-Year Effect for Cost per Life-Yeara
a: Calculated by subtracting Model 1A results from submodel results
Negative values indicate submodel values are lower than those for Model 1A, and vice-versa for positive
values.
C/E, cost-effectiveness ratio; kg/m2, kilogram per meters-squared; LY, life-year
Table 5.16 Comparison of Model 1A and the Submodels (Based on BMI 
subgroups) for a Three-Year Duration of Intervention and a 
Three-Year Effect for Cost per QALYa
a: Calculated by subtracting Model 1A results from submodel results
Negative values indicate submodel values are lower than those for Model 1A, and vice-versa or positive
values.











Placebo -$7,319 +0.33 -$581/QALY -$1,195/QALY
Lifestyle -$9,009 +0.42 -$653/QALY
Placebo +$4,245 -0.20 +$352/QALY +$886/QALY
Lifestyle +$5,327 -0.26 +$409/QALY
BMI of 30 kg/m 2 to less than           
35 kg/m2











Placebo -$7,319 +0.50 -$382/LY
Lifestyle -$9,009 +0.61 -$452/LY
Placebo +$4,245 -0.31 +$233/LY




BMI of 30 kg/m2 to less than            
35 kg/m2
BMI of greater than or equal           
35 kg/m2
Table 5.17 Comparison of Model 1A and the Submodels (Based on BMI
subgroups) for a Three-Year Duration of Intervention and a 
Lifetime Effect for Cost per Life-Yeara
a: Calculated by subtracting Model 1A results from submodel results
Negative values indicate submodel values are lower than those for Model 1A, and vice-versa for positive
values.
C/E, cost-effectiveness ratio; kg/m2, kilogram per meters-squared; LY, life-year
Table 5.18 Comparison of Model 1A and the Submodels for a Three-Year 
Duration of Intervention and a Lifetime Effect for Cost per QALYa
a: Calculated by subtracting Model 1A results from submodel results
Negative values indicate submodel values are lower  than those for Model 1A, and vice-versa for positive
values.











Placebo -$7,319 +0.33 -$581/QALY
Lifestyle -$8,340 +0.36 -$556/QALY
Placebo +$4,245 -0.20 +$352/QALY
Lifestyle +$8,597 -0.40 +$606/QALY
BMI of 30 kg/m2 to less than           
35 kg/m2













Placebo -$7,319 +0.50 -$382/LY
Lifestyle -$8,340 +0.52 -$384/LY
Placebo +$4,245 -0.31 +$233/LY
Lifestyle +$8,597 -0.57 +$420/LY
BMI of 30 kg/m2 to less than           
35 kg/m2




5.2 The Maximum Acceptable Cost of Lifestyle Intervention
The following section examines the maximum acceptable cost of the lifestyle inter-
vention for each of the models presented in the dissertation. "Maximum acceptable cost"
is defined as the maximum cost of the intervention that still allows for lifestyle to domi-
nate placebo.  In particular, the effects of the modifications to the dissertation models for
obesity (including those related to disease-state exclusions found in the DPP study cohort
design) are examined.  A final discussion reexamines the effect of varying control cost of
illness on this analysis.
5.2.1 MODELS 1A, 1B, 2A, AND 2B      
While all models presented generated an outcome of "lifestyle dominates" when
analyses were run, there were substantial differences in cost-effective ratios across the
scenarios presented as noted in Section 5.1.3.  It also appears that this wide range of incre-
mental cost-effectiveness ratios depends at least in part on control cost of illness, as well
as the obesity-adjusted modifications.  To test if the maximum acceptable cost of lifestyle
intervention reflected the same wide range of incremental cost-effectiveness ratios, the
following comparisons were performed.
Table 5.19 compares the maximum acceptable cost of lifestyle intervention as well as
cost per life-year for Models 1A and 1B.   The values are presented for a three-year inter-
vention and a three-year effect, a three-year intervention and a lifetime effect, and a life-
time intervention and a lifetime effect.  The final analysis is presented as a sensitivity
analysis.  Due to the uncertainty surrounding QALYs in the dissertation, the following
comparisons are performed using the life-year outcome only.  Table 5.20 gives the same
comparison of Models 2A and 2B.  All calculations are made using the Markov technique
values from Tables 5.1, 5.4, 5.5, and 5.6.
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Table 5.19 Comparison of Maximum Acceptable Cost of Intervention Per Year 
for Model 1A, the Unadjusted Model, to Model  1B, the Obesity-
Adjusted Modela
a: Presented as maximum cost of intervention and cost per life-year over the duration of the model








































Table 5.20 Comparison of Maximum Acceptable Cost of Intervention Per Year 
for Model 2A, the Unadjusted Model, to Model 2B, the Obesity-
Adjusted Modela
a: Presented as maximum cost of intervention and cost per life-year over the duration of the model
The cost per life-year is calculated using the values given for the maximum acceptable cost of 
intervention.
LY, life-year
5.2.2 THE INFLUENCE OF OBESITY-ADJUSTED  VARIABLES
By examining comparisons made in Tables 5.11- 5.14, it is apparent that the obesity-
adjusted models (Model 1B and 2B) have lower overall lifetime costs for the scenario that
includes a three-year duration of effect  However, as the duration of effect approaches life-
time, overall costs becomes higher in the obesity-adjusted lifestyle arm than in the non-
adjusted lifestyle arm.  Overall life-expectancy is lower in the obesity adjusted models for
both placebo and lifestyle intervention.  Obesity-adjusted models cost more per life-year,
and have a lower maximum acceptable cost of intervention than the unadjusted models 
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(Models 1A and 2A).  The following analyses were run to evaluate the effect of the vari-
ables used for these "obesity" adjustments on the maximum acceptable cost of interven-
tion.
5.2.2.1 The Influence of Obesity-Adjusted Variables on Model 1A and Model 1B
Table 5.21 illustrates the different maximum acceptable costs of intervention that
occur by adding each set of the obesity-adjusted variables to Model 1A (the unadjusted
model) both singly and in combinations for both the three-year and lifetime duration of
effect of the three-year intervention.  The results ultimately give the maximum acceptable
cost of intervention for the total adjusted model, Model 1B.   
For clarification, Model 1A has the following characteristics: no cost-multiplier for
NGT; a triangular distribution for the hazard ratio for mortality for IGT (0.8, 1.1, and
1.6)386 and a triangular distribution for the hazard ratio for mortality for T2DM (1.4, 1.9,
and 2.5).387, 388 The total adjusted model is Model 1B.  This model includes an increased
cost multiplier for NGT subjects (a triangular distribution of 1.02, 1.34, and 1.74),389 and
increased hazard ratios for mortality of 1.3 for NGT subjects and 1.7 for IGT subjects
(addressing the issue of increased hazard ratio for mortality for obese subjects in study
cohorts with multiple disease-state exclusion criteria).390, 391, 392 An increased hazard ratio 
386  Saydah SH, Miret M, Sung J, et al. Postchallenge hyperglycemia and mortality in a national 
sample of U.S. adults. Diabetes Care. 2001;24:1397-1402.
387  Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of
death in the U.S. Diabetes Care. 2001;24:447-453.
388 Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burden of death attributable to diabetes
in the United States. American Journal of Epidemiology. 2002;156:714-719.
389  Thompson D, Brown JB, Nichols GA, et al. Body mass index and future healthcare costs: a 
retrospective cohort study. Obesity Research. 2001;9:210-218.
390  Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. New
England Journal of Medicine. 1995;333:677-685.
391  Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life
expectancy: a life-table analysis. Annals of Internal Medicine. 2003;138:24-32.
392  Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of
U.S. adults. New England Journal of Medicine. 1999;341:1097-1105.
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for mortality for T2DM subjects of 2.64 is also added to address the possible increase in
this ratio for T2DM subjects secondary to increasing BMI.393
The table itself is set up to report the maximum acceptable cost of intervention from
the lowest derived value to the highest derived value.  The order reported in the table is
described below.  The first analysis, which has the lowest maximum cost of intervention,
includes the increased cost-multiplier for NGT subjects, no hazard ratio of mortality for
NGT subjects, the triangular distribution found in Model 1A for IGT subjects, and a haz-
ard ratio for mortality of 2.64 for T2DM subjects. The next highest value is given by
Model 1B itself (includes a cost multiplier for NGT, and a hazard ratio for mortality of
1,3, 1.7 and 2.64 for NGT, IGT, and T2DM subjects).
The third highest maximum acceptable cost of intervention is derived when a cost-
multiplier is included for NGT subjects, but the Model 1A values are used for the hazard
ratios for mortality (no increase for NGT, and the triangular distribution for IGT and
T2DM).  The fourth highest value omits the increased cost-multiplier for NGT subjects,
and includes the Model 1A hazard ratios for NGT and IGT (no multiplier for NGT, and
triangular distribution for IGT), and includes the 2.64 hazard ratio for mortality value for
T2DM subjects.
The fifth highest maximum acceptable cost of intervention scenario does not include
an increased cost-multiplier for NGT subjects, but includes all of the increased hazard
ratios for mortality in the adjusted model, Model 1B (NGT = 1.3, IGT = 1.7, and T2DM
= 2.64).  The sixth highest value is Model 1A, the unadjusted model.  This model has no
cost multiplier for NGT, no increased hazard ratio for mortality for NGT subjects, and
lower triangular distributions for hazard ratios for mortality for IGT and T2DM.
393  Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and
diabetes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
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The highest maximum acceptable cost of intervention is derived from an analysis that
includes no cost-multiplier for NGT subjects, the Model 1B values for NGT and IGT (1.3
and 1.7, respectively), and the Model 1A triangular distribution for T2DM (1.4, 1.9, and
2.5). 
Table 5.21 The Variation in Maximum Acceptable Cost of Intervention 
Secondary to Changes in Obesity-Adjusted Variables to the 
Unadjusted Model (Model 1A)
The cost multiplier (CM) for NGT is 1.02, 1.34, and 1.74.
The triangular values for hazard ratio for mortality for IGT are 0.8, 1.1, and 1.6.
The triangular values for hazard ratio for mortality for T2DM are 1.4, 1.9, and 2.5.
CM, cost multiplier; HRM, hazard ratio of mortality; IGT, impaired glucose tolerance; NGT, normal 
glucose tolerance; T2DM, type 2 diabetes mellitus
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Three-Year Effect Lifetime Effect
Maximum Acceptable Cost of 
Intervention
$810 $2,600
Maximum Acceptable Cost of 
Intervention
$1,020 $3,180
Maximum Acceptable Cost of 
Intervention
$1,250 $4,180
Maximum Acceptable Cost of 
Intervention
$1,370 $4,910 
Maximum Acceptable Cost of 
Intervention
$1,560 $5,350
Maximum Acceptable Cost of 
Intervention
$1,820 $6,500 
Maximum Acceptable Cost of 
Intervention
$2,000 $7,000 
No CM-NGT, No HRM-NGT, Triangular IGT, Triangular T2DM (Model 
1A)
No CM-NGT, HRM-NGT = 1.3, HRM-IGT = 1.7, Triangular T2DM 
Increased CM-NGT, No HRM-NGT, Triangular IGT, HRM-T2DM = 2.64
Increased CM-NGT, HRM-NGT = 1.3, HRM-IGT = 1.7, HRM-T2DM = 
2.64 (Model 1B)
Increased CM-NGT, No HRM-NGT, Triangular IGT, Triangular T2DM
No CM-NGT, No HRM-NGT, Triangular IGT, HRM- T2DM  = 2.64
No CM-NGT, HRM-NGT = 1.3, HRM-IGT = 1.7, HRM-T2DM = 2.64
Table 5.22 is presented to show that the maximum acceptable cost of intervention val-
ues for the above scenarios trend in the same direction as incremental cost-effectiveness
ratios for the seven scenarios presented.  This analysis is done to test for trending only,
and is only performed on the results for the lifetime duration of effect.
Table 5.22 The Variation in Incremental Cost-Effectiveness Ratios Secondary to 
Changes in Obesity-Adjusted Variables to the Unadjusted Model 
(Model 1A)
The cost multiplier (CM) for NGT is 1.02, 1.34, and 1.74.
The triangular values for hazard ratio for mortality for IGT are 0.8, 1.1, and 1.6.
The triangular values for hazard ratio for mortality for T2DM are 1.4, 1.9, and 2.5.
C/E, cost-effectiveness; CM, cost multiplier; HRM, hazard ratio for mortality; K, thousands; 
IGT, impaired glucose tolerance; LY, life-year; NGT, normal glucose tolerance; 









Increased CM-NGT, No HRM-
NGT, Triangular IGT, HRM-
T2DM = 2.64
$4,828 -2.16 -$2.2KLY
Increased CM-NGT, HRM-NGT 
= 1.3, HRM-IGT = 1.7, HRM-
T2DM = 2.64 (Model 1B)
$6,694 -1.62 -$4.1K/LY
Increased CM-NGT, No HRM-
NGT, Triangular IGT, 
Triangular T2DM
$9,613 -1.41 -$6.8K/LY
No CM-NGT, No HRM-NGT, 
Triangular IGT, HRM- T2DM  
= 2.64
$11,886 -2.16 -$5.5K/LY
No CM-NGT, HRM-NGT = 1.3, 
HRM-IGT = 1.7, HRM-T2DM     
= 2.64
$13,164 -1.61 -$8.2K/LY
No CM-NGT, No HRM-NGT, 
Triangular IGT, Triangular 
T2DM (Model 1A)
$16,644 -1.41 -$11.8K/LY
No CM-NGT, HRM-NGT = 1.3, 
HRM-IGT = 1.7, Triangular 
T2DM 
$17,872 -0.88 -$20.3K/LY
This analysis shows that, in general, the maximum acceptable cost of intervention
trends upward with increasing incremental cost-effectiveness ratios, but adjustments made
for mortality to each of the glucose homeostasis states will also have an effect on the
analysis.  This is in contrast to the findings in Section 5.1.5, which is understandable, in
that life-years were held constant in that analysis (involving the effect of increasing the
cost of intervention on incremental cost/effectiveness ratio for Model 2A).
5.2.2.2 The Influence of Obesity-Adjusted Variables on Model 2A and Model 2B
A similar analysis as that found in section 5.2.2.1 is performed in this section for
Model 2A and Model 2B.  These models are much more straight-forward, as there are only
two adjustments due to obesity.  This is because these are the "generalized" models, and
using findings in current available literature, there appears to be no need to address obe-
sity adjustments due to exclusion criteria found in the initial study design as were required
in Model 1B.  The adjustments found in Model 2B include an increased cost multiplier for
NGT subjects (triangular distribution of 1.02, 1.34, and 1.74),394 and an increased hazard
ratio for mortality for T2DM subjects of 2.64395 (versus the NHANES II based value of
1.4, 1.9, and 2.5).396, 397
Table 5.23 gives the results of this analysis.  Once again, the table is presented from
the lowest to the highest maximum acceptable cost intervention.  The lowest value is
obtained using Model 2B (the adjusted model).  The next highest value is obtained when-
the cost multiplier for NGT is inserted, but the triangular distribution is used for T2DM  
394  Thompson D, Brown JB, Nichols GA, et al. Body mass index and future healthcare costs: a 
retrospective cohort study. Obesity Research. 2001;9:210-218.
395  Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and
diabetes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
396  Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of
death in the U.S. Diabetes Care. 2001;24:447-453.
397  Saydah SH, Miret M, Sung J, et al. Postchallenge hyperglycemia and mortality in a national 
sample of U.S. adults. Diabetes Care. 2001;24:1397-1402.
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(1.4, 1.9, and 2.5) instead of the 2.64 value.  If the increased hazard ratio for mortality is
inserted (2.64) for the T2DM subjects instead of the triangular distribution, and no cost
multiplier is inserted for NGT subjects, the third highest value is obtained.  The highest
value is obtained for Model 2A (the unadjusted model), a model that has no cost multi-
plier for NGT and no increased hazard ratio for mortality for T2DM (the triangular distri-
bution is used).  
Table 5.23 The Variation in Maximum Acceptable Cost of Intervention 
Secondary to Changes in Obesity-Adjusted Variables in Model 2A
The cost multiplier (CM) of NGT is a triangular distribution of 1.02, 1.34, and 1.74. 
The triangular values for hazard ratio for mortality for T2DM are 1.4, 1.9, and 2.5
CM, cost multiplier; HRM, hazard ratio of mortality; IGT, impaired glucose tolerance; 
NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus
Table 5.24 is presented to again to show the results of incremental cost-effectiveness
ratio analysis for the above scenarios, and to test if maximum acceptable cost of inter-
vention trends in the same fashion as the incremental cost-effectiveness ratios.  Once
again, this analysis is done to test for trending only, and is only performed on the result-
for the lifetime duration of effect.
205
Three-Year Effect Lifetime Effect
Maximum Acceptable Cost of 
Intervention
$1,380 $3,950
Maximum Acceptable Cost of 
Intervention
$2,060 $6,330
Maximum Acceptable Cost of 
Intervention
$2,230 $7,390
Maximum Acceptable Cost of 
Intervention
$2,910 $9,750 
Both increased CM-NGT and increased HRM for T2DM = 2.64 (Model 2B)
CM for NGT but no increased HRM for T2DM (Triangular T2DM)
Increased HRM for T2DM (2.64) but no increased CM for NGT
No increased CM-NGT and Triangular T2DM (Model 2A)
Table 5.24 The Variation in Incremental Cost-Effectiveness Ratios Secondary to 
Changes in Obesity-Adjusted Variables in the Unadjusted Model 
(Model 2A)
The cost multiplier (CM) of NGT is a triangular distribution of 1.02, 1.34, and 1.74. 
The triangular values for hazard ratio for mortality for T2DM are 1.4, 1.9, and 2.5
C/E, cost-effectiveness; CM, cost multiplier; HRM, hazard ratio of mortality; K, thousands; LY, life-year;
IGT, impaired glucose tolerance; NGT, normal glucose tolerance; 
T2DM, type 2 diabetes mellitus
This analysis again shows that, in general, maximum acceptable cost of intervention
trends upward with increasing incremental cost-effectiveness ratios, but adjustments made
for mortality to each of the glucose homeostasis states will also have an effect on the
analysis. 
5.2.3 THE EFFECT OF CONTROL COST OF ILLNESS ON MAXIMUM 
ACCEPTABLE INTERVENTION COST
As a sensitivity analysis, Model 2A and Model 2B were run using a control cost of ill-
ness of $2,688 as well as $3,968 (the value used in the above tables).  Table 5.25 gives a
comparison of the maximum acceptable cost of intervention for each of the control cost
of illness values for Model 2A and Model 2B, and the percent difference between the two.
In this analysis, maximum acceptable cost of intervention varies directly with increasing









Both increased CM-NGT and 
increased HRM for T2DM = 2.64 
(Model 2B)
$8,991 -2.10 -$4.3K/LY
CM for NGT but no increased 
HRM for T2DM (Triangular 
T2DM)
$16,054 -1.35 -$11.9K/LY
Increased HRM for T2DM (2.64) 
but no increased CM for NGT
$19,287 -2.10 -$9.2K/LY
No increased CM-NGT and 
Triangular T2DM (Model 2A)
$26,320 -1.35 -$19.5K/LY
Table 5.25 Comparison of Maximum Acceptable Cost of Intervention Using 
Control Cost of Illness Values of $2,688 and $3,968
MACI, maximum acceptable cost of intervention
5.2.4 THE SUBMODELS OF 1A
To complete the analysis of maximum acceptable cost of intervention, Table 5.26 com-
pares the maximum acceptable cost of lifestyle intervention for Model 1A and the sub-
models of 30 to < 35 kg/m2 and ≥ 35 kg/m2.  The values are presented for a three-year 
intervention and a three-year effect, a three-year intervention and a lifetime effect, and a 
lifetime intervention and a lifetime effect.  The final analysis is presented as a sensitivity
analysis.  A comparison is made between the Model 1A maximum acceptable cost of inter-
vention value compared to those of the submodels by dividing each separate submodel
value by the Model 1A value, to derive values for the BMI 30 kg/m2 to < 35 kg/m2 and
the ≥ 35 kg/m2 subcategories.  Due to the uncertainty surrounding QALYs in this analy-





























Cost of Intervention MACI at $2,688 
as a Percent of 
MACI at $3,968
Table 5.26  Comparison of Maximum Acceptable Cost of Intervention of Model 
1A and Submodels Based on BMI Subcategory
a: Presented as maximum cost of intervention and cost per life-year over the duration of the model
b: Calculated by dividing maximum acceptable cost of intervention value of the BMI subcategories 
by the maximum acceptable cost values for Model 1A
kg/m2, kilograms per meter-squared; LY, life-year
5.3  Time Free of Diabetes and Cost Breakdown by Markov State
This section of the results gives the analysis of the time free of diabetes for Models
1A, 1B, 2A and 2B.  The Model 1A submodels are not analyzed because of uncertainty
about input data.
Markov modeling allows for an analysis of time spent in each Markov state (NGT,
IGT, T2DM, and death).  This is accomplished through a Markov cohort analysis. Using
the methodology recommended in the TreeAge training course, the half-cycle correction
is removed from the IGT branches, which results in values for life-expectancy that are 0.5
years lower than the above-presented results.398




























$1,820 $2,390 131.3% $1,470 80.8%
Cost/LY
$4,770/   
LY
$4,380/   
LY










$6,500 $6,830 105.1% $5,150 79.2%
Cost/LY
$4,593/   
LY
$6,114/   
LY










$720 $750 104.2% $570 79.2%
Cost/LY
$4,602/   
LY
$6,124/   
LY
$7,030/   
LY
Table 5.27 gives the results for the time free of diabetes for Model 1A and Model 1B 
for a three-year intervention and a three-year effect and a three-year intervention and a
lifetime effect.  Table 5.28 does the same for Models 2A and 2B.
Table 5.27 Years in Each Markov State and Years Free of T2DM for 
Model 1A and Model 1B (Three-Year and Lifetime Effect)
a:  Years free of T2DM presented as actual years and percent of total life expectancy in parentheses.
IGT, impaired glucose tolerance; NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus
Model 1A - 
Three-Year 
Effect
Model 1A - 
Lifetime 
Effect
Model 1B - 
Three-Year 
Effect
Model 1B - 
Lifetime 
Effect
Years in Each 
Markov Stage
Placebo
   NGT
   IGT
   T2DM
Total
Years Free of 
T2DM a
Years in Each 
Markov Stage
Lifestyle
   NGT 6.51 11.87 6.16 11.06
   IGT 6.97 7.17 6.69 7.35
   T2DM 11.55 6.97 10.00 6.07
Total 25.03 26.01 22.85 24.48
Years Free of 
T2DM a




12.85   
(56.24%)













Table 5.28 Years in Each Markov State and Years Free of T2DM for 
Model 2A and Model 2B (Three-Year and Lifetime Effect)
a:  Years free of T2DM presented as actual years and percent of total life expectancy in parentheses.
IGT, impaired glucose tolerance; NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus
Using the same methodology, the cost per Markov state was also calculated and is pre-
sented in Table 5.29 for Models 1A and 1B, and Table 5.30 for Models 2A and 2B.
Model 2A - 
Three-Year 
Effect
Model 2A - 
Lifetime 
Effect
Model 2B - 
Three-Year 
Effect
Model 2B - 
Lifetime 
Effect
Years in Each 
Markov Stage
Placebo
   NGT
   IGT
   T2DM
Total
Years Free of 
T2DM a
Years in Each 
Markov Stage
Lifestyle
   NGT 6.43 11.72 6.43 11.72
   IGT 6.88 7.08 6.88 7.08
   T2DM 11.39 6.87 10.08 6.10
Total 24.70 25.67 23.39 24.90




18.80   
(73.24%)















Table 5.29 Total Cost in Each Markov State for Model 1A and Model 1B
(Three-Year and Lifetime Effect)
IGT, impaired glucose tolerance; NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus
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Model 1A - 
Three-Year 
Effect
Model 1A - 
Lifetime 
Effect
Model 1B - 
Three-Year 
Effect
Model 1B - 
Lifetime 
Effect




   NGT
   IGT
   T2DM
Total




   NGT $17,204 $31,627 $22,260 $40,230
   IGT $28,532 $29,374 $27,394 $28,045
   T2DM $75,315 $44,056 $63,390 $38,312









Table 5.30 Total Cost in Each Markov State for Model 2A and Model 2B 
(Three-Year and Lifetime Effect)
IGT, impaired glucose tolerance; NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus
5.4 Sensitivity Analyses
The sensitivity analyses listed in the introduction of this section will complete the
results section.  As a reminder, these analyses include: 
(1)  altering the duration of effect of the three-year intervention (from a three-year 
duration to a lifetime-duration);
(2)  comparing the base-case results at discount rates of 0%, 3%, and 5%;
(3) decreasing the treatment effect by 20% (by increasing the progression from 
IGT to T2DM by 20% in the lifestyle arm and decreasing the rate of reversion 
from IGT to NGT by the same percentage in the same arm);
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Model 2A - 
Three-Year 
Effect
Model 2A - 
Lifetime 
Effect
Model 2B - 
Three-Year 
Effect
Model 2B - 
Lifetime 
Effect




   NGT
   IGT
   T2DM
Total




   NGT $25,736 $46,738 $35,093 $63,796
   IGT $47,708 $48,920 $47,708 $43,920
   T2DM $107,510 $64,920 $95,159 $57,591









(4) increasing the progression from NGT to IGT in both arms by 20%; 
(5) adding a possible reversion from T2DM to IGT due to the intervention (in 
Models 2A and 2B only)
A more in-depth description of each of these analyses will be provided with their results.
5.4.1 THE EFFECT OF DURATION ON INTERVENTION ON THE   
INCREMENTAL COST-EFFECTIVENESS RATIO
It is apparent from examining Tables 5.1-5.6 (the base-case results) that there is a large
difference in incremental cost-effectiveness ratios between a three-year intervention with
a three-year duration of effect, and a three-year intervention with a lifetime duration of
effect.  Table 5.31 has been constructed to illustrate the percentage difference in the ratio
for each scenario (three-year and lifetime duration of effect) for each of the models pre-
sented in the dissertation.  All values are taken from the Markov technique values given
in Tables 5.1 -5.6.  The cost per QALY results are not included due to the uncertainty sur-
rounding these values in the analysis.
Duration of effect improves incremental cost-effectiveness ratios in all scenarios, but
the values vary according to the model analyzed.
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Table 5.31 The Effect of Duration of Effect of Intervention on the Incremental 
Cost-Effectiveness Ratio
a: Calculated by dividing the three-year duration of effect result by the lifetime duration of effect result
C/E, cost-effectiveness ratio; K, thousands; kg/m2, kilogram per meter-squared; 
LY, life-year
5.4.2  THE EFFECTS OF DISCOUNTING AT 3% AND 5%
Current literature suggests analyzing the results of a cost-effectiveness analysis using
both a 3% and 5% rate.399 Both costs and rewards are discounted in this model. Table 5.32
gives the results of discounting at these rates for Models 1A, 1B, 2A, and 2B.  Table 5.33
gives the results for Model 1A and the submodels based on BMI subcategory. The analysi-
sis performed for cost per life-year.  Cost per QALY analysis is not performed due to the 
399  Drummond M, McGuire A. Economic Evaluation in Health Care: Merging Theory With Practice.

































uncertainty surrounding the input data.  
All discount analyses result in lifestyle dominating placebo except for the three-year
intervention results of Model 1B.  At 3% and 5%, positive incremental cost-effectiveness
ratio differences are obtained.
Table 5.32 The Effect of 3% and 5% Discounting on the Analysis (Models 1A, 
1B, 2A, and 2B)
a: Given in years
Slight inconsistencies in incremental cost-effectiveness ratio values are due to rounding













Pl $121.7K 25.10 $121.7K 25.10
L $119.1K 25.52 $105.1K 26.51
Pl $79.5K 17.10 $79.5K 17.10
L $77.9K 17.33 $69.4K 17.78
Pl $62.3K 13.80 $62.3K 13.80
L $61.4K 13.96 $55.0K 14.24
1B
Pl $113.2K 22.86 $113.2K 22.86
L $112.9K 23.35 $106.5K 24.48
Pl $75.90 15.96 $75.9K 15.96
L $76.0K 16.23 $71.6K 16.77
Pl $60.4K 13.05 $60.3K 13.05
L $60.7K 13.24 $57.2K 13,58
2A
Pl $186.9K 25.20 $186.9K 24.83
L $180.9K 24.83 $160.6K 26.18
Pl $124.9K 16.92 $124.9K 16.92
L $120.8K 17.11 $108.4K 17.56
Pl $99.6K 13.66 $99.6K 13.66
L $96.5K 13.79 $87.3K 14.07
2B
Pl $179.3K 23.30 $179.3K 23.30
L $177.9K 23.89 $170.3K 25.40
Pl $122.3K 16.17 $122.3K 16.17
L $121.2K 16.48 $115.6K 17.18
Pl $98.6K 13.17 $98.6K 13.17





































Table 5.33 The Effect of 3% and 5% Discounting on the Analysis (Model 1A, 
and Submodels Based on BMI Subcategory)
a: Given in years
Slight inconsistencies in incremental cost-effectiveness ratios are secondary to rounding.
C/E, cost-effectiveness ratio; K, thousands; L, lifestyle; LY, life-year; Pl, placebo
5.4.3  A 20% REDUCTION IN THE EFFECT OF THE LIFESTYLE 
INTERVENTION
In the DPP presentation of within trial cost-effectiveness of the study, a sensitivity
analysis was run lowering the effectiveness of the lifestyle intervention400 For this disser-
tation, the effect of lowering the effectiveness of the intervention by 20% on the intermit-
tent cost effectiveness ratio was evaluated.  This analysis was run by lowering the rate of 
400 Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle inter-













Pl $121.7K 25.10 $121.7K 25.10
L $119.1K 25.52 $105.1K 26.51
Pl $79.5K 17.10 $79.5K 17.10
L $77.9K 17.33 $69.4K 17.78
Pl $62.3K 13.80 $62.3K 13.80
L $61.4K 13.96 $55.0K 14.24
Pl $114.4K 25.60 $114.4K 25.60
L $110.1K 26.13 $96.7K 27.03
Pl $74.6K 17.34 $74.6K 17.34
L $71.9K 17.61 $63.9K 18.03
Pl $58.5K 13.95 $58.5K 13.95
L $56.7K 14.14 $50.7K 14.40
Pl $126.0K 24.79 $126.0K 24.79
L $124.4K 25.14 $113.7K 25.94
Pl $82.5K 16.94 $82.5K 16.94
L $81.7K 17.14 $75.0K 17.51
Pl $64.7K 13.70 $59.4K 13.70





















1A: 30 kg/m2 to < 35 kg/m2








reversion from IGT to T2DM by 20% and raising the rate of progression from IGT to
T2DM by 20%.  The results are presented for a three-year effect of the three-year inter-
vention in Table 5.34, and a lifetime effect of the three-year intervention in Table 5.35.
The 20% decrease in the effect of the intervention results has one value for which lifestyle
does not dominate placebo, and this is for Model 1B (obesity-adjusted) given a three-year
intervention with a three-year effect (see Table 5.34).  The results are given for cost per
life-year.  Cost per QALY values are not given due to uncertainty surrounding QALY val-
ues for the dissertation.  The results are only given for Models 1A, 1B, 2A, and 2B.  The
Model 1A submodels are not analyzed due to uncertainty surrounding input data.  
Table 5.34 The Effect of a 20% Decrease in the Effect of the Lifestyle 
Intervention Given a Three-Year Intervention and a Three-Year Effecta
a: Calculated by increasing the rate of progression of conversion form IGT to T2DM by 20% and 
decreasing the rate of reversion from IGT to NGT by 20% in the lifestyle arm
b: Given in years.
Slight inconsistencies in incremental cost-effectiveness ratios are secondary to rounding.














Pl $121.7K 25.10 $121.7K 25.10
L $119.0K 25.52 $120.8K 25.41
Pl $113.2K 22.86 $113.2K 22.86
L $112.9K 23.35 $113.9K 23.22
2A Pl $186.9K 24.83 $186.9K 24.83
L $181.0K 25.20 $181.9K 25.16
2B Pl $179.3K 23.30 $179.3K 23.30








Table 5.35 The Effect of a 20% Decrease in the Effect of the Lifestyle 
Intervention Given a Three-Year Intervention and a Lifetime Effecta
a: Calculated by increasing the rate of progression of conversion form IGT to T2DM by 20% and 
decreasing the rate of reversion from IGT to NGT by 20% in the lifestyle arm
b: Given in years.
Slight inconsistencies in incremental cost-effectiveness ratios are secondary to rounding.
C/E, cost-effectiveness; K, thousands; L, lifestyle; LY, life-year; Pl, placebo
5.4.4 A 20% INCREASE IN THE PROGRESSION FROM NGT TO IGT
Due to the uncertainty of the values derived for progression from NGT to IGT in both
arms of the study (neither value is given in the DPP results), a sensitivity analysis was con-
ducted increasing the rate of progression from NGT to IGT in both the placebo and
lifestyle arms of the analysis.  This was done, in part, secondary to the finding that the rate
of progression in the placebo arm from IGT to T2DM (0.1075)  was higher than what was
predicted in the initial study design (0.0065).   It is possible that progression from NGT
to IGT could mimic this elevated progression.
The results of this sensitivity analysis are given in Table 5.36 for the three-year dura-
tion of effect given a three-year duration of intervention, and in Table 5.37 for a lifetime 
401  Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes
with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
402  Diabetes Prevention Program Research Group. The Diabetes Prevention Program: design and














Pl $121.7K 25.10 $121.7K 25.10
L $105.1K 26.51 $110K 26.17
Pl $113.2K 22.86 $113.2K 22.86
L $106.5K 24.48 $108.8K 24.10
2A Pl $186.9K 24.83 $186.9K 25.84
L $160.6K 26.18 $168.2K 24.83
2B Pl $179.3K 23.30 $179.3K 23.30









duration of effect given a three-year duration of intervention.  In the three-year effect table
(Table 5.36), the analysis as performed with the following methodology: (1) increase the
rate of progression of NGT to IGT in the placebo arm from 0.0767 to 0.0920; (2) increase
the rate of progression of NGT to IGT in the lifestyle arm by 0.0406 to 0.0487 in the first-
three cycles, and then to 0.0920 for the duration of the model. 
In the lifetime-effect table (Table 5.37), the analysis was run by: (1) increasing the rate
of progression from NGT to IGT in the placebo arm from 0.0767 to 0.0920; and (2)
increasing the rate of progression from NGT to IGT in the lifestyle arm by 0.0406 to
0.0487.
All incremental cost–effectiveness ratio values derived in this analysis are higher, and
therefore less cost-effective (although very similar) than those found in the base-case
analysis.   This analysis also results in one value in which no strategy dominates (model
1B, three-year effect of intervention).
Table 5.36 The Effect of Increasing the Rate of Progression of NGT to IGT by 
20% in Both Arms of the Study for a Three-Year Effect of the
Interventiona
a:  Analysis performed by increased the progression of NGT to IGT in the placebo arm from 0.0767 to 0.0920,
and increasing the rate of progression of NGT to IGT in the lifestyle are from 0.0406 to 0.0487 in the first
–three cycles, and then to 0.0920 for the duration of the model.
b; Given in years.
Slight inconsistencies in incremental  cost-effectiveness ratios are secondary to rounding.














Pl $121.7K 25.10 $122.7K 25.04
L $119.0K 25.52 $120.3K 25.44
Pl $113.2K 22.86 $113.6K 22.79
L $112.9K 23.35 $113.4K 23.25
2A Pl $186.9K 24.83 $188.2K 24.77
L $181.0K 25.20 $182.8K 25.13
2B Pl $179.3K 23.30 $179.8K 23.22




Rate of Progression from NGT 




Table 5.37 The Effect of Increasing the Rate of Progression of NGT to IGT by 
20% in Both Arms of the Study for a Lifetime Effect of the
Interventiona
a:  Analysis performed by increasing the rate of progression from NGT to IGT in the placebo arm from
0.0767 to 0.0920, and increasing the rate of progression from NGT to IGT in the lifestyle arm by 0.0406
to 0.0487.
b; Given in years.
Slight inconsistencies in incremental cost-effectiveness ratios are secondary to rounding.
C/E, cost-effectiveness; K, thousands; L, lifestyle; LY, life-year; Pl, placebo
5.4.5 THE POSSIBILITY OF REVERTING FROM T2DM TO IGT
Section 2.1.2.3.5 suggests that there is a possibility of reverting from T2DM to IGT
secondary to intensive lifestyle intervention.  The current literature suggests that this is a
short-lived state (approximately one year), and is most probably secondary to a negative
caloric balance rather than stable weight loss maintenance.403
A sensitivity analysis was performed on Models 2A and 2B to include a possibility of
T2DM subjects reverting to IGT in the first Markov cycle by a transition probability of
0.20.  This change is only reflected in this cycle, as this is the time of the most intensive
403  Turner RC, Cull CA, Firghi V, et al. Glycemic control with diet, sulfonylurea, metformin, or














Pl $121.7K 25.10 $122.6K 25.04
L $105.1K 26.51 $106.0K 26.46
Pl $113.2K 22.86 $113.6K 22.79
L $106.5K 24.48 $106.9K 24.43
2A Pl $186.9K 24.83 $188.3K 24.77
L $160.6K 26.18 $162.1K 26.13
2B Pl $179.3K 23.30 $179.80 23.33




Rate of Progression From NGT 





lifestyle intervention, and therefore, the cycle at which this event is most likely to occur.
In addition, this analysis is not performed in Models 1A and 1B as these models are those
that most closely approximated the DPP, and the assumption is made that subjects with
T2DM are removed from the analysis upon diagnosis.
The results of this analysis give almost identical answers to those derived in the base
case for Models 2A and 2B (for both three-year duration of effect and lifetime duration of
effect).  Therefore, no tables have been constructed for this analysis.
5.5 Summary of Results
It is apparent that lifestyle dominates placebo in all of the models presented in this dis-
sertation, but there is a vast range of values for the incremental cost-effectiveness ratios
generated by the analyses.  In addition, maximum acceptable cost of intervention has a
wide range of values, which seems in part to depend on the wide range of incremental
cost-effectiveness values.  Chapter 6 presents a discussion of these results and their poten-
tial implications for health policy.
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CHAPTER 6 – DISCUSSION
While there have been few studies in the literature to date assessing the cost-effec-
tiveness of long-term, intensive lifestyle intervention for the prevention of T2DM, those
that are available suggest that this treatment plan is generally cost effective.404, 405, 406, 407 The
DPP reports that the cost per case of diabetes prevented over the three-year duration of the
study is $15,655 (using a "health system" perspective).  These numbers were obtained by
multiplying the incremental cost between the placebo arm and the lifestyle intervention
arm by the number needed to treat to prevent one case of diabetes (6.9 participants).408
The DPP researchers did not choose to calculate a cost per LY gained, which may be sec-
ondary to the low mortality rates that were found in the study, or the limited time frame
(three years).  This makes direct comparisons of the results of the DPP study and the dis-
sertation difficult. 
A cost per QALY of $31,512 was obtained by the DPP by dividing incremental cost
($2,269) by incremental QALYs gained (0.072).409 When the dissertation model is run for
a three-year period (taking out the half-cycle correction), a similar result is obtained (cost 
404  Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle inter-
vention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
405  Palmer AJ, Roze S, Valentine WJ, et al. Intensive lifestyle changes or metformin in patients with
impaired glucose tolerance: modeling the long-term health economic implications of the Diabetes
Prevention Program in Australia, France, Germany, Switzerland, and the United Kingdom. Clinical
Therapeutics. 2004;26:304-321.
406  Palmer AJ, Roze S, Cabrieres L, et al. Long-term projection of the costs of the Diabetes
Prevention Program in the USA using the CORE diabetes prevention model: intensive lifestyle changes
and metformin are both cost-effective. Paper presented at: 18th International Diabetes Federation
Congress, 2003; Paris.
407  Segal L, Dalton A, Richardson J. Cost-effectiveness of the primary prevention of non-insulin
dependent diabetes mellitus. Health Promotion International. 1998;13:197-209.
408  Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle inter-
vention or metformin for the primary prevention of type 2 diabetes. Diabetes Care.. 2003;26:2518-2523.
409 Ibid.
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per QALY = $33,726, with slight inconsistencies due to assumptions about cost of illness
values and cost multipliers used in the dissertation model).  Unfortunately, the incomplete
information regarding QALYs for the long-term analysis required for this dissertation
limit the use of this outcome.
The Palmer et al. studies are also not directly compatible to the results generated in
this dissertation due to differences in the Markov models used for the respective analyses.
The most substantial difference between the two basic models is that the Palmer et al.
model does not include transitioning back to the NGT state from IGT.  The international
evaluation performed by these authors suggests that in four of the five countries examined
(Australia, France, Germany, and Switzerland), lifestyle dominates placebo, and that in
the U.K., the incremental cost-effectiveness ratio is £6,381/life-year gained (approxi-
mately US$11,700).410 In the similar analysis that the authors have performed on imple-
menting a DPP-like program in the U.S., findings suggest that the cost per life-year gained
for the lifestyle intervention is $11,518.411 These results were found to be sensitive to the
duration of the intervention and the costs of the intervention program, as were the results
of this dissertation.
The Segal et al. study also found that an intensive diet and behavioral modification
program using a model that included transitioning from IGT to NGT was highly cost
effective, with a "gross cost of life-year saved" of $4,300, and a "net cost of life-year
saved" of $1,900.412 The reduction in incidence of progression from IGT to T2DM in this  
410  Palmer AJ, Roze S, Valentine WJ, et al. Intensive lifestyle changes or metformin in patients with
impaired glucose tolerance: modeling the long-term health economic implications of the Diabetes
Prevention Program in Australia, France, Germany, Switzerland, and the United Kingdom. Clinical
Therapeutics. 2004;26:304-321.
411 Palmer AJ, Roze S, Cabrieres L, et al. Long-term projection of the costs of the Diabetes
Prevention Program in the USA using the CORE diabetes prevention model: intensive lifestyle changes
and metformin are both cost-effective. Paper presented at: 18th International Diabetes Federation
Congress, 2003; Paris.
412 Segal L, Dalton A, Richardson J. Cost-effectiveness of the primary prevention of non-insulin
dependent diabetes mellitus. Health Promotion International. 1998;13:197-209.
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model was from 70% to 30% (a 57% reduction).
How do the results of this dissertation, which can be classified as a "what if" analysis
in that much of the input data were derived from multiple studies (in other words, the
model is not based on actual trial data), add to the above results?  It is apparent that inten-
sive lifestyle intervention to prevent progression from IGT to T2DM appears to be "high-
ly cost-effective."  The results generated by this dissertation may help to address the
problems that policy makers may encounter as they attempt to decide how best to imple-
ment this treatment option on a global scale in the U.S.
The first problem the results suggest that policy makers may encounter is that while
all scenarios proposed by the dissertation models give a result of lifestyle dominating
placebo, there are a large range of values for the incremental cost-effectiveness ratios, and
these values depend on the model proposed.  Therefore, input data included in the model,
as well as the actual model itself, will affect the outcome generated.  One important area
that appears to affect the model substantially is the potential effect of obesity on transition
probabilities and Markov rewards.  Another appears to be the effect of exclusion criteria
in the study design of the DPP.  This becomes important as DPP results are used as the pri-
mary data for the dissertation models.  The most important result of these DPP "exclusion
criteria" may be that the subjects of the DPP may not be particularly representative of the
U.S. population.  A final important variable that emerges as the results are examined
appears to be the underlying direct medical costs included in the model.
A second important problem that policy makers may face is "What is the upper limit
of the maximum acceptable cost of the intensive lifestyle intervention?"  In other words,
"What is the most I can spend on the lifestyle intervention and still have it dominate place-
bo in a cost-effectiveness analysis?" The results suggest that the maximum cost value
appears to vary according to the model, and with no surprise, seems to be influenced by 
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both the incremental cost difference range and the incremental reward (life-years in the 
case of the analyses performed).  These values, in turn, are influenced by all of the above
mentioned variables.
This discussion section of this dissertation attempts to address these problems.  The
chapter is divided into four sections.  The first examines the individual results derived
form the dissertation.  The second section attempts to summarize these individual results
to present an overall picture that may be helpful to policy makers dealing with the prob-
lem of implementing intensive lifestyle interventions for preventing T2DM.  Section three
addresses the limitations of the study, and section four discusses potential areas for further
research on this topic.
6.1 Discussion of Specific Results
The specific results of the dissertation as outlined in Chapter 5 are now discussed.  The
section first gives an analysis of the base-case results and comparisons for Models 1A and
1B, and Models 2A and 2B.  A similar analysis is also given for Model 1A and the sub-
models of 1A based on BMI subcategory.  In particular, this section of the analysis
describes in greater detail the large range of values generated for incremental cost-effec-
tiveness ratios, and sets the stage for a discussion of maximum acceptable cost of inter-
vention.
6.1.1 THE BASE-CASE RESULTS AND COMPARISONS 
As noted in the results section, all base-case models for Models 1A, 1B, 2A and 2B
used in this dissertation generated a result of lifestyle dominating placebo (Tables 5.1, 5.4,
5.5, and 5.6).   In addition, all proposed hypotheses are not rejected based on these base-
case findings.
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The first thing to note is the large difference in values for incremental cost-effective-
ness ratios.  As noted in 5.1.3 and specifically in Table 5.7, the range of values for a three-
year intervention for a three-year duration of effect  for life-years is -$551/LY to
-$16,064/LY, and for a three-year intervention with a lifetime duration of effect is 
-$4,132/LY to -$19,496/LY (using the values derived from the Markov technique method-
ology).  The model with the lowest incremental cost-effectiveness ratio, and therefore, the
model that is potentially the most cost-effective is Model 2A (lifetime duration of effect).
The model with the highest incremental cost-effectiveness ratio, and therefore, the model
that is the least cost-effective is Model 1B (three-year duration of effect).  The following
section attempts to address the role of cost inputs in the models as an explanation for the
differences found in the incremental cost-effectiveness ratios.
6.1.1.1 The Differences Between the Upper and Lower Range Models
As noted above, the model with the highest cost-effectiveness ratio is Model 2A (life-
time effect of duration), and the model with the lowest cost-effectiveness ratio is Model
1B (three-year effect of duration).  There are several important factors that differentiate
these models that can potentially explain this large range of incremental cost-effectiveness
ratios.  To someone investigating the possibility of implementing long-term, intensive
lifestyle intervention for T2DM prevention, the questions become, "What makes Model
1B appear to be less cost-effective?" and, "What makes Model 2A appear to be more cost-
effective?"  
Referring to the data input references in Appendices 2 and 3, the following differences
may be ascertained.  The first is that Model 1B is an obesity-adjusted model that uses DPP
data for transition probabilities and Markov cost rewards, while Model 2A is an obesity-
unadjusted model that attempts to address a more generalized population than that stud-
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ied by the DPP.  The Markov transition probabilities differ between the models, in that a
lower overall mortality is used in Model 1B than in Model 2A for the first-three Markov
cycles, reflecting the mortality rates of the DPP study.  On the other hand, the hazard ratios
for mortality are larger for all three stages of glucose homeostasis for Model 1B than
Model 2A.  The end result is that life-expectancy is longer in the placebo arm and lifestyle
arm for Model 2A for both durations of effect. 
It is also important to note that while life expectancy is longer in Model 2A, time free
of T2DM is very similar in both models. One may see upon examining Tables 5.27 and
5.28 that the Model 2A subjects live in a similar range or slightly longer range in the NGT
and IGT stages than those subjects in Model 1B.  On the other hand, Model 2A subjects
live approximately 14% longer in the T2DM stage than those subjects in Model 1B. These
results are found for placebo and lifestyle, regardless of duration of effect. This can be
explained in part by the increased hazard ratio for mortality for T2DM subjects in Model
1B (2.64)413 versus that found in Model 2A (a triangular distribution of 1.4, 1.9, and
2.5).414, 415 As a summary, Model 2A subjects live longer, and in particular, live longer in
the T2DM state.  The end result adds to the increased total lifetime cost found in the model
because subjects live longer, and in particular, live longer in a more expensive state
(T2DM).
The other major difference in the models involves the direct medical control cost of
illness for all stages of glucose homeostasis.  The total cost differences between the mod-
els, outlined in Table 5.7, show that overall, total lifetime costs in Model 2A are greater  
413  Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and
diabetes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
414 Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of death
in the U.S. Diabetes Care. 2001;24:447-453.
415  Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burden of death attributable to diabetes
in the United States. American Journal of Epidemiology. 2002;156:714-719.
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than in Model 1B, at least in part because the control cost of illness is greater  ($3,968 for
model 2A416 vs. $2,688 for Markov cycles three and greater for Model 1B417, 418).  On the
other hand, Model 1B does include a cost-multiplier for NGT subjects (adjusting for obe-
sity) using a triangular distribution of 1.02, 1.34, and 1.74, which is not included in Model
2A.419 This cost-multiplier does not offset the increased costs found in Model 2A.
6.1.1.1.1 The Incremental Cost and Life-Year Differences between the Two Models
Model 2A has higher lifetime costs for subjects in the placebo and lifestyle arm, but
the model has a lower (more negative) incremental cost-effectiveness ratio, making it
appear to be more cost-effective.  In addition, Model 2A subjects live longer than Model
1B subjects.  Continuing the process, incremental differences between overall costs and
total life-years between the two models must be examined.  The following results are
derived when comparing the incremental cost values for Model 2A as a percent of Model
1B, (calculated by taking the total incremental cost of Model 2A and dividing by that of
Model 1B from Table 5.7):
Model 2A (three-year effect) vs. Model 1B (three-year effect):
Model 2A incremental cost is 2,202% of that of Model 1B ($5,944/ $270);
Model 2A (lifetime effect) vs. Model 1B (lifetime effect): 
Model 2A incremental cost is 393% of that of Model 1B ($26,319/ $6,694).
416  American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care.
2003;26:917-932.
417  Brown JB, Nichols GA, Glauber HS, et al. Type 2 diabetes: incremental medical care costs dur-
ing the first 8 years after diagnosis. Diabetes Care. 1999;22:1116-1124.
418  Nichols GA, Glauber HS, Brown JB. Type 2 diabetes: incremental medical care costs during the
8 years preceding diagnosis. Diabetes Care. 2000;23:1654-1659.
419  Thompson D, Brown JB, Nichols GA, et al. Body mass index and future healthcare costs: a ret-
rospective cohort study. Obesity Research. 2001;9:210-218.
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The incremental life-year values for the two models are compared below (see Table
5.7):
Model 2A (three-year effect) vs. Model 1B (three-year effect): 
Model 2A incremental life-years are 76% of that of Model 1B (-0.37 / -0.49);
Model 2A (lifetime effect) vs. Model 1B (lifetime effect): 
Model 2A incremental life-years are 83% of that of Model 1B (-1.35 / -1.62).
Therefore, it is no surprise that Model 2A appears more cost-effective than Model 1B
based on the above numbers.  The total life-year results are very similar for the two mod-
els, but when these values are divided into the total incremental costs, very large incre-
mental cost-effectiveness ratio ranges result.  
One key to this analysis then is the answer to the following question, "What makes
Model 2A total costs so much greater than those in Model 1B?"  An obvious answer is the
increased control cost of illness found in this model ($3,968) vs. that found in model 1B
($1,100 for the first-three cycles, and then $2,689 for the duration).  It therefore appears
that in this analysis, the control cost of illness used in the model will have a very large
effect on the incremental cost-effectiveness ratio output.  
6.1.1.1.2 The Actual Incremental Cost between Placebo and Lifestyle
Additional questions that must be addressed are, "What is the actual incremental cost
between placebo and lifestyle in Model 1B and Model 2A?" and "How do these values
compare between models?" The answers may be found by comparing the placebo and
lifestyle arms for the two scenarios of Model 1B and Model 2A.  The results, found in
Table 5.7, are the following (derived by dividing the placebo values of each model by the
lifestyle model).  For the three-year effect scenarios, the placebo arm incremental cost
value is 100.24% of that of the lifestyle arm of Model 1B.  For the same scenario of Model 
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2A, the placebo arm incremental cost value is 103.28% of that of the lifestyle arm of
Model 2A.  For the lifetime-effect values, the placebo arm incremental cost value is
106.28% of that of the lifestyle arm of Model 1B, and in Model 2A, the placebo arm
incremental cost value is 116.39% of that of the lifestyle arm.
Summarizing the above analysis, it again becomes apparent that a great deal of the
large difference between the two models (2A vs. 1B) results from the greater incremental
cost value for 2A than that found in 1B.   The actual total cost value should be emphasized
here because when percentage comparisons are made between placebo and lifestyle arms
of the two models, these values are very similar.
The above findings may be summarized in the following way: 
(1) Model 2A total costs are greater than Model 1B total costs.
(2) The value calculated dividing the total costs of the placebo arm by the lifestyle 
arm of Model 2A and this same value calculated for Model 1B is very similar.  
The value calculated dividing the total life-years using the same methodology 
for both models is also very similar.
(3) The actual numerical value for incremental cost difference is much higher for 
Model 2A than 1B (which is most probably secondary to the higher control 
cost of illness of Model 2A).  On the other hand, the value for incremental life-
years for Model 2A is very similar to the same value for Model 1B.
(4) In Model 2A, a lower incremental cost-effectiveness ratio is obtained when 
these higher incremental cost values are divided by incremental life-years, giv-
ing the appearance of greater cost-effectiveness.
Further analysis of the effect of control cost of illness as well as cost of intervention
is now given.  
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6.1.1.1.3 The Effect of Control Cost of Illness on Incremental Cost-effectiveness Ratios
The summary above implies that increasing the control cost of illness in the model
appears to make incremental costs greater, and therefore, increases the incremental cost-
effectiveness ratio (holding all other variables constant).  Tables 5.8 and 5.9 test this
hypothesis and show that incremental costs increase with increased control cost of illness,
and while holding incremental reward constant, incremental cost-effectiveness ratios also
increase.  Therefore, at least part of the cost-effectiveness found in Model 2A is potentially
a result of the approximately 1.5 times higher control cost of illness of the model com-
pared to Model 1B.
The influence of total incremental costs on the analysis is consistent with the findings
presented in Table 5.22 and Table 5.24.  The results presented in these tables, which com-
pared trends of maximum acceptable cost of intervention to incremental cost-effectiveness
ratio, found that maximum acceptable cost of intervention was most likely to trend with
total incremental costs than incremental cost-effectiveness ratios.  This finding appears to
be secondary to adjustments made to mortality in the model. 
6.1.1.1.4 The Effect of Increasing the Intervention Cost on Model 2A
One other way to evaluate the etiology of why Model 1B appears to be more cost-
effective than Model 2A involves evaluating the cost of the intensive lifestyle intervention
in the models.  The direct medical cost of Model 2A is approximately 1.5 times higher
than that found in Model 1B, but the intervention cost has been held constant at the same
value used in the DPP study.  The results of the effect of increasing the intervention cost
by 1.5 times, to approximate the increase in control cost of illness are presented in Table
5.10  It is apparent that increasing the intervention cost in Model 2A (the most cost-effec-
tive model) does decrease incremental cost differences, and also decreases incremental 
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cost-effectiveness ratios.  Cost of intervention in this analysis, in relationship to direct
medical control cost, also plays a role in the ultimate incremental cost-effectiveness ratio
result of any given model.
6.1.1.1.5 Summary
Evaluating the base-case results reveals that lifestyle dominates placebo in all models
of the dissertation.  The results also show that there is a large range of incremental cost-
effectiveness ratios that are derived from the dissertation models, with the most "cost-
effective" model being Model 2A, and the "least cost-effective" model being 1B.  Some
factors contributing to these ‘cost-effectiveness" differences, as defined by incremental
cost-effectiveness ratio, are evaluated in the above discussion.  It becomes apparent that
the control cost of illness and the cost of intervention (as it relates proportionately to this
cost of illness) are important variables that must be considered when modeling diabetes
prevention as these variables have the ability to greatly affect the final cost-effectiveness
ratio of any analysis.  
It is also apparent that the control cost of illness and intervention costs are not the only
explanations of why Model 2A appears to be more cost-effective than Model 1B.  The "A"
models are referred to throughout this dissertation as the ‘unadjusted" models, and the "B"
models are referred to as the "obesity-adjusted" models.  The influence of the obesity-
adjusted variables on cost-effectiveness is now presented.
6.1.1.2 The Obesity-Adjusted Versus Unadjusted Models
Cost input in the dissertation models explains part of the differences in the range of
incremental cost-effectiveness ratios, but it is apparent that the variables adjusting the
models for obesity also contribute to this range.  Comparing Models 1B to 1A and Models 
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2B to 2A allows for an examination of the effect of the specific obesity-adjusted variables
on each of these models (both the DPP specific model, and a more generalized model).
These comparisons are found in Tables 5.11- 5.14, and are described in further detail in
the following sections.
6.1.1.2.1 A Comparison of Model 1A to Model 1B
The comparison of these two models begins by examining total lifetime costs (see
Table 5.11 and 5.12).  This value is less for the obesity-adjusted model (Model 1B) than
the unadjusted model (Model 1A) for the scenario of a three-year duration of effect for
both the placebo arm and the lifestyle arm.  While this trend holds true for total lifetime
costs for the placebo arm in the scenario with a lifetime duration of effect, the results show
that lifetime total costs are actually greater in the lifestyle arm for the obesity-adjusted
models (Model 1B and Model 2B).  The apparent reasoning for the lower costs for the
placebo and lifestyle arm of the three-year effect and the placebo arm of the lifetime effect
(Model 1B vs. Model 1A) appears to be the increased hazard ratio for mortality for all
three states of glucose homeostasis in Model 1B.  Subjects in these scenarios of the model
do not live as long, and the result is lower total lifetime costs.
The difficulty comes in explaining the lifetime effect scenario of the lifestyle arm
comparing Model 1B to Model 1A.  In this comparison, Model 1B costs are higher than
those found in Model 1A, in spite of the fact that subjects continue to live longer in Model
1A than in Model 1B.  The answer lies in looking at Table 5.29.  This table, which breaks
down the costs per stage per model, allows for a comparison of Model 1A with a lifetime
effect to Model 1B with a lifetime effect.  The results show that while subjects do live
longer in the NGT state in Model 1A, this NGT state is more expensive in Model 1B
($40,230 for Model 1B vs. $31,627 for Model 1A).  This appears to result from the addi-
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tion of the cost-multiplier to adjust for obesity for NGT subjects in Model 1B.  Therefore,
this adjustment for obesity has a substantial effect on total costs in this model.
It has already been noted that subjects live longer in Model 1A than in Model 1B, and
this most likely results from the increased hazard ratios for mortality for all three glucose
homeostasis states in Model 1B (see Table 5.27).  This effect is more pronounced in the
three-year effect scenario than the lifetime scenario.  While in the lifetime scenario, sub-
jects live longer in Model 1A in the NGT and T2DM states, but they actually live for less
time in the IGT state (Model 1B subjects live 0.48 years longer in IGT than Model 1A sub-
jects).  A possible explanation is the longer duration of effect of the intervention with the
possibility of more subjects moving into the NGT state.
The obesity-adjusted model (Model 1B) has a higher cost-effectiveness ratio for both
durations of effect, making it less cost-effective than the unadjusted model (Model 1A).
This follows the rationale presented in the above discussion about the effect of costs on
the model results.  Model 1A total costs are greater than Model 1B, but the life-years are
similar.  When the reward (the life-years) is divided into these greater costs, which in this
case appear to be heavily influenced by the greater total life-years in the unadjusted mod-
els (resulting from the increased hazard ratios for mortality for all three glucose home-
ostasis states), lower cost-effectiveness ratios are produced, and the unadjusted model
(Model 1A) appears more cost-effective.  This effect become more pronounced in the
comparison of Model 1B vs. Model 1A for the lifetime effect secondary to the added influ-
ence of the cost-multiplier for NGT subjects in Model 1B.
6.1.1.2.2 A Comparison of Model 2A to Model 2B
Examining Tables 5.13 and 5.14, it is evident that once again total lifetime costs fol-
low a similar pattern to that found in the comparison of Model 1A to Model 1B.  Lifetime 
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costs are lower for the three-year duration of effect for both the placebo and lifestyle arms.
This is most likely due to the decreased life-years found in the obesity-adjusted model
(Model 2B).  Subjects die earlier in Model 2B due to increased hazard ratios for mortali-
ty, but in this model there is no increased hazard ratio for mortality for NGT subjects, and
the IGT subjects share the same hazard ratio for both Model 2A and Model 2B because no
obesity adjustments are made for mortality in these states due to the generalized nature of
the models (i.e., there are no exclusion criteria for health states for the starting cohort).  On
the other hand, there continues to be an increased hazard ratio for mortality for T2DM
subjects to adjust for increasing BMI (see Appendix 3).420
Evaluating the lifetime duration scenario for these two models, the results again indi-
cate that the total lifetime costs for the lifestyle arm of the lifetime effect duration scenario
for Model 2B (the obesity-adjusted model) are again greater than those found in the unad-
justed model (Model 2A).  By referring to Tables 5.28 and 5.30, the reasons for the
increased costs become evident.  Comparing the NGT state for the lifestyle arm for both
Model 2A and Model 2B, one notes that subjects live for the exact same length of time
(11.72 years).  On the other hand, the cost for this state is greater ($63,796 for Model 2B
and $46,738 for Model 2A).  This increased cost can be attributed to the increased cost-
multiplier for NGT subjects included to adjust for obesity in Model 2B.  
As noted above, subjects live longer in Model 2A than in Model 2B, and this effect is
again more pronounced in the three-year effect scenario than the lifetime scenario.  The
etiology of this difference appears to be due to the duration of effect of the intervention
with more subjects in the NGT and IGT states.
420  Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and
diabetes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
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6.1.1.2.3 Summary: The Explanation of the Range of Incremental C/E Ratios
The above comparisons of the obesity-adjusted (Models 1B and 2B) to unadjusted
(Models 1A and 2A) models indicate that in addition to the influence of cost input (such
as control cost of illness and cost of intervention) on the model, the obesity adjustments
made to the models have substantial impact.  These adjustments include increases in haz-
ard ratios for mortality as well as increased cost of illness for NGT subjects.  The reason-
ing behind the large range of incremental cost-effectiveness ratio ranges, and particularly
between Model 1B and Model 2A (the least and most cost-effective models) is two-
pronged: (1) the increased cost-input variables in Model 2A ultimately increases the incre-
mental total costs, which results in increased incremental cost-effectiveness ratios
compared to Model 1B; and (2) the obesity-adjusted corrections to Model 1B, which
include increases in hazard ratio of mortality and an increased cost-multiplier for NGT,
subjects make further adjustments to both incremental costs and incremental rewards and
result in further increases to the incremental cost-effectiveness ratio.
6.1.1.3 Model 1A and the BMI –Specific Submodels
This section of the discussion concludes with a discussion of the base-case results of
Model 1A and the submodels based on BMI subcategory presented in Tables 5.1-5.3.  The
most important finding is that regardless of the BMI subcategory, lifestyle dominates
placebo for all of these models, including the subcategory of ≥ 35 kg/m2.
Comparisons of these models are given in Tables 5.15-5.18.  The results are consistent
with the DPP study findings.421 Incremental cost-effectiveness ratios are lower for the
BMI subgroup of 30 kg/m2 to < 35 kg/m2 than the overall DPP study cohort, or the BMI
subgroup with a BMI ≥ 35 kg/m2 for the three-year and lifetime scenarios of all three 
421  Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes
with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
236
models.  Total costs are higher for the BMI ≥ 35 kg/m2 subgroup, and this group also has
lower total life-years. 
6.1.1.4 The Use of QALYs in the Analysis
As noted in the introduction to this discussion, the main addition of the use of QALYs
in this analysis enabled a check of the accuracy of the dissertation model compared to that
of the DPP (comparing the dissertation results after three cycles to the DPP results).  The
use of QALYs for the long-term analysis remains limited due to the lack of standardized
values for the different glucose homeostasis states, as well as the effect of obesity on qual-
ity of life.  As this information becomes more available with future research, the accura-
cy of the cost per QALY values derived in the dissertation may be verified.
6.1.2 THE MAXIMUM ACCEPTABLE COST OF LIFESTYLE 
INTERVENTION
Finding that all models result in lifestyle dominating placebo in this dissertation is use-
ful, but it might also be helpful if policy makers had a proposed maximum acceptable cost
of intervention to use when beginning to design intensive lifestyle intervention programs.
The problem is that just as there is a large range of cost-effectiveness ratios among the
models, there is an equally large range of values derived for maximum acceptable cost of
intervention.  
With no surprise, when comparing Models 1A, 1B, 2A and 2B for three-year and life-
time duration of effect (using Tables 5.19 and 5.20), the lowest maximum acceptable cost
of intervention is that found for Model 1B, three-year duration of effect ($1,020 per year
for each of the three-years of the intervention), and the highest value is that found for
Model 2A, lifetime duration of effect ($9,750 per year for each of the three-years of the
intervention).  
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Once again, examining Tables 5.19 and 5.20, the reader may see that the obesity-
adjusted models (Model 1B and Model 2B) all have lower maximum acceptable costs of
intervention than those found in the unadjusted models.  These results generally trended
with the results of the incremental cost-effectiveness ratios found for these same models,
but were actually more likely to trend with the incremental costs (see Table 5.22 and 5.24).
Therefore, it appears that the cost input variables that influence incremental costs as well
as incremental cost-effectiveness ratios have very similar influences on the maximum
acceptable costs of intervention, depending on mortality adjustments made to a given
model.  Of great importance is the trend that models with a higher control cost of illness
(such as Models 2A and 2B) have a higher maximum acceptable cost of intervention.  
The emphasis of the following discussion deals with the effect of the obesity-adjusted
variables added to the models, and how their addition to the models influences the maxi-
mum acceptable control cost of intervention.
6.1.2.1 The Effect of Obesity-Adjusted Variables on Model 1A
Table 5.21 allows the reader to examine the effects of adding separately, and in com-
bination, the obesity-adjusted variables found in Model 1B to Model 1A.  These effects
include the following:
(1) The increased hazard ratio for mortality for NGT and IGT subjects to adjust for 
obesity relating to the findings of these increased hazard ratios in situations 
with multiple health care exclusions in study design.  (Model 1A has no haz-
ard ratio for mortality for NGT, and a triangular distribution of 0.8, 1.1, and 1.6 
for IGT.422 Model 1B has a hazard ratio of mortality of 1.3 for NGT subjects,
422  Saydah SH, Miret M, Sung J, et al. Postchallenge hyperglycemia and mortality in a national sam-
ple of U.S. adults. Diabetes Care. 2001;24:1397-1402.
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and 1.7 for IGT subjects.423, 424, 425)
(2) The increased hazard ratio for mortality for the T2DM subjects in Models 1B 
to adjust for increased hazard ratios with increased BMI (Model 1A has a tri-
angular distribution of 1.4, 1.9, and 2.5.426, 427 Model 1B has a value of 2.64.428)
(3) A cost-multiplier for NGT subjects (triangular distribution of 1.02, 1.34, and 
1.74)429 to adjust for added costs due to obesity versus none in Model 1A.
Table 5.22 shows that maximum acceptable cost of intervention is most likely to trend
with incremental costs in this model.  Maximum acceptable cost of intervention general-
ly trends with incremental cost-effectiveness ratios, but is affected by adjustments made
to the models for mortality.  The other important trend is that the scenarios with the low-
est maximum acceptable cost of intervention, and therefore, the lowest incremental cost-
effectiveness ratios all include the cost-multiplier for NGT subjects. Probably of most
importance is that there are at least seven ways to model this analysis, and each gives a
different result depending on which obesity-adjusted variable is added.
6.1.2.2 The Effect of Obesity-Adjusted Variables on Model 2A
A similar analysis of Model 2A is easier to interpret, as the obesity-adjustments to the  
423  Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. New England
Journal of Medicine. 1995;333:677-685.
424  Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life
expectancy: a life-table analysis. Annals of Internal Medicine. 2003;138:24-32.
425  Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S.
adults. New England Journal of Medicine. 1999;341:1097-1105.
426  Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of death
in the U.S. Diabetes Care. 2001;24:447-453.
427  Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burden of death attributable to diabetes in the
United States. American Journal of Epidemiology. 2002;156:714-719.
428  Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and dia-
betes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
429  Thompson D, Brown JB, Nichols GA, et al. Body mass index and future healthcare costs: a retrospec-
tive cohort study. Obesity Research. 2001;9:210-218.
239
hazard ratio for mortality for NGT and IGT (#1 above in section 6.1.2.1) are not required
because this is the generalized model, and the assumption is made that there are no exclu-
sions made for healthcare states in the cohort.
In this more straightforward example, illustrated in Table 5.23, one may see that the
addition of both adjustments for obesity (both the increased cost-multiplier for NGT sub-
jects and the increased hazard ratio for mortality for T2DM subjects) to yield the lowest
maximum acceptable cost of intervention.  Adding each of the adjustments separately
changes the maximum acceptable cost of intervention to an intermediate level.  As in the
above analysis, scenarios including the cost-multiplier for NGT give the lower maximum
cost of intervention values.  In addition, Table 5.24 again shows that maximum cost of
intervention in this model is more likely to trend with incremental costs than incremental
cost-effectiveness ratios due to the adjustments for mortality made to the models.
6.1.2.3 Summary of the Obesity Adjustments
A discussion of the maximum acceptable cost of intervention is important in several
ways.  The analysis verifies that maximum cost of intervention in this analysis appears to
depend on the incremental cost.  The maximum cost of intervention also depends on the
incremental cost-effectiveness ratio to a lesser extent, and this appears to depend on the
adjustments made to the model for mortality.  The analysis also shows that the lowest val-
ues for maximum cost are found for both sets of models when the increased cost multi-
plier for NGT and the increased hazard ratio for mortality for T2DM subjects are both
included.  If only one of these adjustments is added to this set of models, the increased
cost-multiplier for NGT seems to have a greater effect on lowering both the incremental
costs and the cost-effectiveness ratios, and therefore, the maximum acceptable cost of
intervention.
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6.1.2.4  A Test of the Effect of Direct Medical Costs
As with the analysis of incremental cost-effectiveness ratios, the analysis of the max-
imum acceptable cost of intervention reveals (as shown in Table 5.24) that increasing
direct medical costs in this model increases the maximum cost of intervention.  Once
again, this seems to directly trend with the increase in incremental cost-effectiveness ratio.
6.1.2.5 The Submodels of 1A
For completeness, this section includes an analysis of maximum acceptable cost of
intervention for the submodels of 1A based on BMI subcategories as found in Table 5.26.
These values are found to be highest in the model with a BMI of 30 kg/m2 to < 35 kg/m2.
The values for the model with a BMI of ≥ 35 kg/m2 are about 80% of those found for the
overall DPP study cohort.  
6.1.3 TIME FREE OF DIABETES AND COST BREAKDOWN BY STATE
The discussion section has made liberal use of the data found in Tables 5.27 and 5.28,
which illustrate the years free of diabetes for the models, and Tables 5.29 and 5.30, the
cost breakdown by Markov healthcare state.  It is important to note the value of the abil-
ity to run a Markov cohort analysis, which is the methodology used for these tables, in
order to more closely evaluate specific models, and in particular, their input variables.
6.1.4 SENSITIVITY ANALYSES
The discussion of the specific results concludes with examining the sensitivity analy-
ses described in section 5.4.  
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6.1.4.1 Duration of Effect
With no surprise, incremental cost-effectiveness ratios increased with increased dura-
tion of effect.  Duration of effect also appears to have effects on total costs in the lifetime
scenarios of the obesity adjusted value by being part of the etiology that makes these val-
ues higher than the non-adjusted model values (see Tables 5.11-5.14, and the discussion
in Sections 6.1.1.2.1 and 6.1.1.2.2).
6.1.4.2 The Effects of Discounting
For the lifetime effect of all models, discounting at 3% and 5% improved incremental
cost-effectiveness ratios (see Tables 5.32 and 5.33).  This did not hold true for Models 1A
(including submodels) and 1B for a three-year duration of effect.  In Model 1A, the incre-
mental cost-effectiveness ratio, while still showing lifestyle dominating placebo,
increased at the 5% discount rate.  In the obesity-adjusted model (Model 1B), discounting
at both 3% and 5% resulted in no strategy dominating another (versus lifestyle dominat-
ing placebo), with values of ($0.3/LY AND $1.8K/LY, respectively.  The overall increase
in incremental cost-effectiveness when discounting is incorporated in the models with
increased range of duration of effect is of even greater encouragement for the use of inten-
sive lifestyle intervention to prevent T2DM.
6.1.4.3 Changes in Effect and Transition Probabilities
The effect of changes in transition probabilities will complete the discussion of the
results. The first change, that of decreasing the effect of the intervention by 20%, was also
performed by the DPP in their within cost analysis.430 The results show that in Model 1B, 
430  Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle inter-
vention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
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with a three-year duration of effect, no strategy dominates (incremental cost-effectiveness
ratio of +$1.9K/LY).  In all other scenarios for Models 1A, 1B, 2A, and 2B, lifestyle dom-
inates placebo.  
Due to the uncertainty found for the transition probability from NGT to IGT, this value
was increased by 20% in Models 1A, 1B, 2A, and 2B.  This increase also resulted in no
strategy dominating for Model 1B with a three-year duration of effect (+0.3K/LY).  In all
other scenarios, lifestyle dominated placebo.
Using the current clinical literature as a guide, adding a transition of T2DM subjects
to IGT had little to no effect on the results of the model.  The literature on this transition
probability was not as robust as that for the transition from IGT to NGT, and this remains
an area of the model where further refinement is needed.
6.2 Conclusion: How the Results May Apply to Policy Related to Prevention of 
T2DM
Current literature related to the cost-effectiveness of preventive services generally
brings up several points that are very important for healthcare financing: (1) Monetary
resources are scarce; (2) Limitless spending cannot be the result of placing a high value
on health; and (3) Limitless spending cannot occur because an intervention is successful.431
Bonneux and Birnie state these points this way: "If resources are scarce, trade offs have
to be made between investing in the cure of existing disease and in the prevention of future
disease."432
The U.S. Preventive Services Task Force made the following recommendation in
December 2003: "The USPSTF recommends that clinicians screen all adult patients for 
431  Probstfield JL. How cost-effective are new preventive strategies for cardiovascular disease? The
American Journal of Cardiology. 2003;22:22-27.
432  Bonneux L, Birnie E. The discount rate in the economic evaluation of prevention: a thought
experiment. Journal of Epidemiology and Community Health. 2001;55:123-125.
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obesity and offer intensive counseling and behavioral interventions to promote sustained 
weight loss for obese adults."433 The DPP study was one reference used to support this
recommendation. 
Cost-effectiveness analysis is not a requirement for recommendations by the Task
Force434 though the following is suggested, "Evidence of effectiveness should be supple-
mented when possible by information on cost-effectiveness in any decision-making con-
text in which available resources can be used for multiple purposes."435 They also state,
"Cost-effectiveness analysis raises important questions about opportunity costs of alter-
native choices that decision-makers should consider."436
Therefore, this dissertation is a starting point to look at the ultimate cost of imple-
menting the above recommendation on a long-term basis, or to answer the first of the
three-main questions asked in this dissertation, "What is the long-term cost-effectiveness
of intensive lifestyle intervention to prevent T2DM from the state of IGT?"
The analysis is very encouraging in that all four of the basic models (Models 1A, 1B,
2A, and 2B) of the dissertation result in lifestyle dominating placebo at a discount rate of
0%.  The importance of this is that these varied models attempt to address the impact of
obesity on the evaluation as well as attempt to project the DPP findings onto a more gen-
eralized population, the second and third goals of this study.  The positive results allow
the reader to determine that while there is a varied range of results of incremental cost-
effectiveness ratios that are produced in the analyses, overall, long-term diabetes preven-
433  U.S. Preventive Services Task Force. Screening for Obesity in Adults: Recommendations and
Rationale. Agency for Healthcare Research and Quality. Available at: http://www.ahrq.gov/clinic/3rdusp-
stf/obesity/. Accessed October 2004.
434  U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd Edition.





tion by intensive lifestyle intervention dominates placebo.
Discounting is very important for cost-effectiveness analyses of preventive services,
and the dissertation results are encouraging in that only one model (the obesity-adjusted
model that is most like the DPP study cohort with a three-year duration of effect (Model
1B)) results in a scenario where there is no dominate strategy at discount rates of both 3%
and 5%.  The Model 1B results are still encouraging as the values generated are very close
to the break-even level ($0.3K/LY and $1.8K/LY, respectively).
In addition, it is also very encouraging that lifestyle dominates placebo in the BMI
subcategory of ≥ 35 kg/m2.  While the effect of the intervention in this subcategory is less
than found for the overall cohort, it appears that intensive lifestyle intervention in this sub-
category of patients should not be discouraged by clinicians based on cost-effectiveness. 
The range of incremental cost-effectiveness ratios points out the great importance of input
variables in any model of diabetes prevention.  Above all, the model must be as transpar-
ent as possible.  The current ISPOR Best Practice Guidelines stress transparency as a
requirement.437 As further cost-effectiveness studies are published on diabetes prevention,
it will be important to examine variables that are included in the models presented.  From
this dissertation, the input data that appear to have the most substantial influence on the
model include: (1) direct medical control cost of illness; (2) cost of intervention; (3) dura-
tion of intervention effect; (4) adjustments to control cost of illness for obese non-diabet-
ic subjects; and (5) adjustments to mortality rates for all subjects, regardless of glucose
homeostasis level.  Additionally, future models should carefully examine the actual tran-
sitions that are present in the DPP study, and should attempt to include a transition from
IGT to NGT.
437  Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic
modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices -
Modeling Studies. Value in Health. 2003;6:9-17.
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The maximum acceptable cost of intervention results generated in the model are also
an important starting point for policy makers.  It is one thing to state that intensive lifestyle
intervention for T2DM prevention from an IGT state appears cost-effective, but it is
another to begin to determine how much the healthcare community may spend on the
intervention.  This range of intervention costs also varied widely, as did the wide range of
incremental cost-effectiveness ratios that resulted in the study.  
An example of how the large range of maximum cost of interventions might affect pol-
icy is the following. If the only value generated was that found in the scenario of Model
2A (an annual expenditure of $9,750 in a generalized, unadjusted model with a three-year
intervention and a lifetime effect), policy makers might begin to think that a very viable
suggestion for diabetes prevention might be invasive intervention such as gastric bypass
surgery.  The rationale might be the following; (1) The model projects that the healthcare
system has approximately $30K to spend over a three-year period; (2) A gastric bypass
procedure might be the most effective way to maintain weight loss, which appears to
influence the effect of the intervention; and (3) the surgical procedure costs approximate-
ly $30K.  Adjustments to the models show this is just one maximum acceptable cost value
that may be projected for cost-effectiveness of diabetes prevention.  The example shows
the importance to modeling of data input, sensitivity analyses, and transparency.
The prevailing cost of illness in a community appears to have a great influence on the
incremental cost-effectiveness ratios and maximum acceptable cost of intervention values
found in this dissertation.    This may be because of the model design that uses this value
as a starting point from which additional multipliers are used to increase cost of illness for
the different Markov healthcare states.  Another reason for the importance of this variable
may be the limited effect of the intervention of life expectancy as projected in this model 
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(as well as those used by Palmer et al.),438, 439 which tends to hold the denominator of the
cost-effectiveness ratio fairly constant.  For other modelers that use this technique, the
potential influence of the control cost of illness must be recognized.
6.3 Directions for Future Research
Out of this dissertation research arise several areas where future research is needed.
The first involves the fact that the study is performed on a cohort that is not particularly
representative of the U.S. population (due to healthcare exclusion criteria in the study
design), and we have no evidence that the results obtained by the DPP will be similar in
a more generalized population.  Clinical research is suggested in this area to determine the
effect of intensive lifestyle intervention on a more generalized population of subjects with
IGT to prevent T2DM.
Further research is required to establish the effect of obesity on non-diabetic subjects.
This is important because it appears that much of the cost of illness of obese diabetics is
related to their diabetes.  If one is basing cost of illness of obese subjects on a population
that includes diabetics and non-diabetics, it is possible that inaccuracies might occur in
cost values.  
The effect of obesity on mortality rates in non-diabetics also remains controversial.  As
noted in the dissertation, there are two schools of thought on this subject.  For this disser-
tation, the assumption was made that mortality rates appear to increase in studies based on
baseline cohorts that do not have broad healthcare exclusions in their study design.  The 
438  Palmer AJ, Roze S, Cabrieres L, et al. Long-term projection of the costs of the Diabetes
Prevention Program in the USA using the CORE diabetes prevention model: intensive lifestyle changes
and metformin are both cost-effective. Paper presented at: 18th International Diabetes Federation
Congress, 2003; Paris.
439 Palmer AJ, Roze S, Valentine WJ, et al. Intensive lifestyle changes or metformin in patients with
impaired glucose tolerance: modeling the long-term health economic implications of the Diabetes
Prevention Program in Australia, France, Germany, Switzerland, and the United Kingdom. Clinical
Therapeutics. 2004;26:304-321.
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reason for this discrepancy also requires further analysis.
Further clinical research is required to determine the potential duration of effect of dia-
betes prevention based on weight loss and physical activity.  The results of this disserta-
tion are encouraging in that lifestyle dominates placebo for all models even in the least
optimistic scenario in which the effect of duration is only three-years (at a discount rate
of 0%).
6.4 Limitations
One major limitation of this study is that DPP study data were not available.  While
having the data is important, the fact that it may have limited generalizability to the U.S.
population must also be considered.  The possibility that the effect from the lifestyle inter-
vention found in the DPP study might not reflect that which would be found if intensive
lifestyle intervention was implemented in a population without exclusions of healthcare
states, and in particular, exclusion of cardiovascular disease (an early, macrovascular com-
plication) is a great limitation.
The large number of assumptions required for the model (see Appendix 4) adds to the
limitations of this study.  At least part of this is secondary to the paucity of data about the
effect of obesity on the Markov transition probabilities and rewards found in the models.
This limitation is addressed in part by the four scenarios presented for the models and the
extensive sensitivity analyses performed.  It is clear that further adjustments will be
required in future research on diabetes prevention, obesity, and the role of weight loss on
these areas.  
An additional limitation to the study is the inability to capture the effect of weight loss
on other medical conditions that appear to be causally linked to obesity.  This limitation
potentially underestimates the cost-effectiveness of the analysis.  The fact that a 7% 
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weight loss still placed the average intervention subject in a category of obese class I (as
defined by the WHO)440 somewhat tempers this limitation.
6.5 Conclusion
Intensive lifestyle intervention to prevent T2DM appears to be cost-effective on a
long-term basis based on the results found in this dissertation.  Until further clinical
research is completed examining the actual long-term results of lifestyle intervention on
diabetes prevention, modeling must be employed.  In light of the fact that the DPP study
is not particularly generalizable to the current U.S. population, the need for modeling in
any diabetes prevention analysis is also emphasized.  
This dissertation becomes a starting point for other researchers in the field of diabetes
prevention to evaluate the effect of the variables included in cost-effectiveness models.
The dissertation also hopefully helps to start introducing values for maximum acceptable
cost of lifestyle intervention for diabetes prevention as the December 2003 recommenda-
tion by the U.S. Preventive Service Task Force for "intensive counseling and behavioral
interventions to promote weight loss for obese adults" begins to be implemented.
440  World Health Organization. Obesity: Preventing and Managing the Global Epidemic.  Report of
the WHO Consultation on Obesity. Geneva: World Health Organization; 2000.
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H1          
Model 1A
+ 30 kg/m2 to  35 kg/m2 +  Mortality, utility and cos t Values from the 
DPP will be used for the firs t three years





 to   35 
kg/m2
+  Mortality, utility and cos t Values from the 
DPP will be used for the firs t three years




Greater than or 
equal        35 kg/m 2
+
 Mortality, utility and cos t Values from the 
DPP will be used for the firs t three years
Multiplier added for 
costs of NGT subjects   
Increased HR for 
mortality for T2DM 
subjects
H5        
Model 2A
30 kg/m2 to  35 kg/m2
Increas ed control costs and 
increased mortali ty rates over 
DPP va lues   Last  DPP 
Utili ty value used
Multiplier added for 
costs of NGT subjects   
Increased HR for 
mortality for T2DM 
subjects
Appendix 1
H4         
Model  1B
+ 30 kg/m2 to  35 kg/m2 +
Hypotheses and Models
H6          
Model  2B
30 kg/m2 to  35 kg/m2
Increaed HR for mortality for NGT and IGT subjects
Increas ed control costs and 
increased mortali ty rates over 
DPP va lues   Last  DPP 
Utili ty value used
 Mortality, utility and cos t Values from the 
DPP will be used for the firs t three years
APPENDIX 2
Model 1A  Data Input (Including Equations for Lifetime and Three-Year Effect)
251
Variable with Description (Specific 
Variable Names are in Bold Font)
Value Reference
Age: start age of cohort 50 years a
Progression from IGT to T2DM in 
placebo arm
0.1075 a
Reversion from IGT to NGT in placebo 
arm
0.0678 a
Progression from NGT to IGT in placebo 
arm
0.0767 b,c,d
Progression from IGT to T2DM in 
lifestyle arm
0.0505 a
Progression from IGT to NGT in lifestyle 
arm
0.1121 a




probability of progression from IGT to 
T2DM for the lifestyle arm (three-year 
duration of effect)




probability of progression from IGT to 
NGT for the lifestyle arm (three-year 
duration of effect)




probability of progressing from NGT to 
IGT for the lifestyle arm (three-year 
duration of effect)
0.0406 for the first-three cycles, 
and then 0.0767
-
Hazard ratio of mortality for NGT none -
HRI_mort_1A: hazard ratio of mortality 
for IGT
Triangular distribution of 0.8, 
1.1, and 1.6
e
HRT_mort_1A: hazard ratio of mortality 
for T2DM




rates for the placebo arm
0.0017 for the first-three cycles, 
and then reverts to U.S. Life 
Tables
h,i
mort_L_1A[Age+_stage]: mortality rates 
for the lifestyle arm
0.0010 for the first-three cycles, 
and then reverts to the U.S. Life 
Tables
h,i
pDie_Pl_NGT_1A: probability of death 




pDie_Pl_IGT_1A: probability of death 
for an IGT subject in the placebo arm
1-exp(-mort_Pl_1A   
[Age+_stage]*HR_I_mort_1A)
-
pDie_Pl_T_1A: probability of death for a 
T2DM subject in the placebo arm
1-exp(-mort_Pl_1A       
[Age+_stage]*HR_T_mort_1A
-
pDie_L_NGT_1A : probability of death 
for a NGT subject in the lifestyle arm
1-exp(-mort_L_1A          
[Age+_stage])
-
pDie_L_I_1A: probability of death for an 
IGT subject in the lifestyle arm
1-exp(-mort_L_1A        
[Age+_stage]*HR_I_mort_1A)
-
pDie_L_T_1A: probability of death for a 
T2DM subject in the lifestyle arm
1-exp(-mort_L_1A         
[Age+_stage]*HR_T_mort_1A)
-
cSC_1A: Cost of screening $139 j
cINT_pl-1A[Age+_stage] : cost of 
intervention for placebo arm
Values for first-three cycles: $43, 
$18, $18, and the $0
j
cINT_L_1A:[Age+_stage] cost of 
intervention for lifestyle arm
Values for first-three cycles: 
$1,399, $679, and $702, and then 
$0
j
cNGT_1A[Age+_stage]: direct medical 
costs (cost for a subject with NGT)
$1,100 for the first-three cycles, 
and then $2,688 
j,k,l
CM_I_1A: cost multiplier of IGT in 1A
Triangular distribution of 1.35, 
1.48, and 1.79
k
CM_T_1A: cost multiplier of T2DM in 
1A
Triangular distribution of 2.03, 
2.27, and 2.83
l,m,n
uPl_1A[Age+_stage] ; the cycle 
dependent utilites required for the placebo 
arm
0.686, 0.675, and 0.657 for the 
first-three cycles, and then 0.657
h
uLife_1A[Age+_stage]





a:, Knowler WC, Barrett-Conner E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
b: Weyer C, Tataranni PA, Bogardus C, et al. Insulin resistance and insulin secretory dysfunction are inde-
pendent predictors of worsening glucose tolerance during each stage of type 2 diabetes development.
Diabetes Care.2001:24:89-94.
c: Edelstein SI, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to
NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701-710.
d: Meigs, JB, Mueller DC, Nathan DM, et al. The natural history of progression from normal glucose tol-
erance to type 2 diabetes in the Baltimore Longitudinal Study of the Aging. Diabetes. 2003;52:1475-1484.
e: Saydah SH, Miret M, Sung J, et al.  Postchallenge hyperglycemia and mortality in a national sample of
U.S. adults.  Diabetes Care. 2001;24:1397-1402.
f: Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of death
in the U.S.  Diabetes Care. 2001;24:447-453.
g: Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burdens of death attributable to diabetes in the
United States.  American Journal of Epidemiology. 2002;156:714-719.
h:The Diabetes Prevention Program Research Group.  Within-trial cost-effectiveness of lifestyle interven-
tion or Metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
i: Arias E. United States Life Tables, 2000. Hyattsville, MD: National Center for Health Statistics, 2002.
vol.51,3.
j:  Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2
diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36-47.
k: Nichols GA, Glauber HS, Brown JB.  Type 2 diabetes: incremental medical care costs during the 8
years preceding diagnosis.  Diabetes Care. 2000;23:1654-1659.
l: Brown JB, Nichols GA, Glauber HS, et al.  Type 2 diabetes: incremental medical care costs during the
first eight years after diagnosis.  Diabetes Care. 1999;22:1116-1124.
m: American Diabetes Association. Economic costs of diabetes in the US. In 2002. Diabetes Care.
2003;26:917-932.
n: Ramsey S, Summers K, Leong SA, et al. Productivity and medical costs of diabetes in a large employer
population. Diabetes Care. 2002;25:23-29.
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Model 1A Submodel Input Data for BMI Subcategory of 30 kg/m2 to < 35 kg/m2
(Including Equations for Lifetime and Three-Year Effect)
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Variable with Description (Specific 
Variable Names are in Bold Font)
Value Reference
Age: start age of cohort 50 years a
Progression from IGT to T2DM in 
placebo arm
0.0851 a
Reversion from IGT to NGT in placebo 
arm
0.0885 a
Progression from NGT to IGT in placebo 
arm
0.0602 b
Progression from IGT to T2DM in 
lifestyle arm
0.0363 a
Progression from IGT to NGT in lifestyle 
arm
0.1653 a




probability of progression from IGT to 
T2DM for the lifestyle arm (three-year 
duration of effect)




probability of progression from IGT to 
NGT for the lifestyle arm (three-year 
duration of effect)




probability of progressing from NGT to 
IGT for the lifestyle arm (three-year 
duration of effect)
0.0433 for the first-three cycles, 
and then 0.0602
-
Hazard ratio of mortality for NGT none -
HRI_mort_1A: hazard ratio of mortality 
for IGT
Triangular distribution of 0.8, 
1.1, and 1.6
c
HRT_mort_1A: hazard ratio of mortality 
for T2DM





rates for the placebo arm
0.0017 for the first-three cycles, 
and then reverts to U.S. Life 
Tables
-
mort_L_1A[Age+_stage]: mortality rates 
for the lifestyle arm
0.0010 for the first-three cycles, 
and then reverts to the U.S. Life 
Tables
-
pDie_Pl_NGT_1A: probability of death 




pDie_Pl_IGT_1A: probability of death 
for an IGT subject in the placebo arm
1-exp(-mort_Pl_1A   
[Age+_stage]*HR_I_mort_1A)
-
pDie_Pl_T_1A: probability of death for a 
T2DM subject in the placebo arm
1-exp(-mort_Pl_1A       
[Age+_stage]*HR_T_mort_1A
-
pDie_L_NGT_1A : probability of death 
for a NGT subject in the lifestyle arm
1-exp(-mort_L_1A          
[Age+_stage])
-
pDie_L_I_1A: probability of death for an 
IGT subject in the lifestyle arm
1-exp(-mort_L_1A        
[Age+_stage]*HR_I_mort_1A)
-
pDie_L_T_1A: probability of death for a 
T2DM subject in the lifestyle arm
1-exp(-mort_L_1A         
[Age+_stage]*HR_T_mort_1A)
-
cSC_1A: Cost of screening $139 f
cINT_pl-1A[Age+_stage] : cost of 
intervention for placebo arm
Values for first-three cycles: $43, 
$18, $18, and the $0
f
cINT_L_1A:[Age+_stage] cost of 
intervention for lifestyle arm
Values for first-three cycles: 
$1,399, $679, and $702, and then 
$0
f
cNGT_1A[Age+_stage]: direct medical 
costs (cost for a subject with NGT)
$1,100 for the first-three cycles, 
and then $2,688 
g,h
CM_I_1A: cost multiplier of IGT in 1A
Triangular distribution of 1.35, 
1.48, and 1.79
g
CM_T_1A: cost multiplier of T2DM in 
1A
Triangular distribution of 2.03, 
2.27, and 2.83
h,I,j
uPl_1A[Age+_stage] ; the cycle 
dependent utilites required for the placebo 
arm
0.686, 0.675, and 0.657 for the 
first-three cycles, and then 0.657
k
uLife_1A[Age+_stage]




a: Knowler WC, Barrett-Conner E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
b: Miegs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose toler-
ance to type 2 diabetes in the Baltimore Longitudinal Study of the Aging. Diabetes. 2003;52:1475-1484.
c: Saydah SH, Miret M, Sung J, et al.  Postchallenge hyperglycemia and mortality in a national sample of
U.S. adults.  Diabetes Care. 2001;24:1397-1402.
d: Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of death
in the U.S.  Diabetes Care. 2001;24:447-453.
e: Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burdens of death attributable to diabetes in the
United States.  American Journal of Epidemiology. 2002;156:714-719.
f: k: The Diabetes Prevention Program Research Group.  Within-trial cost-effectiveness of lifestyle inter-
vention or Metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523
g: Arias E. United States Life Tables, 2000. Hyattsville, MD: National Center for Health Statistics, 2002.
vol.51,3.
h: Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2
diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36-47.
i: Nichols GA, Glauber HS, Brown JB.  Type 2 diabetes: incremental medical care costs during the 8
years preceding diagnosis.  Diabetes Care. 2000;23:1654-1659.
j: Brown JB, Nichols GA, Glauber HS, et al.  Type 2 diabetes: incremental medical care costs during the
first eight years after diagnosis.  Diabetes Care. 1999;22:1116-1124.
k: American Diabetes Association. Economic costs of diabetes in the US. In 2002. Diabetes Care.
2003;26:917-932.
l: Ramsey S, Summers K, Leong SA, et al. Productivity and medical costs of diabetes in a large employer
population. Diabetes Care. 2002;25:23-29.
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Model 1A Submodel Input Data for BMI Subcategory of  ≥ 35 kg/m2 (Including
Equations for Lifetime and Three-Year Effect)
Variable with Description (Specific 
Variable Names are in Bold Font)
Value Reference
Age: start age of cohort 50 years a
Progression from IGT to T2DM in 
placebo arm
0.1332 a
Reversion from IGT to NGT in placebo 
arm
0.0567 a
Progression from NGT to IGT in placebo 
arm
0.0767 b
Progression from IGT to T2DM in 
lifestyle arm
0.0704 a
Progression from IGT to NGT in lifestyle 
arm
0.0853 a




probability of progression from IGT to 
T2DM for the lifestyle arm (three-year 
duration of effect)




probability of progression from IGT to 
NGT for the lifestyle arm (three-year 
duration of effect)




probability of progressing from NGT to 
IGT for the lifestyle arm (three-year 
duration of effect)
0.0465 for the first-three cycles, 
and then 0.0767
-
Hazard ratio of mortality for NGT none -
HR_I_mort_1A: hazard ratio of mortality 
for IGT
Triangular distribution of 0.8, 
1.1, and 1.6
c
HR_T_mort_1A: hazard ratio of 
mortality for T2DM






rates for the placebo arm
0.0017 for the first-three cycles, 
and then reverts to U.S. Life 
Tables
-
mort_L_1A[Age+_stage]: mortality rates 
for the lifestyle arm
0.0010 for the first-three cycles, 
and then reverts to the U.S. Life 
Tables
-
pDie_Pl_NGT_1A: probability of death 




pDie_Pl_IGT_1A: probability of death 
for an IGT subject in the placebo arm
1-exp(-mort_Pl_1A   
[Age+_stage]*HR_I_mort_1A)
-
pDie_Pl_T_1A: probability of death for a 
T2DM subject in the placebo arm
1-exp(-mort_Pl_1A       
[Age+_stage]*HR_T_mort_1A
-
pDie_L_NGT_1A : probability of death 
for a NGT subject in the lifestyle arm
1-exp(-mort_L_1A          
[Age+_stage])
-
pDie_L_I_1A: probability of death for an 
IGT subject in the lifestyle arm
1-exp(-mort_L_1A        
[Age+_stage]*HR_I_mort_1A)
-
pDie_L_T_1A: probability of death for a 
T2DM subject in the lifestyle arm
1-exp(-mort_L_1A         
[Age+_stage]*HR_T_mort_1A)
-
cSC_1A: Cost of screening $139 f
cINT_pl-1A[Age+_stage] : cost of 
intervention for placebo arm
Values for first-three cycles: $43, 
$18, $18, and the $0
f
cINT_L_1A:[Age+_stage] cost of 
intervention for lifestyle arm
Values for first-three cycles: 
$1,399, $679, and $702, and then 
$0
f
cNGT_1A[Age+_stage]: direct medical 
costs (cost for a subject with NGT)
$1,100 for the first-three cycles, 
and then $2,688 
g,h
CM_I_1A: cost multiplier of IGT in 1A
Triangular distribution of 1.35, 
1.48, and 1.79
g
CM_T_1A: cost multiplier of T2DM in 
1A
Triangular distribution of 2.03, 
2.27, and 2.83
h,I,j
uPl_1A[Age+_stage] ; the cycle 
dependent utilites required for the placebo 
arm
0.686, 0.675, and 0.657 for the 
first-three cycles, and then 0.657
k
uLife_1A[Age+_stage]




a: Knowler WC, Barrett-Conner E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
b: Miegs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose toler-
ance to type 2 diabetes in the Baltimore Longitudinal Study of the Aging. Diabetes. 2003;52:1475-1484.
c: Saydah SH, Miret M, Sung J, et al.  Postchallenge hyperglycemia and mortality in a national sample of
U.S. adults.  Diabetes Care. 2001;24:1397-1402.
d: Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of death
in the U.S.  Diabetes Care. 2001;24:447-453.
e: Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burdens of death attributable to diabetes in the
United States.  American Journal of Epidemiology. 2002;156:714-719.
f: k: The Diabetes Prevention Program Research Group.  Within-trial cost-effectiveness of lifestyle inter-
vention or Metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523
g: Arias E. United States Life Tables, 2000. Hyattsville, MD: National Center for Health Statistics, 2002.
vol.51,3.
h: Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2
diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36-47.
i: Nichols GA, Glauber HS, Brown JB.  Type 2 diabetes: incremental medical care costs during the 8
years preceding diagnosis.  Diabetes Care. 2000;23:1654-1659.
j: Brown JB, Nichols GA, Glauber HS, et al.  Type 2 diabetes: incremental medical care costs during the
first eight years after diagnosis.  Diabetes Care. 1999;22:1116-1124.
k: American Diabetes Association. Economic costs of diabetes in the US. In 2002. Diabetes Care.
2003;26:917-932.
l: Ramsey S, Summers K, Leong SA, et al. Productivity and medical costs of diabetes in a large employer
population. Diabetes Care. 2002;25:23-29.
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Model 1B Data Input (Including Equations for Lifetime and Three-Year Effect)
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Variable with Description (Specific 
Variable Names are in Bold Font)
Value Reference
Age: start age of cohort 50 years a
Progression from IGT to T2DM in 
placebo arm
0.1075 a
Reversion from IGT to NGT in placebo 
arm
0.0678 a
Progression from NGT to IGT in placebo 
arm
0.0767 b,c,d
Progression from IGT to T2DM in 
lifestyle arm
0.0505 a
Progression from IGT to NGT in lifestyle 
arm
0.1121 a




probability of progression from IGT to 
T2DM for the lifestyle arm (three-year 
duration of effect)




probability of progression from IGT to 
NGT for the lifestyle arm (three-year 
duration of effect)




probability of progressing from NGT to 
IGT for the lifestyle arm (three-year 
duration of effect)
0.0406 for the first-three cycles, 
and then 0.0767
-
HRM_T_1B: hazard ratio of mortality for 
NGT
2.64 e
HRM_I_1B: hazard ratio of mortality for 
IGT
1.7 f,g,h
HRM_N_1B: hazard ratio of mortality 
for T2DM
1.3 f,g,h
mort_pl_1B[Age+_stage] : mortality rates 
for the placebo arm
0.0017 for the first-three cycles, 




mort_L_1B[Age+_stage] : mortality rates 
for the lifestyle arm
0.0010 for the first-three cycles, 
and then reverts to the U.S. Life 
Tables
i,j
pDie_Pl_N_1B: probability of death for a 
NGT subject in the placebo arm
1-exp(-mort_pl_1B            
[Age+_stage]*HRM_N_1B)
-
pDie_Pl_I_1B: probability of death for an 
IGT subject in the placebo arm
1-exp(-mort_pl_1B   
[Age+_stage]*HRM_I_1B)
-
pDie_Pl_T_1B: probability of death for a 
T2DM subject in the placebo arm
1-exp(-mort_pl_1B       
[Age+_stage]*HRM_T_1B)
-
pDie_L_N_1B : probability of death for a 
NGT subject in the lifestyle arm
1-exp(-mort_L_1B          
[Age+_stage]*HMR_N_1B)
-
pDie_L_I_1B: probability of death for an 
IGT subject in the lifestyle arm
1-exp(-mort_L_1B        
[Age+_stage]*HRM_I_1B)
-
pDie_L_T_1B: probability of death for a 
T2DM subject in the lifestyle arm
1-exp(-mort_L_1B         
[Age+_stage]*HRM_T_1B)
-
cSC_1B: Cost of screening $139 g
cINT_pl-1B[Age+_stage] : cost of 
intervention for placebo arm
Values for first-three cycles: $43, 
$18, $18, and the $0
g
cINT_L_1B:[Age+_stage] cost of 
intervention for lifestyle arm
Values for first-three cycles: 
$1,399, $679, and $702, and then 
$0
g
cNGT_1B[Age+_stage] : direct medical 
costs (cost for a subject with NGT)
$1,100 for the first-three cycles, 
and then $2,688 
h,i
CM_N_1B: cost multiplier of NGT in 1B
Triangular distribution of 1.02, 
1.34, and 1.74
j
CM_I_1B: cost multiplier of IGT in 1B
Triangular distribution of 1.35, 
1.48, and 1.79
h
CM_T_1A: cost multiplier of T2DM in 
1B
Triangular distribution of 2.03, 
2.27, and 2.83
i,k,l
uPl_1A[Age+_stage] ; the cycle 
dependent utilities required for the 
placebo arm
0.686, 0.675, and 0.657 for the 
first-three cycles, and then 0.657
m
uLife_1A[Age+_stage]




a: Knowler WC, Barrett-Conner E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
b: Weyer C, Tataranni PA, Bogardus C, et al. Insulin resistance and insulin secretory dysfunction are inde-
pendent predictors of worsening glucose tolerance during each stage of type 2 diabetes development.
Diabetes Care.2001;24:89-94.
c: Edelstein SI, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to
NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701-710.
d: Meigs, JB, Mueller DC, Nathan DM, et al. The natural history of progression from normal glucose tol-
erance to type 2 diabetes in the Baltimore Longitudinal Study of the Aging. Diabetes. 2003;52:1475-1484.
e: Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and dia-
betes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
f: Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women.  New England
Journal of Medicine. 1995;333:677-685.
g: Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life
expectancy: a life-table analysis. Annals of Internal Medicine. 2003;138:24-32.
h: Calle EE, Thun MJ, Petrelli JM, et al.  Body-mass index and mortality in a prospective cohort of U.S.
adults. New England Journal of Medicine. 1999;341:1097-1105.
i: The Diabetes Prevention Program Research Group.  Within-trial cost-effectiveness of lifestyle interven-
tion or Metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
j: Arias E. United States Life Tables, 2000. Hyattsville, MD: National Center for Health Statistics, 2002.
vol.51,3.
k:  Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2
diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36-47.
l: Nichols GA, Glauber HS, Brown JB.  Type 2 diabetes: incremental medical care costs during the 8
years preceding diagnosis.  Diabetes Care. 2000;23:1654-1659.
m: Brown JB, Nichols GA, Glauber HS, et al.  Type 2 diabetes: incremental medical care costs during the
first eight years after diagnosis.  Diabetes Care. 1999;22:1116-1124.
n: Thompson D, Brown JB, Nichols GA, et al. Body mass index and future healthcare costs: a retrospec-
tive cohort study.  Obesity Research.2001;9:210-218.
o: American Diabetes Association. Economic costs of diabetes in the US. In 2002. Diabetes Care.
2003;26:917-932.
: Ramsey S, Summers K, Leong SA, et al. Productivity and medical costs of diabetes in a large employer
population. Diabetes Care. 2002;25:23-29.
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APPENDIX 3
Model 2A Data Input (Including Equations for Lifetime and Three-Year Effect)
263
Variable with Description (Specific 
Variable Names are in Bold Font)
Value Reference
Age: start age of cohort 50 years a
Progression from IGT to T2DM in 
placebo arm
0.1075 a
Reversion from IGT to NGT in placebo 
arm
0.0678 a
Progression from NGT to IGT in placebo 
arm
0.0767 b,c,d
Progression from IGT to T2DM in 
lifestyle arm
0.0505 a
Progression from IGT to NGT in lifestyle 
arm
0.1121 a




probability of progression from IGT to 
T2DM for the lifestyle arm (three-year 
duration of effect)




probability of progression from IGT to 
NGT for the lifestyle arm (three-year 
duration of effect)




probability of progressing from NGT to 
IGT for the lifestyle arm (three-year 
duration of effect)
0.0406 for the first-three cycles, 
and then 0.0767
-
Hazard ratio of mortality for NGT none -
HRI_mort_2A: hazard ratio of mortality 
for IGT
Triangular distribution of 0.8, 
1.1, and 1.6
e
HRT_mort_2A: hazard ratio of mortality 
for T2DM




a:Knowler WC, Barrett-Conner E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
b: Weyer C, Tataranni PA, Bogardus C, et al. Insulin resistance and insulin secretory dysfunction are inde-
pendent predictors of worsening glucose tolerance during each stage of type 2 diabetes development.
Diabetes Care. 2001;24:89-94.
c: Edelstein SI, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to
NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701-710.
d: Meigs, JB, Mueller DC, Nathan DM, et al. The natural history of progression from normal glucose tol-
erance to type 2 diabetes in the Baltimore Longitudinal Study of the Aging. Diabetes. 2003;52:1475-1484.
e: Saydah SH, Miret M, Sung J, et al.  Postchallenge hyperglycemia and mortality in a national sample of
U.S. adults.  Diabetes Care. 2001;24:1397-1402.
f: Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of death
in the U.S.  Diabetes Care. 2001;24:447-453.
g: Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burdens of death attributable to diabetes in the
United States. American Journal of Epidemiology. 2002;156:714-719.
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mort_2A[Age+_stage]: mortality rates 
for the placebo arm
U.S. Life Table Values for the 
year 2000
f
pDie_NGT_2A: probability of death for a 
NGT subject in the placebo and the 
lifestyle arms
1-exp(-mort_2A  [Age+_stage]) -
pDie_IGT_2A: probability of death for 
an IGT subject in the placebo arm
1-exp(-mort_2A   
[Age+_stage]*HRI_mort_2A)
-
pDie_T2DM_2A: probability of death for 
a T2DM subject in the placebo and 
lifestyle arms
1-exp(-mort_Pl_1A       
[Age+_stage]*HR_T_mort_1A
-
cSC_1A: Cost of screening $139 f
cINT_pl-1A[Age+_stage] : cost of 
intervention for placebo arm
Values for first-three cycles: $43, 
$18, $18, and the $0
f
cINT_L_1A:[Age+_stage] cost of 
intervention for lifestyle arm
Values for first-three cycles: 
$1,399, $679, and $702, and then 
$0
f
cNGT: direct medical costs (cost for a 
subject with NGT)
$2,688 or $3,968 g,h,i
CM_I_2A: cost multiplier of IGT in 2A
Triangular distribution of 1.35, 
1.48, and 1.79
g
CM_T_2A: cost multiplier of T2DM in 
2A






of reversion from T2DM to IGT
0.20 for the first cycle, and then 
0.00
l,m
f: Arias E.  United States Life Tables,2000.Hyattsville, MD: National Center for Health Statistics; 2002.
vol. 51;3.
h: The Diabetes Prevention Program Research Group.  Within-trial cost-effectiveness of lifestyle interven-
tion or Metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
i: Arias E. United States Life Tables, 2000. Hyattsville, MD: National Center for Health Statistics, 2002.
vol.51,3.
j:  Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2
diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36-47.
k: Nichols GA, Glauber HS, Brown JB.  Type 2 diabetes: incremental medical care costs during the 8
years preceding diagnosis.  Diabetes Care. 2000;23:1654-1659.
l: Brown JB, Nichols GA, Glauber HS, et al.  Type 2 diabetes: incremental medical care costs during the
first eight years after diagnosis.  Diabetes Care. 1999;22:1116-1124.
m: American Diabetes Association. Economic costs of diabetes in the US. in 2002. Diabetes Care.
2003;26:917-932.
n: Ramsey S, Summers K, Leong SA, et al. Productivity and medical costs of diabetes in a large employer
population. Diabetes Care. 2002;25:23-29.
o: Pascale RW, Wing RR, Butler BA, et al. Effects of a behavioral weight loss program stressing calorie
restrictions versus calorie restriction versus calorie plus fat restriction in obese individuals with NIDDM
or a family history of diabetes. Diabetes Care. 1995;18:1241-1248.
p: Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss on type II diabetic
patients.  Archives of Internal Medicine. 147:1749-1753.
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Model 2B Data Input (Including Equations for Lifetime and Three-Year Effect)
Variable with Description (Specific 
Variable Names are in Bold Font)
Value Reference
Age: start age of cohort 50 years a
Progression from IGT to T2DM in 
placebo arm
0.1075 a
Reversion from IGT to NGT in placebo 
arm
0.0678 a
Progression from NGT to IGT in placebo 
arm
0.0767 b,c,d
Progression from IGT to T2DM in 
lifestyle arm
0.0505 a
Progression from IGT to NGT in lifestyle 
arm
0.1121 a




probability of progression from IGT to 
T2DM for the lifestyle arm (three-year 
duration of effect)




probability of progression from IGT to 
NGT for the lifestyle arm (three-year 
duration of effect)




probability of progressing from NGT to 
IGT for the lifestyle arm (three-year 
duration of effect)
0.0406 for the first-three cycles, 
and then 0.0767
-
Hazard ratio of mortality for NGT none -
HRI_mort_2B: hazard ratio of mortality 
for IGT
Triangular distribution of 0.8, 
1.1, and 1.6
e




a: Knowler WC, Barrett-Conner E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393-403.
b: Weyer C, Tataranni PA, Bogardus C, et al. Insulin resistance and insulin secretory dysfunction are inde-
pendent predictors of worsening glucose tolerance during each stage of type 2 diabetes development.
Diabetes Care. 2001;24:89-94.
c: Edelstein SI, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to
NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701-710.
d: Meigs, JB, Mueller DC, Nathan DM, et al. The natural history of progression from normal glucose tol-
erance to type 2 diabetes in the Baltimore Longitudinal Study of the Aging. Diabetes. 2003;52:1475-1484.
e: Saydah SH, Miret M, Sung J, et al.  Postchallenge hyperglycemia and mortality in a national sample of
U.S. adults.  Diabetes Care. 2001;24:1397-1402.
f: Rogers RG, Hummer RA, Krueger PM. The effect of obesity on overall, circulatory disease, and dia-
betes-specific mortality. Journal of Biosocial Science. 2003;35:107-129.
g: Arias E. United States Life Tables, 2000. Hyattsville, MD: National Center for Health Statistics, 2002.
vol.51,3.
h:  Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2
diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36-47.
mort_2B[Age+_stage]: mortality rates 
for the placebo arm
U.S. Life Table Values for the 
year 2000
e
pDie_NGT_2B: probability of death for a 
NGT subject in the placebo and the 
lifestyle arms
1-exp(-mort_2B  [Age+_stage]) -
pDie_IGT_2B: probability of death for 
an IGT subject in the placebo arm
1-exp(-mort_2B   
[Age+_stage]*HRI_mort_2B)
-
pDie_T2DM_2B: probability of death for 
a T2DM subject in the placebo and 
lifestyle arms
1-exp(-mort_Pl_1B       
[Age+_stage]*HR_T_mort_1B
-
cSC_1A: Cost of screening $139 f
cINT_pl-1B[Age+_stage] : cost of 
intervention for placebo arm
Values for first-three cycles: $43, 
$18, $18, and the $0
f
cINT_L_1A:[Age+_stage] cost of 
intervention for lifestyle arm
Values for first-three cycles: 
$1,399, $679, and $702, and then 
$0
f
cNGT: direct medical costs (cost for a 
subject with NGT)
$2,688 or $3,968 g,h,i
CM_N_2B 1.02, 1.34, and 1.74 j
CM_I_2B: cost multiplier of IGT in 2B
Triangular distribution of 1.35, 
1.48, and 1.79
g
CM_T_2B: cost multiplier of T2DM in 
2B






of reversion from T2DM to IGT




i: Nichols GA, Glauber HS, Brown JB.  Type 2 diabetes: incremental medical care costs during the 8
years preceding diagnosis.  Diabetes Care. 2000;23:1654-1659.
j: Brown JB, Nichols GA, Glauber HS, et al.  Type 2 diabetes: incremental medical care costs during the
first eight years after diagnosis.  Diabetes Care. 1999;22:1116-1124.
k: American Diabetes Association. Economic costs of diabetes in the US. In 2002. Diabetes Care.
2003;26:917-932.
l: Thompson D, Brown JB, Nichols GA, et al. Body mass index and future healthcare costs: a retrospec-
tive cohort study.  Obesity Research. 2001;9:210-218.
l: Ramsey S, Summers K, Leong SA, et al. Productivity and medical costs of diabetes in a large employer
population. Diabetes Care. 2002;25:23-29.
m: The Diabetes Prevention Program Research Group.  Within-trial cost-effectiveness of lifestyle inter-
vention or Metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
n: Pascale RW, Wing RR, Butler BA, et al. Effects of a behavioral weight loss program stressing calorie
restrictions versus calorie restriction versus calorie plus fat restriction in obese individuals with NIDDM
or a family history of diabetes. Diabetes Care. 1995;18:1241-1248.
o: Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss on type II diabetic
patients.  Archives of Internal Medicine. 147:1749-1753.
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APPENDIX 4: 
Explicit Assumptions Made in the Dissertation Analysis Over and Above Those
Noted in Appendix 2 and Appendix 3
1) A subject does not progress from NGT to T2DM in any of the Markov models.
2) A subject does not revert from T2DM to IGT in any of the Markov models.  A sensi-
tivity analysis is performed inserting this reversion probability into Model 2A and 
Model 2B (see Section 5.4.5).
3) The upper and lower ranges of the intervention effect are a three-year and lifetime 
duration.
4) Progression from NGT to IGT is assumed to be similar to that found in the Pima 
Indian Study in all models but the Model 1A submodel based on a BMI subcategory 
of 30 kg/m2 to < 35 kg/m2 (see Section 4.3). 
5) A lower transition probability from NGT to IGT (0.0602) based on Meigs et al. data 
is used for the submodel of Model 1A based on a BMI subcategory of 30 kg/m2 to 
< 35 kg/m2. 442
6) The control cost of illness for Model 1A and Model 1B is assumed to be $2,688 based 
on Kaiser Permanente research (see Section 4.3.1.1.1).).443, 444
7) The transition from IGT to NGT in the Model 1A submodels based on BMI subcate-
gory was based on the percentage difference in rate of progression from IGT to T2DM 
for the overall cohort versus that of the specific subcategory (the value of the percent-
442  Weyer C, Tataranni P, Bogardus C, et al. Insulin resistance and insulin secretory dysfunction are
independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes develop-
ment. Diabetes Care. 2001;24(1):89-94.
443  Meigs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose
tolerance to type 2 diabetes in the Baltimore Longitudinal Study of the Aging. Diabetes. 2003;52:1475-
1484.
445  Nichols GA, Glauber HS, Brown JB. Type 2 diabetes: incremental medical care costs during the
8 years preceding diagnosis. Diabetes Care. 2000;23:1654-1659.
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age change is applied to the original value for the DPP cohort: see Section 4.3.1.4.1). 
8) The transition from NGT to IGT in the Model 1A submodels based on BMI subcate-
gory was also altered in the models using the above methodology (see Section 
4.3.1.4.1).
9) The treatment effect of the intervention in Model 2A and 2B, the more "generalized" 
models is assumed to be the same as that found in the DPP.  The concern is that there 
were multiple healthcare exclusions found in the study design of the DPP, and the 
intervention may not have the same effect in subjects without these exclusions. 
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